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Abstract 
Cervical cancer is the second most common female cancer in The Gambia, and there have been 
few studies carried out on the causative agent, human papillomavirus (HPV) in this country. The 
Gambia introduced the quadrivalent HPV vaccine for girls between the ages of 9-13 years in the 
urban area in 2014; nationwide immunization will take place in 2019. This study determined the 
common circulating oncogenic HPV types in the urban region where most cervical cancer cases 
were reported. Two hundred and thirty-two women between 20 – 49 years of age from the urban 
region who attended a polyclinic were recruited for this work. 
Endocervical and high vaginal swabs were collected, and a socio-demographic questionnaire was 
administered to capture potential risk characteristics associated with HPV. Nucleic acid 
amplification techniques and DNA sequencing were carried out to determine the HPV genotype 
using PGMY09/11 consensus primers. Phylogenetic analysis was carried out on the Gambian HPV 
sequences to further confirm the identification of The Gambian HPV genotypes and its relatedness 
to sequences of the same types from other geographical locations. Microbiological and nucleic acid 
amplification analyses were used to determine the prevalence of other sexually transmitted 
pathogens in the participants. Blood samples, endocervical swab, and Pap smear were collected 
from HIV positive participants and these participants were followed up and re-examined every nine 
months for 24 months, to determine the persistence of cervical HPV infection, HPV antibodies, 
and cytological cervical changes. Pseudo-typed neutralisation assays were performed to 
characterise high-risk HPV antibodies in HIV positive women.  
Among the sample population studied, HPV prevalence was found to be 12% (28/232). HPV 52 
was the most prevalent (17.9%) genotype detected in cervical samples. The Gambian high-risk 
HPV genotypes, except for a novel putative HPV 35 genotype, were 98 -100% identical to those 
submitted in the GenBank database. Prolonged (> 5 years) use of hormone contraceptive was the 
only variable found to associate statistically with HPV infection. Fifty percent (14/28) of 
participants infected with HPV were co-infected with Ureaplasma urealyticum/parvum and 25% 
(7/28) with HIV. HPV sero-prevalence was found to be 51.7% (15/29) in HIV positive participants. 
HIV positive women had been exposed to multiple HPV types and HPV 52 antibody was more 
prevalent 24% (7/29). Other high-risk HPV genotypes were found to cause high-grade cervical 
lesions and cancer in HIV positive women.  Future studies to investigate oncogenic HPV genotypes 
in cervical cancer specimens will be useful in providing evidence for policies and future evaluation 
of the quadrivalent HPV vaccine in The Gambia. 
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1 Introduction 
1.1 Study country profile and population data 
The Gambia is a small country in West Africa with a population of less than 2 million (Gambia 
Bureau of Statistics, 2013).  Females between the ages of 15-64 years represent more than 50% 
of the population. The Gambia has three main ethnic groups namely; Mandinka, Fula, and 
Wollof. Mandinka is the largest ethnic group representing 42% of the population. The Gambia 
has a relatively young population and children under the age of 5 years old account for more 
than 300,000 of the population. Based on the 2015 global population census, the United 
Nations estimated that by 2017 nearly half a million of the female population will be comprised 
of 15-49 years old (Fig 1.1). 
The Gambia has a total land area of 11, 300 km
2
.  The river Gambia and a vegetation of 
open Sudan savannah dominate the geography of the area. The Gambia has an estimated 
total population of less than 2 million people (GBOS, 2013 census). Subsistence farming, stock 
rearing, and petty trading are the major occupations particularly, in the middle and eastern 
hinterlands. The Gambian government is the major health service provider. The public health 
care system has three tiers, based on the primary health care strategy. Primary health care is 
delivered through 492 village health posts, dispensaries, and minor health centres. Secondary 
health care is provided by qualified medical doctors at 38 major health centres. There are five 
(5) hospitals that provide tertiary care and /or specialist care in the country. The health work 
force distribution has an urban bias as 66% of personnel are in the urban region (WHO, 2016 
country cooperative strategy). The distribution of health workers is hindered by poor 
infrastructure and insufficient availability of health technology for service delivery in the less 
well-developed rural regions. The system is complemented by more than 30 private and non- 
governmental organizations (NGO) clinics mainly in or around the capital city that provide 
general medical care. 
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Figure 1.1 Estimated population pyramids for The Gambia, 2017 
The Gambia has a relatively young population and was estimated that the under 5 years old accounts for 
190,765 and the 15 - 49 years old 429,606 of the total female population (1,001,933) in 2017 (Data 
source: United Nations, Department of Economic and Social Affairs, Population Division (2017).  
World Population Prospects: The 2017 Revision, DVD Edition 
(https://esa.un.org/unpd/wpp/Download/Standard/Population/) [Accessed on 05/08/2018]. 
 
1.2 Viruses 
Viruses are small obligate intracellular organisms and their genomes are made up of either RNA 
or DNA, which is surrounded by a protective coat. The nucleic acid contains the genetic 
information necessary to program the synthetic machinery of the host cell for viral replication 
(Gelderblom, 1991). A fully assembled infectious virus is called a virion. The simplest virions 
consist of two basic components: nucleic acid and a protein shell called the capsid. The 
functions of the capsid are to protect the viral genome from nucleases and it facilitates the 
attachment of the virion to specific receptors exposed on the host cell (Lodish et al., 2000). The 
various virion components are synthesized separately within the cell after which, it is assembled 
to form progeny particles. This assembly type of replication is unique to viruses and 
distinguishes them from all other small, obligate, intracellular organisms. Self-assembly of 
virus capsids follows two basic patterns: helical symmetry, in which the protein subunits and 
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the nucleic acid are arranged in a helix, and icosahedral symmetry, in which the protein subunits 
assemble into a symmetric shell that covers the nucleic acid-containing core. Some virus 
families have an additional covering, called the envelope, which is usually derived in part from 
modified host cell membranes and can be considered as an additional protective coat 
(Gelderblom, 1991) 
1.2.1 Classification of viruses 
Viruses are grouped based on morphology, chemical composition, and structure of the genome, 
and mode of replication. The genome of a virus may consist of DNA or RNA, which may be 
single-stranded (ss) or double-stranded (ds), linear or circular (Lodish et al., 2000).  
 
RNA viruses 
Seventy percent (70%) of viruses are RNA virus and their genomic structure varies 
considerably. The entire genome may occupy either one nucleic acid molecule (monopartite 
genome) or be distributed on two or more nucleic acid segments (multipartite genome). In 
addition, the strand of single-stranded RNA (ssRNA) may be either a sense strand (plus strand) 
that serves as a messenger RNA (mRNA) or an antisense strand (minus strand), which is 
complementary to the sense strand and has no translational function and hence cannot produce 
viral components (Fields et al., 1996, Gelderblom, 1991). Single-stranded RNA e.g. the 
retrovirus genome has two identical sense strand ssRNA, which is transcribed into double-
stranded, circular proviral DNA. This DNA, facilitated by the viral integrase, becomes 
covalently bonded into the DNA of the host cell to initiate the subsequent transcription of the 
sense strands that eventually give rise to retrovirus progeny. On the other hand, the double- 
stranded RNA (dsRNA) viruses e.g., members of the reovirus family, have several separate 
segmented genomes and each segment has a complementary sense and antisense strand that is 
hydrogen bonded into a linear double-stranded molecule. The replication of these viruses is 
complex; only the sense RNA strands are released from the infecting virion to initiate 
replication (Gelderblom, 1991). 
 
DNA viruses 
Most DNA viruses have either a single genome of linear double-stranded DNA (dsDNA), 
however, the papovaviruses including the polyomaviruses and papillomaviruses contain 
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circular dsDNA. The dsDNA act as a template for mRNA and for self-transcription. The 
papovirus capsid has two or three structural proteins. In addition, there are 5-6 nonstructural 
proteins, which are encoded that are functional in virus transcription, DNA replication and cell 
transformation (Lodish et al., 2000). 
Single-stranded linear DNA is found with the members of the Parvovirus family, which includes 
the parvovirus. The virion contains 2–4 structural proteins, which are differently derived from 
the same gene product, whilst the circular single-stranded DNA of only 1.7 to 2.3 kb is found 
in members of the Circovirus family which comprise the smallest propagated viruses. The 
isometric capsid measures 17 nm and is composed of 2 protein species only (Lodish et al., 2000, 
Gelderblom, 1991).  
1.2.2 The human papillomaviruses  
The human papillomaviruses (HPV) are small, non-enveloped, double-stranded 
deoxyribonucleic acid (DNA) icosahedral viruses. HPVs belong to the family Papillomaviridae 
and they infect epithelial cells of the mucosa and skin (deVilliers et al., 2004). HPV has a 
circular genome with a diameter of approximately 55 nm. The circular double-stranded DNA 
virus has a genome size of 8.0 kilo-base (kb) attached to cellular histones, which is enclosed in 
a protein capsid shell (deVilliers et al., 2004; Munoz et al., 2003). The capsid shell is made 
up of approximately 72 pentameric capsomers containing two late structural proteins, namely; 
L1 (major capsid) and L2 (minor capsid), which are involved in the packaging of the virus. In 
addition to coding for the two structural proteins, the HPV genome also encodes the early gene 
proteins (E1–E7) that direct the replication, transcription and oncogenic transformation of the 
virus (Table 1). The HPV viral structure also contains a long control region (LCR), which 
contains the cis-regulatory elements that are important for replication and transcription of the 
viral DNA (IARC, 2011; Buck et al.,2008). Table 1.1 summaries the functions of the HPV 
proteins. 
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Table 1.1 Functions of human papillomavirus early (E) and late gene (L) proteins 
                    HPV proteins Functions 
                         E1 involves in viral replication, has adenosine 
triphosphatase (ATPase) helicase activities, which 
allows it to bind to the viral origin of DNA replication 
as a hexameric complex 
 
                         E2 is the main regulator of the viral gene transcription and 
act as a co-factor to E1 in DNA replication 
 
                         E4 involves in facilitating and supporting viral genome 
amplification, the regulation of late gene expression, and 
the assemble of the virion progeny and the mediation of 
virus release 
 
                         E5 induces unscheduled cell proliferation by inhibiting 
apoptosis 
 
                         E6 involves in viral DNA synthesis, prevents cell 
differentiation and interacts with p53, a tumour 
suppressor and cell apoptosis inducer 
 
                         E7 induces cell proliferation through interaction with 
tumour suppressor proteins, primarily p105Rb 
 
                         L1 is the major viral structural protein and assembles in 
capsomeres and capsids. Together with L2 are involved 
in the packaging of the new virions. L1 also encodes 
neutralizing epitopes of the virus. 
 
                         L2 is the minor viral structural protein and is involves in 
facilitating virion assemble. L1 also encodes 
neutralizing epitopes of the virus 
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1.2.3 Classification of papillomaviruses (PV)  
Papillomavirus classification has been based on genomic cross-hybridisation and restriction 
digest techniques for over three decades. With the advancement of molecular and 
phylogenetic analysis, PV taxonomy became much easier as phylogenetic analysis compares 
either the whole viral genome sequences or sub-genomic fragments. Initially, before the 
improvement of these newer techniques, PV is grouped together with polyomaviruses under 
the Papovaviridae family based on their non-enveloped capsids and circular double-stranded 
DNA structure. However, further genomic analysis revealed the difference in genomic size, 
structural organisation and nucleotide sequences indicating that they are not as similar as 
previously thought (de Villiers et al., 2004). 
Research carried out on the papillomavirus genome has shown that the virus is very stable and 
sequence changes in the genome can arise due to mutation, however, this event is very rare (de 
Villiers et al., 2004). In addition, the rate of mutational changes that occur is proportional to 
those of the infected host DNA genomes. Papillomavirus isolates are classified into types and 
many have been isolated from animals, birds, and humans. Humans are the only host in which 
PV has extensively been studied and more than 200 HPV types have been identified based 
on complete genome analysis (Daudt et al., 2016; Doorbar et al., 2012).  It is widely accepted 
that many HPV types might exist due to the detection of other sub-genomic types.  Presently, 
complete HPV genome sequencing has been carried out on almost all isolated HPV genomes 
and their sequences are entered into a GenBank, PaVE and EMBL databases. Although the 
major capsid (L1) gene, which is the most conserved region of the HPV genome, has been used 
to classify HPV types. HPV is only defined as a new type when the cloned DNA sequences 
of the L1 gene differ by >10% from the closest type on the database. In addition, sequences 
that are different by < 2% and 2-10% to the closest known genotype are defined as HPV variants 
and subtypes, respectively (Bernard et al., 2010; de Villiers et al., 2004). 
1.2.4 HPV genotype  
More than 100 HPV genotypes have been shown to infect both male and female mucosal tracts. 
Approximately, half of these have been shown to infect the genital tract and are termed high-
risk (HR) or low-risk (LR) genotypes depending on their oncogenic potentials (Parkin and 
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Bray, 2006; zur Hausen, 2002). Fourteen HR-HPV genotypes are known to cause cervical 
cancer or are associated with other oropharyngeal and anogenital cancers in humans. These 
HR-HPV types include HPV 16, 18, 31, 33,35,39,45,51,52,56, 58, 59, 66 and 68.  Other HPV 
genotypes including HPV 26, 53, 67, 70, 73 and 82 have been classified as possible 
carcinogenic types; hence they are termed probable HR-HPVs (Bouvard et al., 2009; IARC, 
2011). HR-HPV genotypes 16 and 18 have been documented to be strongly associated with 
invasive cervical cancer and other related cancers such as vaginal, anal, oropharyngeal, head, 
and neck (IARC, 2007; Bulk et al., 2007; Hoots et al., 2007; Smith et al., 2007(a); Khan et al., 
2005; Clifford et al., 2005). Globally, HR-HPV 16 and 18 are accountable for most of these 
cancer cases, however, the distribution of HR-HPV types can vary from one country to another 
or even within the same country (Bruni et al., 2010; Castellsague et al., 2007). 
Infection with the low-risk HPV (LR-HPV) genotypes do not cause cancers but can cause 
benign or low-grade cervical changes (Lacey et al., 2006). LR-HPV genotypes are associated 
with skin warts including verruca vulgaris, deep plantar and palmar, myrmecial warts, flats and 
common warts. These skin warts are normally benign and most of them resolve spontaneously. 
The genital LR-HPV causes juvenile recurrent respiratory papillomatosis, condyloma 
acuminata and the most common LR-HPV associated with genital infections are HPV 6 and 
11(Jablonska et al., 1997). 
1.3 Natural history and epidemiology of genital HPV Infection 
HPV is a ubiquitous pathogen and natural infection has mostly been studied in the cervix. 
However, the natural history of HPV in the cervix may be similar to the natural history of 
HPV lesions in other anogenital areas (IARC, 2007). HPVs are highly epitheliotropic and 
they cause productive infections only within stratified epithelial cells (IARC, 2011). The virus 
initially infects the basal epithelial cells through micro-abrasions in the skin, genital organs and 
oropharyngeal cavity and causes differentiation of the infected basal epithelial cells, which 
maintain the active virus life cycle (Schneider et al., 1987). The replication of the virus occurs 
in the basal differentiating cells and these cells are made up of proliferating cellular 
components of stratified epithelia. The rapid increase in the number of cell components 20-100 
extrachromosomal copies of viral DNA per cell facilitates the establishment of the viral 
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genome into the nucleus of the infected cell (Fig1.2) (Oguchi et al., 2000; Frattini et al., 
1996; Schneider et al., 1987).  
The ability of the virus to establish its genome into infected cells is facilitated by the virus 
early gene proteins (E1 and E2), which are first expressed from the early promoter to regulate 
the host’s cell life cycle and genome replication by forming a complex that binds to sequences 
at the viral origin of replication (Hubert and Laimins, 2000). Since both E1 and E2 replication 
factors are also expressed at the early promoter, the viral copy numbers in undifferentiated cells 
are controlled by E2 expression. The E6 and E7 proteins of the HR-HPV types act as viral 
oncoproteins, however, for the LR-HPV types, no such functions are associated with these 
proteins. High-risk E6 binds to the p53 tumor suppressor protein to form a trimetric complex 
with the cellular ubiquitin ligase E6AP, leading to rapid turnover of p53, whilst E7 binds to the 
Retinoblastoma (Rb) tumor suppressor as well as other proteins involved in cell cycle regulation 
(Flores et al., 2000; Thomas et al., 1999). However, these proteins are expressed at a low level 
during natural infections. 
As HPV infected basal cells undergo cell division, viral genomes are divided into daughter 
cells, whereby one daughter cell loses contact with the basement membrane and migrates into 
the suprabasal compartment. This causes its withdrawal from the cell cycle to commence a 
programme of terminal differentiation of the epithelial cells to become squamous cells. As 
infected cells leave the basal layer, they remain active in the cell cycle due to the action of the 
E7 protein. The infected cells re-enter the S phase in highly differentiated cells and activate the 
expression of cellular replication factors required for viral replication. The presence of E7 
causes the retention of nucleic throughout all layers of infected epithelia (Fig 1.2). The virus 
late genes, L1 and L2 are expressed late and form icosahedral capsids to encapsidate the viral 
genome to form progeny virions in the nucleus (Woodman et al., 2007; Schiffman and Kjaer, 
2003). The virions mature after epithelial cell differentiation and are released during the natural 
shedding of senescent cells at the end of the epithelial cell life cycle (Fig1.2) (zur Hausen, 2002; 
Flores et al., 2000). Although most women will be infected with the virus few will develop 
precancerous and invasive cervical cancer (section 1.6.1). 
Most individuals are infected with genital HPV infection shortly after beginning their first 
sexual encounter with the majority of incidence seen in women below 25 years of age (Moscicki 
et al., 2012; Franceschi et al., 2006; Castle et al., 2005; Collins et al., 2002). Thereafter, 
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prevalence declines and plateaus at 30 - 35 years of age. However, a second HPV prevalence 
peak has been reported in women 50 years old and older in countries such as Costa Rica and 
Colombia (Bruni et al., 2010; Woodman et al., 2007; Franceschi et al., 2006). HPV infections 
in young and adolescent women are known to be transient and can resolve after a few months 
of natural infection or within 2 years (Woodman et al., 2001; Richardson et al., 2003). 
HPV prevalence rates in males are less well defined due to the difficulty of obtaining adequate 
samples for HPV DNA testing (Smith et al., 2007(b)). HPV infection in males is estimated to 
be in the range of 15% to 45%, which is similar to the prevalence reported for women (Partridge 
and Koutsky, 2006; Gerberding, 2004). Infection with HPV is also asymptomatic in men; 
however, they are also at risk of developing HPV-associated diseases such as genital warts, 
penile and anal cancers (Nielson et al., 2007; Schiffman and Kjaer, 2003). 
1.3.1  Immune response against natural infection with HPV 
The innate immune and adaptive cellular and humoral responses control HPV infection and 
clearance of free virions. However, naturally-acquired HPV infection can evade the innate 
immune system thereby causing a delay in activating the adaptive immune response (Moscicki, 
2005; Ho et al., 2004). The poor immune response to HPV infection is linked to a lack of 
induced inflammation and apoptosis during HPV replication, no viraemic phase occurs to fully 
activate the systemic immune response (Bonanni et al., 2009). Secondly, the replication and 
release of HPV virions occur in the suprabasal compartment instead of the basal epithelium, 
where the contiguity to the immune system would have generated a stronger response (Frazer, 
2007). Although the immune system is poorly activated during HPV infections, both humoral 
and cellular responses against HPV have been demonstrated in spontaneous regression of 
genital warts in a mouse model. Infiltration of CD4+ and CD8+ cells and macrophages were 
observed in the mouse wart epithelium and stroma with an increase in the level of pro-
inflammatory cytokines, which is an indication of a T helper 1 immune response (van der Burg 
et al., 2007; Stanley, 2006). 
Antibodies produced during natural HPV infections are type-specific and are directed against 
the L1 major capsid protein conformational epitopes of the virus (Carter et al., 2000). 
However, it has been shown that approximately 60% of individuals will develop IgG 
antibodies to HPV after natural infection; whilst in others, this may take up to eighteen months 
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(Carter et al., 2000). Antibodies developed after natural infection are type-specific and usually 
decline within a year after infection. Although there is little evidence that HPV antibodies 
provide cross-protection in humans, it has been demonstrated that HPV antibodies have 
neutralisation effects on sero-positive animals after re-exposure to the same virus. Dogs that 
were immunised with canine oral papillomavirus (COPV) were found to transfer immunity to 
other susceptible dogs (Suzich et al., 1995). Studies on the natural history of HPV antibodies 
have shown that antibody titres are very low following sero-conversion and the acquisition of 
HPV antibodies is mostly associated with persistent infection (Steele et al., 2008). 
Furthermore, it has been shown that the responses of antibody IgA correlate with that of IgG 
and the detection of the same HPV DNA specific type (Sasagawa et al., 1998; Wang et al., 
1996). 
However, serum IgA antibody conversion is less frequent and occurs later when serum IgG 
conversion has already taken place. Secondly, serum IgA antibodies can be detected up to 
approximately fourteen months after sero-conversion, whilst serum IgG may persist for up to 
two years (Onda et al., 2003; Hagensee et al., 2000). 
 
1.4 HPV transmission and acquisition 
1.4.1 HPV transmission by the sexual route 
The most common mode of anogenital HPV transmission is through the horizontal route (Kjaer 
et al., 2001; Rylander et al., 1994). HPV transmission is mostly by sexual contact with an 
infected cervix, anus, vagina, and penis. Women whose partners were infected with HPV 
were known to develop HPV-related genital warts after 4 - 6 weeks (Bleeker et al., 2002; 
Rylander et al., 1994). Many epidemiological studies have confirmed the role of sexual activity 
in HPV transmission (Castellsagué et al., 2003; Sellors et al., 2003; Bleeker et al., 2002). HPV 
is easily transmitted because it can penetrate the mucosa or skin through a small abrasion of 
the epithelium. HPV prevalence reported in lesbians has demonstrated that HPV transmission 
is not strictly through penetrative intercourse, but it can be transmitted through genital to genital 
sexual contact (Marrazzo et al., 2001). There is overwhelming evidence that HPV infection can 
also be transmitted through other sexual practices such as oral sex, peno-anal intercourse as 
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well as the use of insertive sex toys (Gervaz et al., 2003; Edwards & Carne, 1998; Sonnex et 
al., 1999). 
1.4.2 HPV transmission by non-sexual routes 
HPV transmission can occur through the non- sexual routes such as vertical (perinatal) 
transmission, skin contact, and fomites (Ryndock and Meyers, 2014; Frega et al., 2003; Sonnex 
et al., 1999). HPV infection in one anogenital site such as the introitus can be transferred to 
another site through self-infection (Winer et al., 2003).  Sonnex et al., (1999) have 
demonstrated that patients with genital warts were found to harbour HPV on their hands and a 
similar finding was also reported for university students with HPV genital warts (Winer et 
al., 2010). These findings show further that HPV infection can be transmitted through digital-
genital contact due to individual improper hygiene or that of others through non-sexual physical 
contact. However, some of the studies on genital HPV transmissions by the non-sexual route 
have generated controversial results. HPV research carried out on virginal women have shown 
that HPV transmission through this route is not common (Dillner et al., 1999), while an earlier 
study has shown approximately 50% of participants infected with the virus were sexually 
inexperienced (Sun-Kuie et al., 1990). Nonetheless, a study carried out on pre and post virginal 
women has shed some evidence that HR-HPVs are only transmitted via the sexual route (Kjaer 
et al., 2001). 
HPV infection can also be transmitted perinatally via an infected birth canal during vaginal 
delivery and the HPV genotypes found in infected newborns are similar to those found in their 
mothers (Hahn et al., 2013; Freitas et al., 2013; Hong et al., 2013; Park et al., 2012; Smith 
et al., 2010). Furthermore, nosocomial (hospital-acquired) HPV infection has also been 
documented (Casalegno et al., 2012). Nosocomial infection is a common route for many viruses 
to gain access to their host and HPV is no exception. A potential route for hospital-acquired 
HPV infection is using transvaginal ultrasound probes, which are used to perform endovaginal 
cavity ultrasounds (Ryndock and Meyers, 2014; Casalegno et al., 2012).  Although these probes 
are disinfected after each use, the virus is known to be very stable and most of the clinical 
disinfectants cannot neutralise the virus (Ma et al., 2012; Ryndock and Meyers, 2014). 
Ultrasound probes were found to be positive with HR-HPV types and not only where these 
probes infected with HPV DNA, but with free virion indicating that HPV can also be 
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transmitted through fomites (M’Zali et al., 2014; Casalegno et al., 2012; Ma et al., 2012; Kac 
et al., 2010). 
1.5 Risk factors for acquiring HPV infection 
The link between the acquisition of oncogenic HPV genotypes and sexual activity has been 
established through cross-sectional and longitudinal studies. The most consistent predictor for 
the acquisition of HPV infection is the number of lifetime sexual partners (Cuschieri et al., 
2004(a); Karlsson et al., 1995). The risk of acquiring HPV infection is estimated to be directly 
proportional to the numbers of sexual partners (Moscicki et al., 2001; Ley et al., 1991). Having 
a new sexual partner, short intervals between new sex partners, concurrent sexual partners and 
a male partner with multiple sexual partners are all known risk factors for HPV infection 
(Burchell et al., 2010; Cotton et al., 2007). 
Age is an important risk factor, as HPV infection is consistently most common in sexually 
active women below the ages of 25 years old (Moscicki et al., 2012; Franceschi et al., 2006). 
The overall association with age may be a result of riskier sexual behaviour such as multiple 
sexual partners, non-use of condoms and co-infection with multiple STI pathogens (Ley et al., 
1991). However, there is also evidence that adolescent and young adults are more susceptible 
to HPV infection due to the epithelial cells that make up the cervix. Once puberty occurs, the 
columnar epithelial cells gradually transform into squamous epithelial cells. During this 
transformation, transitional squamous, glandular and metaplastic cells are formed, which all 
promote HPV replication (Moscicki et al., 1999). Early sexual debut may accelerate the process 
of cervical transformation, as adolescents with multiple sexual partners tend to have more 
mature cervices than sexually inexperienced adolescents (Curtis et al., 2004; Moscicki et 
al., 1999). In women older than 45 years old, the strongest risk predictors for HPV persistence 
are linked to older age, early menopause and the use of hormone replacement therapy 
(Gonzalez et al., 2010). 
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1.6 The burden of HPV-related diseases and its role in the development of 
premalignant, malignant and non-malignant disease 
HPV has been associated with cervical, vaginal, vulva, penile and anal precancer and cancers. 
HPV has also been linked to a subset of head and neck cancers. Approximately 70% of these 
HPV-related diseases are known to be caused by HR-HPV16 and 18 (Smith et al., 2007; 
Clifford et al., 2003). Non-malignant HPV-associated diseases such as anogenital warts and 
juvenile recurrent respiratory papillomavirus are caused by LR-HPV 6 and 11. HPV infections 
with HR genotypes can persist and progress to cause precancerous lesions, and eventually 
invasive cancer. The transformation zone of the cervix is the area between the original 
squamocolumnar junction (SCJ) and the new SCJ where the columnar epithelium has been 
replaced or is being replaced with the new metaplastic squamous epithelia. The size and 
shape of the transformation zone depend on age, parity, prior infections and exposure to female 
hormones (Autier et al., 1996). HPV infection in the cervix is most likely to cause cancer at 
the transformation zone (TZ) due to its susceptibility to carcinogenic HPV genotypes (IARC, 
2011; IARC, 2007).  
1.6.1 Pathogenesis of HPV infection 
Most HPV infections are spontaneously cleared by the immune system, but persistent infection 
with oncogenic types may cause low grade squamous intraepithelial lesion (LSIL), high grade 
squamous epithelial lesion (HSIL) or progress to cervical cancer. The risk of persistence and 
progression to cervical cancer is related to the type of HPV, infection with multiple types and 
high viral burden in the cervix (Woodman and Collins, 2002). As explained in section 1.2, HPV 
virions are released during the natural shedding of senescent cells at the end of the epithelial 
cell life cycle to initiate a new infection. In the context of HPV infection leading to cervical 
cancer, persistent infection causes LSIL or cervical intraepithelial neoplasia (CIN), which 
enhances productive viral replication within the host cells. Viral synthesis occurs in both 
productive infections and CIN grade 1 (CIN1). Progression to high-grade CIN (CIN 2/3) 
develops with de-regulated gene expression (IARC, 2007). Unlike the early viral promoter, the 
late promoter expression is not regulated by E2 protein, and high levels of expression occur 
upon differentiation, leading to increased viral DNA copy number. The increase in viral DNA 
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copy number also increases the expression of the replication proteins (Schiffman et al., 2007). 
In CIN 1/2 infections, the HR-HPV genomes are present as episomes. However, during 
progression to high-grade CIN 3 and cervical cancer, the episomal viral DNA often becomes 
integrated into the host genome. This integration normally occurs within the E2 open reading 
frame (ORF) resulting in loss of E2 recessive action, which leads to high expression of 
oncoprotein E6 and E7. The oncogenic E6 forms a trimetric complex with p53 and E6AP, 
resulting in ubiquitination of p53 and subsequent degradation, leading to a reduction in the half-
life of p53. Furthermore, the function of the Rb gene as major regulators of the cell cycle exit 
during epithelial differentiation is abrogated by the binding of oncogenic E7 protein to Rb 
(Woodman et al., 2007; Jeon et al., 1995). The rapid turnover of p53 and the blocking of the 
Rb gene lead to a cellular state which cannot support the full viral life cycle resulting in 
cervical carcinoma (Fig. 1.2). 
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Figure 1.2 Progression of persistent HPV infection to cervical diseases (adapted from 
Woodman et al., 2007). 
Stage 1: Human papillomavirus access the basal cells through micro-abrasions of the cervical 
epithelium. Once the basal cells are infected, the HPV early genes E1-E7 are expressed and the viral 
genome is replicated from the episomal DNA (purple nuclei). Stage 2: The viral genome is further 
amplified in the suprabasal compartment (midzone and superficial zone), and within the compartment 
both the L1 and L2 (late genes) capsids are expressed. The viral genome is then encapsidated by the 
L1 and L2 genes to assembly the progeny virions, which are shed to initiate a new infection. Persistent 
infection leads to cervical intraepithelial lesions (CIN1/2) that can spontaneously regress. Stage 3: 
Persistent infection with oncogenic HR-HPV genotypes can progress to high grade CIN3, which left 
untreated progresses to micro-invasive cancer by integration of the viral genome into the host DNA 
(red nuclei). Stage 4: The upregulation of the two high risk oncogenes E6 and E7 are responsible for 
invasive cancer. The E7 forms a complex with the product of the Retinoblastoma gene (Rb) to cause 
uncontrolled cell proliferation (Chellappan et al., 1992). Binding of the E6 gene to the p53 gene protein 
product degrade the complex and lead to loss of DNA repair, thus preventing the cell to undergo 
apoptosis (Thomas et al.,1996). This leads to a cellular state that can no longer support the full viral 
life cycle therefore results in invasive carcinoma. 
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1.6.2 Epidemiology of cervical cancer 
Cervical cancer is the second most common cancer affecting women, worldwide with 
530,000 new cases reported each year (de Martel et al., 2017; Ferlay et al., 2013). Nearly all 
cervical cancer cases reported each year are attributed to HPV infection with approximately 
half of the cases diagnosed in women below the age of 50 years old (de Martel et al., 2017). 
An incidence rate of 60,240 cervical cancer burden is observed in Western Europe compared 
to 120,000, 93,000 and 69,000 ca s e s  reported for In d ia ,  sub-Saharan Africa, and Latin 
America, respectively (Ferlay et al., 2013) (Table1.3).  
Cervical cancer is a leading cause of mortality in women with more than 250, 000 cases 
reported each year, approximately 80% of which occurs in resource- limited countries (Ferlay 
et al., 2004). It is expected that 60% of women living in developing countries will succumb 
to cervical cancer as the 5-year survival rate depends at which stage the disease is presented as 
well as treatment availability (Sankaranarayanan et al., 1998). The unavailable or inadequate 
cervical cancer screening programmes together with a lack of effective treatment may have 
contributed to the low 5-year survival rates reported, in many developing countries. It is 
estimated that if the current trend continues, cervical cancer mortality will rise from 80% to 
90% in developing countries by the year 2020 (Ferlay, 2001).  
HPV genotypes 16 and 18 have been reported to be the most types detected in cervical cancer 
cases, worldwide with HPV 16 more prevalent in squamous cell carcinoma (Clifford et al., 
2017). HPV 16 may be found either in an integrated or episomal form in invasive cervical 
cancers (Sigurdsson et al., 2007; Munoz et al., 2003). The frequency with which HPV 16 is 
found in integrated forms increases with the severity of the lesion (Cricca et al., 2006). In 
contrast, HPV 18 is the type most strongly associated with cervical adenocarcinoma and it is 
most frequently found in integrated forms in high grade cervical intraepithelial lesion (HGCIN) 
or invasive cancers (Clifford et al., 2003). However, HPV16 prevalence remains high in 
both cell carcinomas (Clifford et al., 2017; de Sanjose et al., 2007). 
Although HPV 16/18 are mostly detected in 70% of cervical cancer specimens, their prevalence 
is slightly higher (77%) in Europe and North America than in Africa, Asia 
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and Central and South America, which have a prevalence rate of 70% (Smith et al, 2007; 
Clifford et al., 2006). 
1.6.3 Cervical cancer burden in The Gambia 
More than 50% of the reproductive age female population in The Gambia is at risk of being 
diagnosed with HPV infections. Analysis of The Gambia National Cancer Registry (GNCR) 
data from 1990 - 2009 showed 7, 991 cases of malignant tumours were diagnosed, 48% of the 
total cases were in females. Of these malignant tumours, cervical cancer was the most common 
female cancer accounting for 33% of all female cancers (Table 1.2). Liver cancer is the second 
most common female cancer (24%), followed by breast cancer (11%) and non-Hodgkins 
lymphoma (4%) (Bah et al., 2013). Eighty percent (80%) of Gambian women diagnosed with 
cervical cancer do not attain the 5-year relative survival rate due to late stage diagnosis of the 
disease. Furthermore, less than 20% of cervical cancer cases are diagnosed histologically with 
squamous cell carcinoma being the most common type reported in The Gambia (Wall et al., 
2005). 
 
  
Table 1.2 Number of cervical cancer cases, ASR per 100,000 person-years with 95% 
confidence intervals of cases by period: The Gambia, 1990-2009 
 
Periods Total female cancer cases  
n *(%) 
**ASR (95% CI) 
1990 -1994 199 (31) 13.9 (11.8-16.0) 
1995 -1999 361 (34) 20.2 (17.9-22.4) 
2000 – 2004 276 (30) 13.7 (11.9-15.4) 
2005 – 2009 418 (34) 19.1 (17.2-21.1) 
Total (1990 – 2009) 1,254 (33) 16.9 (15.9-17.9) 
n *(%) = Number of cervical cancer cases and Percentage of total female cancer cases in period; 
**ASR = Age-standardized incidence rate per 100,000 person-years (Standardized to the World 
Standard Population) (Bah et al., 2013). 
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1.6.4 Cervical cancer prevention and control in The Gambia 
Currently, The Gambia has not fully established integrated cervical cancer prevention and 
control services. At present, there is no cervical cancer screening policy as recommended by 
the World Health Organization and secondly, due to limited resources, the country is unable to 
embark on a population-based screening. There is an “ad-hoc” cervical cancer screening 
program in some parts of the urban area of the country using the direct visual inspection with 
acetic acid (VIA) method. The SOS Mother and Child clinic is a private clinic situated in the 
Kanifying Municipality Council (KMC) and was the first clinic to offer cervical cancer 
screening using VIA in the Gambia. The Gambia Ministry of Health and Social Welfare 
(MOHSW) with assistance from developing partners has recently introduced VIA screening 
in few government health facilities with foresight to expand VIA services across the country 
by 2020 (Cervical cancer strategic plan 2016 - 2020). 
In 2014, the Gambia embarked on a 2 year HPV vaccination school-based demonstration 
project in the urban West Coast Region (WCR) of the country, supported by GAVI. A two-
dose delivery schedule of the quadrivalent HPV vaccine was administered to girls aged 9 -13 
years old as recommended by the WHO. It is envisaged that the quadrivalent vaccine will be 
scaled-up and integrated into the national immunisation program by 2019.  
1.6.5 Global burden of cervical cancer 
Approximately 70% of the global cervical cancer burden occurs in developing countries, 
accounting for almost 12% of all cancers in women. In comparison, cervical cancer accounts 
for <1% of all cancers in women in developed countries (de Martel et al., 2017). Countries with 
a cervical cancer age-standardised rate (ASR) greater than 30 per 100,000 per person are found 
in sub-Saharan Africa (Fig 1.3) (de Martel et al., 2017; Ferlay et al., 2013). In developed 
countries that have introduced the HPV vaccine and cervical cancer screening with wider 
coverage, the incidence of cervical cancer and mortality are less than 10 per 100,000 per person 
(Crosbie et al., 2013). The absence of HPV vaccination and effective cervical cancer screening 
and treatment in the developing countries may increase the annual global cases from 530,000 
to 1 million by 2050, because of a worldwide increase in the number of young women 
(Ferlay, 2001). Although HPV 16 and 18 accounts for 70% of cervical cancer, the six most 
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common HR-HPV types found in cervical cancer after HPV 16/18 are: HPV31/33/35/45/52/58. 
These other HR types and HPV 16/18 together account for approximately 90% of all cervical 
cancers, globally (Table 1.3). Cervical cancer causes nearly 3 million years of life lost and the 
burden is observed more in reproductive age women, globally (WHO, 2017). Mortality due to 
cervical cancer does not only affect families but it also has devastating effects on societies and 
economies. Reproductive age women that are affected are normally in their mid-adult lives, 
working and raising a family as well as contributing to the socio-economic development of their 
societies. 
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Figure 1.3 Age standardised cervical cancer incidence rates associated to HPV infection, 
worldwide. 
Cervical cancer mortality age standardised rate varies 18–fold between countries ranging from less 
than 2 per 100,000 per women in developed countries to greater than 30 per 100,000 per in sub-
Saharan Africa and some developing countries (dark red coloured areas) (de Martel et al., 2017; 
Ferlay et al., 2013). 
Legend: ASR – Age Standardised Rate 
 
1.7 HPV-associated non-cervical anogenital cancers: vulva
 and vaginal cancers 
Although the global cervical cancer incidence is higher than vulvar and vaginal cancers, global 
cases of vulvar carcinoma and vaginal cancer have been estimated to be approximately 8 , 5 0 0  
and 12,000, respectively (de Martel et al., 2017; Plummer et al, 2016). The highest incidence 
of these cases was reported in more developed countries, specifically in Europe (Table 
1.3). A meta-analysis of data in 14 countries has shown that the age range of diagnosis for both 
diseases was between 45-82 years old (Bosch et al., 2007). 
1.7.1 Anal and penile cancers 
Unlike vulvar/vaginal cancers, anal and penile cancers have been reported to account for 
35,000 and 13,000 of cancer cases associated with HPV infection, worldwide (Alemany et al., 
2016; Serrano et al., 2015). The global distribution of anal cancer is seen more in females 
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(51%) than in males (48%). However, it is more frequent in men in less developed countries 
than in developed countries (Table1.3). The incidence of anal cancer has been reported in 
populations that have a large proportion of men who have sex with men (MSM) (de Martel et 
al., 2015; Goldstone et al., 2011; Parkin and Bray, 2006). The anus is susceptible to infection 
with HPV because it has a transformation zone like those observed in the cervix (Heideman et 
al., 2007). Associations between anal cancer and HR-HPV infections, especially with HPV 16 
in HIV-positive MSM have been documented (de Martel et al., 2015; Goldstone et al., 
2011; Hoots et al., 2007). Cancer of the penis is rare and accounts for approximately 0.5% of 
all cancer cases in men, but 21% of HPV-associated cancers in men, globally (Parkin and 
Bray, 2006; Ferlay et al., 2013). The highest incidence rates of penile cancer cases have been 
reported in India (3,200), Europe (2,700) and Latin America (2,000) compared to sub- Saharan 
Africa (1,000) (Table 1.3).  
Male circumcision has been documented to have contributed to HPV clearance and a decreased 
risk of penile cancer cases seen in countries such as North Africa and some parts of Asia (Lu 
et al., 2009; Castellsague et al., 2002). However, the role of male circumcision in preventing 
HPV infections in their female partners is still controversial.   
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Table 1.3  Number of cancer cases caused globally by human papillomavirus by region, cancer sites and gender 
 
* Attributable fraction (AF) for HPV infections is the proportion of cancer cases that would not have occurred if HPV had been totally absent from the population.  
 (de Martel et al., 2017; Ferlay et al., 2013) 
Region Cervix Vulvar/Vagina Anus Penis Head and Neck Attributed 
to HPV 
AF (%) 
       
 F F M             F M F                 M both sexes both sexes 
        
Africa        
sub-Saharan Africa 93, 000 2, 100 1, 000       1, 200 1, 000 150                 360 99, 000 15.8 
Northern Africa/ 10, 000 650 430          350 70 80                 240 12, 000 2.2 
Western Asia        
Asia        
India 120, 000 2, 800 2, 600        1, 900 3, 200 1, 000          5, 600 140, 000 13.8 
Other central Asia 29, 000 460 490            410 30 300               760 31, 000 6.3 
China 62, 000 1, 600 5, 900         3, 600 1, 300 270               950 75, 000 2.5 
Japan / Republic of Korean 13, 000 460 600             560 250 350          1, 500 16, 000 1.8 
Other Eastern  Asia 54, 000 1, 000 550             530 1, 100 280          1,  000 59, 000 6.2 
America        
Latin America 69, 000 2, 500 1, 000         1, 900 2, 000 280               980 78,000 7.1 
Northern America 14, 000 3, 300 1, 800         2, 700 1, 100 1, 900           7, 000 32, 000 1.8 
Europe        
Europe 58, 000 5, 100 2, 700         4, 200 2, 700 2, 800             11, 000 87, 000 2.5 
Oceania        
Australia /New Zealand 940 150 150             190 50 80                  290 1, 900 1.3 
Other Oceania 1, 300 30 10               10 10 10                   30 1, 300 11.1 
Less developed countries 370, 000 8, 300 10,000          7, 600 6, 800 2, 100              8, 600 410, 000 6.7 
More developed countries 160, 000 12, 000 6, 800       10, 000 6, 100 5, 500             22, 000 220, 000 2.8 
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1.7.2 Head and neck cancers 
The burden of head and neck cancers varies widely, and this variability is associated with 
alcohol and tobacco use. Approximately half a million cases and more than 200,000 deaths were 
reported in 2002, with the greatest burden seen in developing countries (Parkin, 2006). Recently, 
a report attributed 38,000 cases of head and neck cancers to HPV infection with 72% of cases 
observed in the developed countries (de Martel et al., 2017; Castellsague et al., 2016; Ferlay et 
al., 2013). In comparison to the global relative contribution of HPV 16/18 in cervical cancer 
(70%), HPV 16/18 are responsible for nearly 85% of head and neck cancers (Table 1.4). 
Three cancer sites in the head and neck region have been associated with HPV infection; namely: 
the oropharynx, oral cavity, and the larynx. HPV-related head and neck cancers are mainly 
represented by oropharyngeal cancer for which consistent evidence has indicated that two main 
types exist: one that is caused by HPV and the other is associated with tobacco and alcohol intake 
(Rietbergen et al., 2014; Marur et al., 2010). The incidence of oropharyngeal cancer has been 
increasing over the past two decades in some high-income countries. This may be due to an 
increase in HPV infection possibly because of more oral-genital sex and an increase in the number 
of lifetime sexual partners (Chaturvedi et al., 2011; Gillison et al., 2008). 
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Table 1.4 Global relative contributions of HPV risk types by invasive cancer at different 
anatomical sites, 2012 
 
 
Sites 
 
Number attributed  
to HPV 
 
Relative contribution   
of HPV 16/18 
 
Number        Percent 
 
Relative contribution of HPV 
6/11/16/18/31/ 33/45/52/58 
 
Number          Percent 
 
Cervix 
 
530, 000 
 
370, 000          70.8 
 
470, 000           89.5 
Head and neck   38, 000   32, 000           84.9    34, 000          89.7 
Anus   35, 000   30, 000           87.0         33, 000          95.9     
Penis   13, 000     9, 100           70.2    11, 000          84.6 
Vagina   12, 000     7, 400           63.7      9, 900          85.3 
Vulva     8, 500     6, 200           76.2      7, 400          87.1 
Total HPV sites in 
women 
570, 000 410, 000           71.4  510, 000          89.6 
Total HPV sites in Men   60, 000    50,000           82.3     55, 000          90.4 
Global total HPV sites 630, 000 460,000            72.4   570, 000          89.7 
HPV infection accounts for 630,000 cancer cases globally in both men and women with the highest 
burden seen in women, 2012. The relative contribution of the nonavalent vaccine was nearly 90% 
compared to the bivalent vaccine (HR-16/18) 72%, therefore making it more suitable against cervical 
cancer prevention, globally (de Martel et al., 2017).  
1.7.3 Anogenital warts 
Anogenital warts or condyloma acuminata are commonly found in the cervix, vagina, vulva 
or perianal and anal in females. In men, the penis, scrotum and perianal and anal regions are the 
most common sites for condyloma acuminata (Moscicki et al., 2005). The prevalence of 
genital warts is estimated to be within the range of 0.2-13% depending on the age distribution 
and the risk of STI in the study population (Patel et al., 2013). Genital wart prevalence also varies 
by region; however, infection risk is higher in the young and adolescent population (Koshiol et 
al., 2004). The incidence of genital warts peaks in women aged 15-24 years old, and in 20-29 
years old men. A sharp decline in incidence rate is observed in women after 29 years old but 
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remains high in men until the age of 40 years (Hoy et al., 2009). All anogenital warts are 
associated with an HPV infection with HPV types 6 and 11 found in 90% of cases, globally. 
Nearly 50% of women infected with HPV 6 or 11 will develop genital warts after a year of 
exposure to the virus with an average time of 2 - 3 months (Garland et al., 2009; Kjaer et al., 
2007). More than twenty-five percent of HPV positive individuals with genital warts will 
spontaneously clear the infection; however, recurrence may occur in 30% of cases, irrespective 
of whether initial clearance occurs spontaneously or with treatment (Wiley et al., 2002). Since 
genital wart infections may persist or recur, there is a greater risk of an increase in HPV 
transmission in communities (Giuliano et al., 2011). However, not all individuals infected with 
HPV 6 or 11 will develop genital warts (Lacey et al., 2006). The primary risk for anogenital wart 
is linked to sexual activity with an infected partner; a high number of sexual partners, anal sex 
and infection with an STI (Goldstone et al., 2011; Giuliano et al., 2011). Anal condyloma is a 
clinical manifestation of HPV 6 or 11 infections in the anal canal and on the perianal skin, but 
HPV 16 and 18 may also be found in the lesions (Chan et al., 2009). Lesions can be 
asymptomatic or symptomatic with itching, burning, spontaneous bleeding or bleeding due to anal 
intercourse (Dunne et al., 2006). 
The clinical manifestation of anal condyloma may differ between HIV-positive and HIV-negative 
individuals. HIV-positive individuals are prone to infection with multiple HPV genotypes due to 
their immunosuppression status. HPV 16 and 18 have been detected in anal and giant condyloma 
(Bushke-Löwenstein tumours) of HIV-positive individuals, which exposes them to a greater risk 
of developing high grade anal intraepithelial neoplasia (AIN) that can progress to invasive anal 
cancer (Anderson et al., 2004; Byars et al., 2001). 
 
1.8 Prevention of HPV infection 
1.8.1 HPV prophylactic vaccines: A primary prevention 
The HPV vaccine has the potential to compliment cervical cancer screening in the prevention of 
HPV infection and the control of cervical cancer morbidity and mortality, worldwide. Currently, 
three recombinant HPV prophylactic vaccines are commercially available: these are Cervarix®, a 
bivalent HPV-16/18 vaccine; Gardasil®, a quadrivalent HPV-6/11/16/18 vaccine; and Gardasil® 
9, a nonavalent HPV6/11/16/18/31/33/45/52/58 vaccine. All three vaccines are prepared from 
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virus-like particles (VLP) using recombinant technology (Zhou et al., 1991; Hagensee et al., 
1993). The preparation of these vaccines is based on HPV L1 protein forming virus-like particles 
(VLP) when expressed alone in a variety of cell types (e.g Saccharomyces cerevisiae) that are 
highly similar to the HPV virus both morphologically and antigenically (Kirnbauer et al., 1992). 
The purified L1 protein does not contain viral genetic material or attenuated live biological 
products; therefore, it cannot multiply and is not infectious (Table 1.5). 
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Table 1.5 Characteristics of human papillomavirus prophylactic vaccine 
 
 
Bivalent Quadrivalent Nonavalent 
Manufacturer   
& trade name 
GlaxoSmithKline, Cervirax® Merck, Gardasil /Silgard® Merck, Gardasil 9® 
 
Virus-like particle 
types 
 
   16,18 
 
6,11, 16, 18 
 
6, 11, 16, 18, 31, 33, 45, 
52, 58 
 
Substrate 
 
Baculovirus expression 
system 
 
Saccharomyces cerevisiae 
(Baker's yeast) 
 
 
Saccharomyces 
cerevisiae (Baker's 
yeast) 
 
Adjuvant Amorphous aluminium  
hydroxide (500 µg) and  
50 µg 3-deacylated  
monophosphoryl lipid A 
 (GSK ASO4 adjuvant) 
 
Amorphous aluminium 
hydroxyphosphate 
sulphate (225 µg) (Merck 
aluminium adjuvant) 
Amorphous aluminium 
hydroxyphosphate 
sulphate (500 µg) 
(Merck aluminium 
adjuvant) 
 
Schedule*: 3 doses 
at interval of 
 
1 month between doses 1 and 
2; 6 months between doses 1 
and 3 
 
  
 2 months between doses 1   
and 2; 6 months between 
doses 1 and 3 
 
 2 months between 
doses 1 and 2; 6 months 
between doses 1 and 3 
*The World Health Organisation Strategic Advisory Group on vaccination made some 
recommendations of reducing the three-dose schedule to a two-dose after reviewing new research 
findings. The new research findings indicated that no immunogenicity difference was observed 
between two doses in adolescent to that of three doses in young adults (Romanowski et al., 2015; 
Dobson et al., 2013). The recommended dose schedules are as follows: 0 and 6 months for the first 
dose, and 12 months for the second dose for females 9 -14 years old (WHO, 2017). Countries under 
the GAVI vaccine alliance have switched their vaccine programmes to the recommended schedule. 
However, a three-dose schedule over 6 months is recommended for those aged 15 years or older and 
those that are immunocompromised (Meites et al., 2016). 
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1.8.2 HPV prophylactic vaccines: mode of action 
The mechanisms by which the HPV vaccines prevent HPV infections have not been fully 
defined. The primary mechanism of action in which the HPV virus-like particle vaccine 
prevents HPV infections caused by the targeted genotypes is by eliciting the production of 
serum neutralising anti-HPV IgG antibodies from the capillaries to the basal epithelial mucosa 
cells. These neutralising antibodies bind to the virus particles and block their entrance into 
the host cells (Joura et al., 2015; Villa et al., 2005; Harper et al., 2004). Protection from 
HPV infection can also be mediated by exudation of the serum anti-HPV IgG onto the 
genital mucosal surface after the formation of micro-abrasions, which activate the innate 
inflammatory immune responses thereby facilitating the recruitment and migration of the 
immune cells to the site of inflammation (Stanley et al., 2014). 
1.8.3 HPV vaccine protection against infections 
Viral vaccines protect against infections that have a bloodstream phase such as hepatitis B, 
rubella and measles, therefore antibodies developed after exposure to these viruses are 
sustained and are good markers of infection (Stanley, 2006). In contrast, HPV infection does 
not have a bloodstream phase as the infection occurs at the mucosa. The antibody response after 
natural infections does not protect against subsequent infections as the responses are slow to 
develop and of low titre and avidity (WHO, 2017; Stanley, 2006). A long-term follow-up 
following administration of the HPV vaccines to pre-sexual adolescent women has shown 
that antibody levels remained stable up to 6 years in women with no prior infection with 
HPV (Dasbach et al., 2007, Gall et al., 2007). Similarly, women with prior or ongoing 
infection with one of the targeted quadrivalent vaccine genotypes were found to have a 
higher immune response to that genotype they were infected with prior to vaccination 
(Villa et al., 2006). This may suggest that vaccination enhances the antibody levels generated 
by natural infection. HPV vaccination with both the bivalent and quadrivalent vaccines have 
been shown to induce an antibody response that is moderately (60 -78%) capable of neutralising 
infections caused by closely related HPV genotypes (Kavanagh et al., 2014; Wheeler et al., 
2012; Smith et al., 2007). This could be due to cross neutralising epitopes and homology 
between the related species, for example, HPV16 and HPV31 genotypes (Drolet et al., 2015; 
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Wheeler et al., 2012).  Although detectable neutralising antibodies have been observed 10 years 
after post-vaccination, no data on antibody persistence beyond 10 years has been reported 
(Garland et al., 2016). These vaccines cannot eliminate pre-existing cervical lesions since the 
target antigens (L1) major capsid proteins are not expressed in infected basal epithelial cells 
(Hildesheim et al., 2016). However, they have been shown to be efficacious in the prevention 
of precancerous lesions such as CIN1/2 and genital warts by preventing initial infections 
(Dominiak-Felden et al., 2015; Ali et al., 2013). 
1.8.4 Global HPV vaccine implementation 
The first HPV prophylactic vaccine was licensed in 2006 and since then two other vaccines 
(quadrivalent and nonavalent) have been developed. All three vaccines have proven to be safe, 
highly immunogenic and induce protection against HPV infections and its associated-diseases 
(Sankaranarayanan et al., 2016; Drolet et al., 2015; Schiller et al., 2012). In 2009, the WHO 
recommended the inclusion of the HPV vaccine into national immunisation programs to prevent 
the burden of HPV-related cervical cancer (WHO, 2009). The HPV vaccines have been 
introduced in more than 85 countries in the past 12 years as a part of their national immunisation 
program, worldwide. More than 80% (74) of these countries are in high-income (HIC) and 
upper-middle-income countries (UMIC). In contrast, only 12 countries (13%) in resource- 
limited countries have a national HPV vaccination program (LaMontagne et al., 2017). Most of 
the national HPV vaccination in resource-limited countries e.g Rwanda in 2011/2012, Bhutan 
(2010), Vanuatu (2013) and South and Central America (2017) were facilitated through donor 
agencies such as pharmaceutical companies, cervical cancer foundations and the Pan American 
Health Organisation (PAHO) (Gallagher et al., 2018; LaMontagne et al., 2017). 
Although the proportion of resource-limited countries with a national HPV vaccination program 
is 13%, thirty-one countries have carried-out HPV vaccine demonstration or small scale 
pilot projects, from 2013-2016 (LaMontagne et al., 2017; Brotherton and Bloem, 2015) 
(Figure 1.4). Sexually inexperienced females, within the ages of 9 -14 years benefitted from 
these HPV pilot projects. In addition, countries like Uganda, Senegal and The Gambia were 
funded through the Global Alliance for Vaccine and Immunization (GAVI) projects (GAVI 
alliance, 2014). Some of these countries are yet to introduce the vaccine in their national 
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immunisation programs. However, more than ten GAVI eligible funded countries have been 
granted approval to include the HPV vaccine in their national immunisation programs by 2019. 
 
 
 
 
Figure 1.4 Global status of HPV vaccine implementation in 2016 
HPV vaccine implementation is higher in high- and upper-income countries compared to 
sub-Saharan Africa where more than 80% of cancer cases are reported. In some countries, 
demonstration was stopped due to the ending of the GAVI project funding (pink colour 
coded) (LaMontagne et al., 2017). 
 
 
1.8.5 HPV vaccine coverage and effectiveness 
High vaccine coverage in a target population is achieved by vaccinating adolescent females prior 
to their first sexual encounter. Targeting this cohort has shown the greatest impact of these 
vaccines (WHO, 2016). Some countries have implemented catch-up programs for older females 
together with the routine school-based 9 -14 years programs to increase overall population 
coverage (Brisson et al., 2016). A successful national HPV vaccination coverage greater than 80% 
was achieved in some developed countries with high-income, for example, Scotland and Australia 
National 
Demonstration 
  National-projected 
Demo-projected 
Demo/National stopped or completed 
Sub-national 
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(Sinka et al., 2014; Brotherton et al., 2011). HPV national vaccination coverage of more than 
80% was also achieved by Bhutan and Rwanda (Dorji et al., 2015; Binagwaho et al., 2013). The 
success of this approach could be the introduction of a catch-up vaccination program (Scotland, 
Australia and Bhutan) targeting females up to 26 years old, and in the case of Bhutan, 18 years 
old (Brotherton et al., 2016; Dorji et al., 2015). In contrast to Scotland or Australia, less than 
50% vaccine coverage was achieved by Japan as their vaccination program was suspended in 
2013 due to negative media reports on vaccine safety (Tanaka et al., 2016; Larson et al., 2014). 
A similar negative social media report on vaccine safety was also reported in Ireland, which 
resulted in a decrease in vaccine coverage from 86% (in 2014) to 50% in (2016). The Global 
Advisory Committee on Vaccine Safety (WHO) and the European Medicines Agency (EMA) 
maintained a vigilant post-licensure survey and have confirmed the continued safe use of the 
vaccine (EMA, 2016; WHO, 2015). 
The recent development on the administration of the HPV vaccine in boys 12-13 years old in 
some high- income countries for example in Australia, America, Demark and in England (from 
next year) is anticipated to reduce the burden of genital HPV infections and increase herd 
immunity amongst the population (Tabrizi et al., 2014). Vaccination of boys alongside girls 
would reduce the non-cervical diseases that can have serious morbidity, healthcare, and socio-
economic burdens. However, there is much controversy surrounding the cost-effectiveness of 
HPV vaccination in boys. In America, the burden of non-cervical diseases was estimated to be 
8% compared to 92% of cervical diseases, thereby the cost of vaccinating boys was reported as 
not being cost- effective (Hu and Goldie, 2008). Similarly, In the United Kingdom, it was 
highlighted that achieving a high HPV vaccine coverage of over 75% in girls and young adults 
is more cost-effective than vaccinating boys (Cuschieri., 2009). Herd immunity studies in 
Australia have shown a reduction in genital warts in both vaccinated women and their heterosexual 
partners (Machalek et al., 2017; Tabrizi et al., 2014). This shows further that vaccinating females 
may lead to a reduction of HPV-associated diseases in men over time. However, others have 
argued that if the primary objective of HPV vaccination is to eradicate HPV infections, a gender-
neutral vaccination approach should be taken as MSM would not benefit from a female-only 
vaccination program (Smith and Canfell, 2014). A gender-neutral approach may not only reduce 
HPV-related diseases in males but will also reduce HPV infection and transmission to females. 
This will eventually result in a reduction in the pool of circulating vaccine-typed infectious virus 
in a community (Lee and Garland, 2017). Despite, the controversies surrounding the cost-
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effectiveness of vaccinating boys, many high-income countries have started offering the vaccine 
to boys as it has been demonstrated that the benefit in reducing HPV infections by vaccinating 
both genders outweigh the cost (Machalek et al., 2017). 
In 2014, only 1% of young females ages 10-20 years living in resource-limited countries were 
reported to have been fully vaccinated (Bruni et al., 2016). Although there may be an increase 
in HPV vaccine coverage since then, the availability of HPV vaccine in resource-limited countries 
is still reported to be low. Therefore, it may take several decades for these countries to include 
boys in their vaccination programs. 
1.9 Methods for detecting genital HPV infections by screening 
Secondary cervical cancer prevention refers to screening of women at risk of cervical cancer, 
most of whom are without symptoms, with the aim of detecting and treating precancerous changes, 
which may, if not treated, lead to cancer (WHO, 2014). 
1.9.1 Detection of HPV by nucleic acids 
The HPV genomes and its transcripts can be directly detected using hybridisation procedures such 
as Northern and Southern blots, in-situ hybridisation, dot blots, Hybrid Capture™.  HPV DNA 
and RNA can also be detected using PCR techniques and genotypes identified by DNA 
sequencing. 
1.9.2  HPV DNA detection and sequencing 
Several screening methods are now available to identify women that are at risk of developing 
cervical cancer. However, an ideal clinical test should be able to correctly identify all women who 
have cervical diseases (sensitivity) and those who do not have cervical diseases (specificity). 
Therefore, ideally, a cervical cancer screening test should have a sensitivity of 100% to detect all 
true positive cases, however, this is rare. The two most common methodologies widely used for 
the detection of genital HPV are the Hybrid Capture™ II and PCR with consensus primers. Both 
assays have equivalent sensitivities (> 90%) and specificities (> 80%) and are suitable for high 
throughput testing, and for automation processing; therefore, they are both useful for large 
epidemiological studies and in clinical settings (Söderlund-Strand et al., 2005). However, many 
of these techniques have their advantages and disadvantages in detecting genital HPV. The 
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consensus primers target the highly conserved region of the HPV L1 gene and have the potential 
to detect more than 30 HPV types. They are widely used in PCR protocols to detect genital HPV 
and the most common types used are: single consensus primers GP5/6 and its modified version 
GP5+/6+ that amplifies 150 bp (base pair) fragment of the L1 gene, multiple primers MY09/11 
and its modified version PGMY09/11 (450 bp) and SPF, which amplifies a smaller fragment 
(65 bp) of the L1 gene. (Gravitt et al., 2000; Jacobs et al., 1995; de Roda Husman et al., 1995). 
Although these consensus primers can detect a broad range of HPV types and are used in many 
epidemiological studies, they may differ considerably in their ability to amplify specific HPV 
types in a multiple infections (Sòderlund-Strand et al., 2009), which contributes to discordant 
results in HPV prevalence studies.  
Currently, there are many commercial PCR-based HPV detection kits available. These include 
the Amplicor™ which detects 13 HR-HPV, linear array HPV genotyping detects 37 HPV 
genotypes (13 HR and 24 LR), Inno-LiPA assay detects 32 HPV types, and the Hybrid Capture™2 
identifies 13 HR-HPV. However, these test kits are expensive and do not discriminate between all 
HPV genotypes making them not cost-effective to use in resource-limited countries. 
On the other hand, DNA sequencing has the advantage of identifying multiple HPV genotypes 
present in clinical samples if consensus primers are used for PCR and the amplimers cloned into 
a plasmid or directly sequenced (Gharizadeh et al., 2003). Although DNA sequencing has the 
advantage of identifying multiple HPV types, direct sequencing has been shown to be unsuitable 
in detecting multiple HPV types in a sample as it only shows the overexpressed type (Vernon et 
al., 2000). 
1.9.3  HPV RNA detection 
The detection of HPV viral RNA transcripts has also been employed to evaluate the expression 
of E6/E7 HPV genes in infected cells by using reverse transcriptase PCR (RT-PCR) and 
quantitative (q) RT-PCR (Culp and Christensen, 2003). Furthermore, studies have shown that 
the detection of E6/E7 transcripts of HR-HPV can show the persistent HPV type and it is more 
specific than HPV DNA detection in identifying individuals who developed high-grade cervical 
disease (Cuschieri et al., 2004(a); Molden et al., 2005). In addition, a strong correlation was seen 
between integrated HR-HPV transcript detection and the development of high-grade cervical 
lesions using HPV RNA studies (Klaes et al., 1999). HPV RNA testing in biological samples is 
 34 
 
hindered by the easy degradation of RNA compared to DNA especially after long storage; 
therefore, it may not be suitable for epidemiological studies (Habis et al., 2004). 
1.9.4 HPV screening by non-molecular techniques 
Unlike nucleic acid-based methods, non-molecular techniques used in the detection of HPV 
infections do not detect the presence of HPV but the clinical sequelae of HPV infection. Cytology 
and histology testing are widely used in the detection of precancerous and cancer cells in the 
cervix of females. In the 1970s, cytological and histological investigations associated the presence 
of koilocytes in cervical smear with HPV infection (Torre et al., 1978). The presence of koilocytes 
in histological sections may sometimes be difficult to interpret due to either the presence of 
fixation artefacts or poor dehydration techniques, which both can result in the presence of cells 
with peri-nuclear halos giving the cells a ‘koilocyte- like’ appearance (Wright et al., 2002). 
1.9.5 Papanicolaou (Pap) smear 
The cytology-based technique most commonly used especially in resource-limited countries is 
the Papanicolaou smear (Pap smear). The Pap smear can show the presence or absence of 
abnormal cervical cells consistent with the histological diagnosis of cervical dysplasia or cancer. 
Although the Pap smear plays an important role in the initial success in reducing cervical 
cancer incidence, the clinical performance of the technology is not without limitations. The Pap 
smear test has been shown to have a false negative rate between 12 - 33% due to an inadequate 
sampling of the transformation zone and /or poor fixation of cervical cells (Hartmann et al., 2002). 
The inclusion of inflammatory and necrotic materials or blood with cervical cells during collection 
has been shown to lead to inaccurate cytopathological diagnosis (Koss, 1993). Studies have also 
revealed that the Pap smear test has a sensitivity range of 30 - 86% in detecting high-grade cervical 
lesions and more than 20% of women diagnosed with cancer had a negative Pap smear results 
(Gibb et al., 2011; Koss, 1989). 
1.9.6  Liquid-based cytology 
The limitations of the Pap smear technique led to the introduction of the liquid-based cytology 
(LBC) in 1996, which is now widely used in many developed countries. Unlike the Pap smear 
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technique, where cervical cells are directly spread on a microscopic slide, the LBC technique 
employs the use of an FDA-approved cervical collection device and transport medium with 
preservative. The improvement in sample quality has increased the clinical sensitivity of LBC 
over Pap smear in the detection of high-grade lesions or cervical cancer from 86% to 93% 
(Chinaka et al., 2014; Claver et al., 2001). In addition, the automated slide processing of the 
samples is thought to minimise obscuring artefacts such as blood cells that hinder cytology result 
interpretation (Chinaka et al., 2014). The LBC technique has been demonstrated to have greater 
sensitivity in detecting glandular lesions /adenocarcinoma than the Pap smear (Wang et al., 2002; 
Schorge et al., 2002). However, a meta-analysis carried out on LBC technologies has shown that 
there was no significant difference between LBC performance over the use of Pap smear (Arbyn 
et al., 2008; Davey et al., 2006). Despite the benefits shown by LBC, studies on cost-effectiveness 
have shown the cost of LBC is very expensive compared with the Pap smear, which may hinder 
its use as a screening method in many resource-limited countries (Chinaka et al., 2014; Denny et 
al., 2006). 
1.9.7  Direct visual inspection 
In resource-limited countries, cervical cancer incidence and mortality have not been decreased by 
cytology screening and early treatment compared to in high-income countries. This may be due 
to several barriers such as lack of specialised equipment and enough technical staff with the 
necessary skills, several health-care visits before treatment is achieved, which patients may be 
loss to follow-up and limited health budget from national budgets. These challenges prompted the 
WHO to propose screening using the visual cervical inspection method as an alternative to 
cytology screening in resource-limited countries. 
The direct visual inspection (DVI) employs the use of either diluted solution of acetic acid 
(VIA) or Lugol’s iodine (VILI) in the cervix. The VIA method involves washing the cervix with 
diluted 3 - 5% acetic acid and directly examined for aceto-whitening after 1 minute. The epithelial 
cells of the cervix will appear aceto-white if infected with mucosal HPV (both HR and LR types). 
The aceto-whitening is a result of a reversible coagulation that occurs to the intracellular 
proteins, upon acetic acid application. The intracellular proteins are found in high amounts in 
neoplasia and produce dense aceto-whitening when 3-5% acetic acid is applied 
(Sankaranarayanan et al., 2007; Denny et al., 2006). Although inflamed and regenerating cervical 
epithelial cells can also become aceto-white with acetic acid, however when associated with 
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CIN is well defined because it is usually densely opaque and localised in the transformation zone 
(Gravitt et al., 2010).  In comparison with the VIA, the VILI stains the abnormal lesions 
mustard-yellow and the glycogen that is found in cervical epithelial cells is stained darker 
by the iodine. However, the iodine partially stains areas of immature squamous metaplasia, 
neoplasia or condyloma or not at all (Sankaranarayanan et al., 2004a). The application of 
DVI as a screening tool in cervical cancer prevention has been evaluated in several large 
clinical trials; these have found VIA to have sensitivity values of approximately 70% and most 
reported low specificities (Bhatla et al., 2007; Cronjé et al., 2003; Denny et al., 2002). In 
addition, all these studies have reported low negative predictive values, which is very important 
for national screening programmes (Bhatla et al., 2007; Cronjé et al., 2003; Denny et al., 2002). 
Comparison studies carried out in India and Africa on VIA with VILI, have found VILI to have 
a greater sensitivity than VIA, however, both methods have equivalent specificity 
(Sankaranarayanan et al., 2004 (a); IARC, 2005). Most evaluation trials on the efficacy of VIA 
in cervical cancer screening have used CIN 2 or 3 and cancer as the outcome measure, which 
can lead to study bias as only women positive for VIA are referred for colposcopy. In several 
publications, it has been argued that the use of CIN 2 as a measure for VIA efficacy is inconsistent 
and unreliable as majority of CIN 2 lesions regress spontaneously, therefore it would be more 
effective to use CIN 3 or CIN3+ to evaluate efficacy of VIA screening (Mittal et al., 2014; 
Moscicki et al., 2010). 
Most resource-limited countries have adopted the use of VIA for cervical cancer screening due 
to its low cost, ease of use and the test can be performed by a trained primary health care 
provider. The test results are obtained immediately making treatment of abnormal cervical lesion 
possible during the same visit (Gravitt et al., 2010; Sankaranarayanan et al., 2004(b)). However, 
the VIA screening has also been shown to have some limitations and one of its major limitations 
is its low positive predictive values (IARC, 2007; Bhatla et al., 2007). In the study of Basu et al 
(2015), 92.8% of women who had a positive result with VIA had a normal cervix or low-grade 
lesions (CIN 1) on colposcopy/biopsy. A similar finding was reported in HIV positive women 
with metaplastic changes, flat condyloma, low-grade lesions and even with cervicitis having a 
false positive result with the VIA test (Denny et al., 2002). Another limitation of the VIA is 
that there is no standardised quality control in place, which is very important due to the 
subjective nature of the test. This can cause over referrals for treatment or colposcopy, which is 
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used to evaluate women with abnormal cytological results. Despite the limitations highlighted 
above, DVI may be best suited screening option for developing countries. 
1.10 Treatment of HPV-associated cervical diseases 
Currently, there is no treatment for HPV infection; screening and treatment of pre-invasive 
cervical lesions are the only available options to prevent progression to cervical cancer (WHO, 
2013). Cervical pre-cancerous lesions can be treated using ablation methods, which include 
destroying abnormal tissues by burning or freezing (cryotherapy) or surgical removing the 
abnormal tissue (cone biopsy or loop electrosurgical excision procedure [LEEP]). In resource- 
limited countries, where cervical cancer screening programmes are available, cryotherapy is most 
commonly used for the treatment of pre-cancerous lesions (WHO, 2011). However, when the 
lesion is large, LEEP is mostly used to surgically remove the affected tissue. 
Treatment of invasive cervical cancer is mainly through radiotherapy, but the combination of 
chemotherapy with radiotherapy has been shown to be more effective in terms of survival rate 
than radiotherapy or surgery alone (Ryu, 2002). Chemotherapy with platinum compounds such 
as cisplatin can be used in conjunction with surgery or radiotherapy or can be used alone as 
palliative care in advanced or recurrent disease. Depending on the stages of the disease, cone 
biopsy to simple or radical hysterectomy and pelvic lymphadenectomy may be performed 
(Shepherd et al., 2001). However, dual therapy such as surgery and radiotherapy are more 
expensive, and the risk of complication is known to be greater than a single radical treatment 
(Waggoner et al., 2003). 
1.11  Sexually Transmitted Infections (STIs)  
Sexually transmitted infections (STIs) are of major public health importance as they 
predominantly affect adolescents and young adults and have complications which constitute a 
great socio‐economic burden. Complications resulting from failure to diagnose and treat infections 
include pelvic inflammatory diseases (PID), infertility, ectopic pregnancy, chronic pelvic pain and 
cervical cancer. The impact on foetuses and newborns can be devastating, as manifested by 
miscarriages, stillbirths, neonatal deaths, mental retardation, neonatal conjunctivitis and 
pneumonia (Yohannes et al., 2013; Boyer et al., 2006). 
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Currently, approximately half a billion STI cases occur each year, worldwide with a million new 
infections acquired every day (WHO, 2015). Out of the estimated, 357 million STI cases reported 
globally for each year, four of the most common STI namely; gonorrhoea, syphilis, Chlamydia, 
and trichomoniasis account for 78 million, 5.6 million, 131 million and 143 million, respectively. 
The impact of these infections is increased due to their potential to facilitate transmission and 
acquisition of HIV infection (WHO, 2014; GDHS, 2013). Studies carried out in African countries 
with a high HIV prevalence have found that HIV infectiousness is increased by more than 5% per 
sexual contact if either sexual partner are infected with an STI as compared to 0.2%, if neither 
partner are infected (Johnson et al., 2012; Boily et al., 2009). Chlamydia and gonorrhoea are 
major precursors for adverse reproductive health outcomes and untreated chronic infections 
account for most health care visits with serious health consequences and additional economic and 
social implications (Ginindza et al., 2017; Basera et al., 2016). 
Global estimates have shown Chlamydia trachomatis (C. trachomatis) prevalence in women to 
be 4.2% with a region prevalence range of 1.8% - 7.6%. The highest prevalence was reported in 
the regions of the Americas (7.6%) and Western Pacific (6.2%) compared to 3.8% reported for 
the African region. In comparison, a higher global estimate prevalence of other STIs such as 
trichomoniasis (11.5%), gonorrhoea (1.7%) and syphilis (1.8%) was reported for the African 
region (Newman et al., 2015; WHO, 2015). Possible contributing factors to this finding could 
be increased condom used, better socio-economic and clinical STI services in developed countries. 
The 3.8% C. trachomatis global estimates reported for the African region could possibly be 
because most African countries do not screen for C. trachomatis and most infections are 
asymptomatic, which can also confound the reported prevalence. In addition, a lack of laboratory 
testing may lead to underestimation of C. trachomatis prevalence in Africa compared to European 
countries that screen and report cases annually. 
In recent years, evidence-based studies have emerged associating Ureaplasma, Mycoplasma 
genitalium (M. genitalium) and Mycoplasma hominis (M. hominis) with sexually transmitted 
infections. M. genitalium is widely accepted as a ‘true’ STI pathogen compared to Ureaplasma 
species, which are common commensals found in the lower genital tracts in healthy individuals 
with a colonisation rate of 40 - 80% in sexually active asymptomatic women and a lesser 
frequency of 20 - 29% in healthy men (Xiao et al., 2010; Kong et al., 2000). Colonisation of the 
female urogenital tract with Ureaplasma is linked to hormonal status and persistence colonisation 
can lead to ascending infection from the vagina to the upper reproductive tracts with a variety of 
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clinical outcomes such as infertility, adverse pregnancy outcomes and bronchopulmonary 
dysplasia in neonates (Yamazaki et al., 2012; Waites et al., 2005). 
Infections with Ureaplasma in men are normally subclinical but can lead to epididymitis, 
spermatocystitis, prostatitis and urethritis as well as a complication in spermatogenesis, sperm 
function and motility (Zhang et al., 2014). Ureaplasma associated changes in the sperm 
membrane are known to induce the production of anti-sperm antibodies, which are associated 
with a higher risk of infertility (Softer et al., 1990). However, the influence of Ureaplasma 
on sperm function is controversial. A reduction in penetration rate in hamster oocytes was 
observed when the sperm was infected with Ureaplasma in an in-vitro study (Guillet-Rosso et 
al., 1987). A similar finding of a reduction in pregnancy rates has also been reported after in-vitro 
fertilisation (IVF), linking IVF failure to Ureaplasma infected sperm (Knox et al., 2003). In 
contrast to these findings, fertility and pregnancy with IVF were found not to be influenced by 
the colonisation of the sperm with Ureaplasma but endometritis associated with Ureaplasma 
(Kanakas et al., 1991). However, significant spontaneous abortion rates have been observed in 
women, whose male partners were infected with Ureaplasma (Stovall et al., 1993). These 
findings, therefore suggest a pivotal role for male partners in female infections.  
The available evidence regarding pathogenicity and clinical importance of Ureaplasma is yet 
inconclusive (Yamazaki et al., 2012; McKechnie et al., 2011), leading to the controversial debate 
on routine screening and treatment of the infection in reproductive age women. However, the 
antibiotics o f  choice for treating Ureaplasma infections include those that inhibit bacterial protein 
synthesis (macrolides and tetracyclines) and DNA synthesis (fluoroquinolones) as Ureaplasma 
are innately resistant to the beta- lactams, sulfamethoxazole, trimethoprim and rifampin 
antibiotics (Waites and Taylor –Robinson, 2011). On the other hand, M. genitalium is linked to 
causing non-gonoccocal urethritis (NGU) in men (Kim et al., 2011). The organism has also been 
implicated in causing cervicitis and was isolated in approximately 29% of women with cervicitis 
attending an STI clinic (Donders et al., 2009). Women with salpingitis and endometritis were 
found to be unresponsive to Cefoxitin and treatment failure was associated with M. genitalium 
infections (Ekiel et al., 2009 (b); Haggerty et al., 2008). There may have been a study bias in 
Haggerty et al., (2008) study, as it was a follow-up study on women with PID. Recurrent infections 
can occur in participants that have engaged in risky sexual behaviours during treatment, 
confounding treatment failure. Although, a study carried out on Peruvian women with 
spontaneous preterm birth has shown evidence of an association between M. genitalium and 
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preterm birth (Hitti et al., 2010), its role in preterm birth delivery is less defined. Nonetheless, 
its role as an STI pathogen in men with NGU and reproductive tract infections in women has been 
documented (Kim et al., 2011; Hilton et al., 2010). 
1.11.1 Association of STIs with HPV infection 
Several studies regarding the role of STIs in the development of CIN and invasive cervical cancer 
in HPV-infected women have been carried out. Several previous studies showed that specific STI 
pathogens including C. trachomatis, herpes simplex virus-2 (HVS-2), Mycoplasma species, 
Ureaplasma species, and Trichomonas vaginalis (T. vaginalis) were associated with HPV 
infection, CIN, and cervical cancer risk. Although a few studies reported no association between 
C. trachomatis, HSV-2 infections with HPV, CIN, or cervical cancer risk (Bhatla et al., 2013; 
Dahlström et al., 2011). 
C. trachomatis is the most frequently investigated pathogen and association with HPV infection, 
especially high-risk HPV, CIN, and invasive squamous cervical carcinoma (SCC) have been 
demonstrated (da Silva Barros et al., 2012; Verteramo et al., 2009). However, no association 
between C. trachomatis with glandular lesions including in-situ adenocarcinoma, invasive 
adenocarcinoma, or adeno-squamous was found; therefore, the role of C. trachomatis in cervical 
carcinogenesis may be restricted to SCC (Quint et al., 2009). According to a meta-analysis on 
invasive cervical cancer by IARC, HSV-2 co-infection with HPV may increase the risk of invasive 
cervical carcinoma including both squamous and adenocarcinoma (Smith et al., 2004). In addition, 
T. vaginalis, Mycoplasma, and Ureaplasma species have been associated with HPV infection and 
abnormal cervical cytology (Lazenby et al., 2014; Donders et al., 2013; Biernat-Sudolska et al., 
2011). 
Although the risk association between STI pathogens with HPV is not well understood, it is 
perhaps a result of an inflammatory reaction at the cervix leading to microabrasion of the 
epithelial cells. The damage of the epithelial cells allows HPV to have direct access to the 
basal epithelial cells, where the virus initiates its life cycle. C. trachomatis is well known in 
causing cervicitis and HSV-2 causes periodic ulcer sores, therefore co-infection with these 
pathogens may induce a more profound inflammatory reaction (Rasmussen et al., 1997).  A 
body of literature has suggested that cervical carcinogenesis may be associated with chronic 
inflammation (Castle and Giuliano, 2003; Chan, 2002). Furthermore, cyclooxygenase-2 (COX-
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2), a prostaglandin G/H synthetase enzyme that is induced in inflammatory cells such as 
macrophages upon stimulation by cytokines and endotoxin (Oshima et al., 1996; Xie et al., 1992) 
was found to be expressed at an increased level in human cervical cancer specimens (Kulkarni et 
al, 2001), this further suggests that inflammation may be linked to cervical carcinogenesis. 
Prostaglandin E2 (PGE2), which is mediated by COX-2 during inflammatory reactions, is a 
potent inducer of interleukin (IL)-10. Both PGE2 and IL-10 are known to suppress the cell-
mediated TH1 responses by inhibiting the production of IL-12 by antigen presenting cells (APC) 
(Harizi et al., 2002). The suppression of IL-12 production during chronic inflammation causes a 
shift from TH1 cell-mediated immune response to TH2 humoral response favouring HPV 
persistence (Moscicki, 2005). Furthermore, an association has been documented between 
cervicitis caused by Ureaplasma infection and high-grade lesions in women infected with HR-
HPV genotypes (Castle et al., 2001). This association may be due to prolonged co-infection, C. 
trachomatis endotoxin, for example, may also promote HPV persistence through a decrease in 
functional antigen presenting cells in the genital tract; thereby inhibiting cell-mediated immune 
response. Similarly, an association between HPV and HIV has been established. The recruitment 
of CD4
+
T cells and macrophages induces inflammatory cytokine production, enhancing the 
replication and reverse transcription of the HIV virus thus facilitating HIV progression to 
Acquired Immuno-deficiency Syndromes (AIDS) (Gage et al., 2000).  
1.11.2  Diagnosis and management of STIs   
The main aim of STI primary control is to interrupt STI transmission and prevent adverse 
consequences through adequate diagnostics, and early and effective treatment. It has been 
demonstrated that control of STIs could contribute considerably to reducing the incidence of HIV 
infection, therefore the syndromic management approach was introduced in resource-limited 
countries as a secondary prevention control. 
STIs are diagnosed in resource-limited countries using the syndromic management approach in 
which clinical algorithms for commonly presenting signs and symptoms (e.g. urethral discharge 
or genital ulcer disease [GUD]) are used in case management. The algorithm provides treatment 
for the commonest biological causes of the syndrome. For example, for GUD, treatment is 
provided concomitantly for the two commonest causes, chancroid and syphilis. Other STI 
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syndromic indicators include vaginal discharge, male urethral discharge, lower abdominal pain, 
scrotal swelling and ophthalmia neonatorum (WHO, 2013). 
These indicators may be important but are not enough to determine the extent and characteristics 
of the changing trend in new and re-emerging pathogens and their antibiotics resistance profile. 
The signs and symptoms of the different STIs are not specific and therefore make accurate clinical 
diagnosis difficult. Furthermore, the syndromic approach for vaginal discharge is poorly 
predictive of the presence of cervical chlamydia and/or gonorrhoea. To improve the sensitivity 
and specificity of the syndromic management algorithm, risk assessment (for example, age < 21 
years, more than one sexual partner, new partner in the last 3 months) was introduced by the WHO, 
but this has not been very successful (Newman et al., 2015; Yohannes et al., 2013). 
In addition, several limitations hinder wide acceptability of syndromic management and these 
include, overtreatment of patients and those with mixed infections may be inadequately managed 
(WHO, 2015). Such patients may have to return for further investigation, suffer prolonged 
morbidity and then be re‐treated at a further cost. Another limitation of this approach is 
asymptomatic cases are missed. The adaptation of syndromic management in the fight against 
HIV by resource-limited countries has been effective in reducing the burden of N. gonorrhoeae 
infection more than other STIs (WHO, 2015). Infection with N. gonorrhoeae is normally 
symptomatic in men; therefore, early treatment reduces the transmission rate. However, non-
treatment of sexual partners can cause re-infection and prolong exposure to antibiotic treatment, 
which can lead to antibiotic resistance.  
1.12  Study rationale 
With recent development of introducing HPV vaccination into The Gambia Expanded Programme 
on Immunization (EPI) and the addition of cervical cancer as AIDS-defining illness by the WHO, 
there is a strong need to have current baseline data on HPV infection rates and circulating 
genotypes for future evaluation of the quadrivalent vaccine in the prevention of HPV infections 
and related diseases in The Gambia. Moreover, the current investigational tools available for 
cervical cancer screening in The Gambia are the VIA and Pap smear tests, which have a lower 
sensitivity in comparison to HPV DNA tests (Cuzick et al., 2006). Secondly, Pap smear screening 
is not systematic in The Gambia and the quality control guidelines for conventional smears are 
often not implemented. Additionally, education of the general population regarding the connection  
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between HPV and cervical cancer, and the necessity to do regular Pap smear for detecting 
precancerous cervical lesions is an utmost importance. Furthermore, to reduce the incidence of 
cervical cancer, it is important not only to diagnose and treat CIN through cytological screening 
but also to identify and eliminate co-factors that are involved in HPV persistence and development 
into CIN and cancer. Therefore, additional evaluation of STIs will be helpful to appropriately 
diagnose and treat patients with oncogenic high-risk HPV result and abnormal cervical cytology. 
1.12.1  Study Aims 
The aims of the study were to establish the circulating HPV genotype distribution, its co-infection 
with selected STI pathogens, and socio-demographic and behavioural risk factors that may be 
associated with HPV/STI in The Gambia. 
1.12.2  Study Objectives 
The following objectives were investigated: 
• To determine HPV prevalence and genotype distribution amongst reproductive age women  
• To determine the intratype variability of the Gambia high-risk HPV sequences and 
compare these with previously published high-risk sequences of HPV isolates from other 
geographical locations  
• To determine HPV co-infection with selected genital pathogens 
• To determine the prevalence and distribution of Ureaplasma and other selected STI 
pathogens  
• To determine socio-demographic and risk factors associated with HPV/ STI  
• To establish HPV sero-prevalence and estimate time of HPV sero-conversion in HIV-
positive women  
• To establish the cytological changes of HPV acquisition and viral persistence in the cervix 
of HIV- positive women. 
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1.12.3  Expected study outcomes 
Data obtained from this study will contribute to existing knowledge and provide the basis 
for The Gambian Government and the Ministry of Health and Social Welfare (MOHSW) to: 
• Decide on reviewing the current indicator tools for STI management 
• Strengthen laboratory evidence base STI diagnosis 
• Have baseline data on circulating oncogenic HPV type in urban Gambia 
• Introduce HPV vaccination on the population at risk 
• Monitor circulating oncogenic HPV genotypes through screening 
• Strengthen the information and communication on HPV and STI prevention and control 
through: 
➢ education, 
➢ raising awareness and other local strategies to promote behaviours that reduce the 
risk of HPV/STI transmission. 
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2 Sample collection and processing 
2.1 Study location 
This study was a collaborative work between Edward Francis Small Teaching Hospital (EFSTH), 
The Gambia and the University of Westminster, London. The EFSTH (formerly the Royal 
Victoria Teaching Hospital) was built in 1953 and is a 650-bedded tertiary hospital located in the 
capital city, Banjul. 
The EFSTH was chosen for the study location because it is the main referral and the only teaching 
hospital in the country with various other departments such as Obstetrics and Gynaecology, 
Internal Medicine, Paediatrics, General Surgery and Accident/Emergency, all devoted to care of 
adult and paediatric medical cases. The EFSTH also runs a busy polyclinic outpatient department 
seeing over 100,000 cases a year. The polyclinic is where the sexually transmitted infection 
(STI) and family planning (FP) clinics are located.  
The infectious disease clinic (IDC) is also in EFSTH and deals with the management of patients 
diagnosed with HIV. These clinics attend to patients from all over the country with more than 
80% from the capital city, Banjul, West Coast Region (WCR) and Kanifying Municipal Council 
(KMC). These three regions are the most populated urban regions of the country and the residents 
are from multicultural backgrounds. 
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Figure 2.1 Map of The Gambia showing the capital city, Banjul where the 
EFSTH  
 
hospital is located (Google map, 2018) 
https://www.google.com/search?ei=PsZW97UKIiIgAb9j7rgAQ&q=The+Gambia+ma
p&oq.  
 
 
2.2 Ethics 
Ethical considerations for participants’ recruitment and sample collection were reviewed and 
approved by The Gambia Government and Medical Research Council (MRC) Joint Ethics 
Committee, Gambia (Appendix E1). Ethical approval was further granted by the University of 
Westminster Research Ethics Committee, London (Appendix E2). Permission was granted for 
the use of laboratory facilities at the clinics for sample reception and preliminary processing by 
the Chief Medical Director of EFSTH (Appendix E 3). In addition, approval was also given to 
use the facilities in the Medical Microbiology laboratory for the processing and storage of 
clinical samples through-out the sample collection period in The Gambia. 
2.2.1 Study design  
This study involved two related studies, a case-control and a cohort longitudinal study. A 
sample size of 346 (173 samples from each study group [case and control], respectively) was 
estimated for the study based on the HPV prevalence rate reported from a previous study (Wall 
et al., 2005).  
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The sample size was calculated using a simple Daniel formula:  
 
          n = Z2 P (1- P) 
 
 
where n = sample size 
Z = Z statistic for a level of confidence of 95%, Z value of 1.96, which is conventional was 
used 
P = expected prevalence (a prevalence of = 0.13 (13%) was used based on the HPV 
prevalence reported (Wall et al., 2005) 
d = precision (d was set at 0.05 (5%), to give the width of confidence interval of 10% (0.1).  
 
Reproductive age women, 20 – 49 years old attending a sexual health clinic / Infectious disease 
clinic (STI/IDC) with symptoms of STI or diagnosed with HIV were recruited in the case 
group. HIV-positive participants with CD4
+ 
T cell count ≥350 cells/mm3 and not on 
antiretroviral therapy (ART) during the time of recruitment were further recruited into a cohort 
group for a longitudinal study and follow-up every 9 months for 24 months. 
Similarly, reproductive age women, 20 - 49 years old with no clinical symptoms of STI 
attending the family planning clinic for contraceptive services were recruited into the control 
group. 
Inclusion criteria 
Participants recruited into the case group had one or more of the following clinical symptoms: 
• Vaginal itching \ discharge with fishy or strong odour 
 
• Pain or burning when urinating 
 
• Bleeding between periods 
 
• Pain during sex 
 
• Sores, skin rashes with rough red or reddish-brown spots on hands or feet 
 
• Genital warts 
 
• Lower abdominal pain 
 
• HIV 
Exclusion criteria 
Participants were excluded from the study if they were diagnosed with cervical cancer or 
cervical lesions, lived outside the study area, were pregnant or were on their menstrual cycle at 
   d2 
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the time of sampling, had reached menopause or were above 49 years old. None of the 
participants was diagnosed with cervical cancer or cervical lesions at the time of recruitment. 
Participation was voluntary, and participants were given a participants’ information sheet (PIS, 
Appendix E 5), which contained detailed information about the project and the reasons for their 
participation in the study. Recruited participants were asked to sign consent forms and copies 
of these were kept at the respective clinics (Appendix E6). 
2.2.2 Data and sample collection 
Recruitment of participants and sample collection was carried out between 2015 and 2017. 
A total of two hundred and thirty-five women (n = 235) attending the STI/IDC and family 
planning clinics at the EFSTH polyclinic, Banjul were recruited. A socio-demographic and risk 
factor questionnaire (Appendix E7) was administered to each consented participant. Each 
collected sample has a unique identifier number that corresponds with the one on the 
questionnaire. All questionnaire entries were double-checked for missing information and all 
entry queries were resolved immediately. 
2.2.3 Case-control study 
Two paired swab samples, endocervical (ECS) and high vaginal swab (HVS) were collected 
from each participant. Participants were subjected to pelvic examination by a clinician or 
qualified healthcare provider. Before the cervix and vagina were sampled, a sterile cotton-
tipped end swab was used to clean the cervical and vaginal canal of any discharge. Swabs 
were inserted and rotated through 360
o 
into the cervical transformation zone and vaginal canal 
to collect the samples. One endocervical and one high vaginal swab were used for routine 
microbiological identification of Streptococcus agalactiae, Candida albicans, Neisseria 
gonorrhoeae, bacterial vaginosis, and Trichomonas vaginalis. Initial processing of the samples 
was carried out at the polyclinic laboratory within 30 minutes of collection and transported to 
the Department of Medical Microbiology, EFSTH. 
The two remaining swabs (endocervical and high vaginal swab) for nucleic acid amplification 
of HPV, C. trachomatis, N. gonorrhoeae, Ureaplasma parvum / urealyticum and M. genitalium 
where immediately placed in a specimen transport media, M4RT, micro-test (Oxoid, 
Basingstoke, UK) and stored at -70
o
C until ready for shipping to the University of Westminster, 
United Kingdom, London. All participants were sampled once except in participants in the 
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longitudinal study, who were sampled at an interval of 9 months for 24 months. During this 
period a total of nine hundred and forty (940) swab samples (two-paired samples, an 
endocervical and high vaginal swabs from each participant) were collected for the case-control 
study. 
2.2.4 Longitudinal cohort study 
Twenty-nine (n=29) of the 235 recruited participants were diagnosed with human 
immunodeficiency virus (HIV) at the IDC clinic. The HIV status of these participants was 
confirmed by rapid HIV screening using point of care determine® and first response rapid HIV 
test kits (Abbott, UK). These participants were grouped into a cohort and were followed 
up and sampled every 9 months in a longitudinal study. 
Papanicolaou smears (Pap smears), blood and endocervical swab samples were collected and 
sexual risk behaviour captured for each visit. Pap smears were collected from the endocervix 
and ectocervix using a cytobrush and wooden Ayre’s spatula by a clinician. The slides were 
fixed in 70% (v/v) alcohol and stored at room temperature. The endocervical swab for HPV 
screening was placed immediately into a specimen transport medium, M4RT, micro-test 
(Oxoid, Basingstoke, UK) and stored at -70
o
C until ready for shipping. Venous blood samples 
for HPV antibodies were collected in a non-anticoagulated tube and centrifuged at 12,000 g for 
5 minutes. The serum was aliquoted into cryovials, labelled and stored at -20
o
C until ready for 
shipping. 
All samples for further processing were shipped to the University of Westminster, United 
Kingdom, London on dry ice using an approved courier and following International Air 
Transportation Association (IATA) instructions on packaging and transportation of biological 
and dangerous goods. 
2.3 Materials 
Materials used in this study were purchased from selected companies including Qiagen 
(Crawley, UK), VWR Ltd (East Grinstead, UK), Sigma–Aldrich (Dorset, UK), Fisher Scientific 
Ltd (Loughborough, UK), National Institute of Biological Standards and Control (NIBSC, 
Hertfordshire, UK) and Addgene Ltd (USA, American). All PCR and DNA sequencing kits 
were obtained from Qiagen and Sigma–Aldrich Ltd, UK. Solid media used for isolating 
bacterial strains were obtained from Oxoid Ltd (Basingstoke, UK) and Fisher Scientific Ltd 
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(Loughborough, UK). They included Sabouraud dextrose agar (SDA) agar, Chocolate agar 
(CA), Blood agar (BA) and Luria-Bertani agar (LB). 
2.3.1 Preparation of media, buffers and stock solutions 
Solid media 
 
The solid media used in this study for isolation of pathogens were blood agar (BA), chocolate 
agar (CA), LB agar and Sabouraud dextrose agar (SDA).  Briefly, the required powdered agar 
(Oxoid, Basingstoke, United Kingdom) were weighed according to manufacturer’s instructions 
and dissolved in distilled water. The mixture was thoroughly mixed to dissolve by either 
heating on a hot plate or by gently stirring or swirling until the entire powdered agar was 
dissolved. The dissolved mixture was sterilised by autoclaving at 121
o
C for 15 minutes. The 
autoclaved media was left to cool to about 50
o
C before supplements such as 7% (v/v) 
defribinated sheep blood (SR0051) were added in the respective media. Every batch of media 
that was prepared was quality controlled for both sterility and the ability to support the growth 
of target organisms.  Bacterial reference strains, Streptococcus pyogenes ATCC®19615 was 
used for the blood agar, Neisseria gonorrhoeae ATCC® 49981™ for chocolate agar, and 
Candida albicans ATCC®10231 for Sabouraud dextrose agar. These reference strains were 
cultured on each of the respective media as media controls. The cultured plates (media quality 
check) and uninoculated plates (sterility check) were incubated for 48hrs at 35 - 37
o
C under 
aerobic conditions and in a moist atmosphere enriched with CO2 (5%). All batches that passed 
quality controls were labelled and stored at 2 - 8
o
C for no more than a week. 
 
Preparation of buffers and liquid media 
 
All buffers and liquid medium used in this study were prepared according to the manufacturer’s 
guidelines and where appropriate, sterilised by autoclaving at 121
o
C for 15 minutes. The 
buffers used were sterile 0.85% physiological saline, phosphate buffer saline (PBS), 50X 
concentration of Tris-acetate- ethylene – diamine- tetra-acetic acid (TAE) buffer (stock), 1X 
TAE buffer (v/v) from stock, 0.5mg /L ethidium bromide, 3% (v/v) acid alcohol, 10% (w/v) 
KOH, 2.5% (w/v) Safranin, 95% (v/v) ethanol, Crystal violet and Grams iodine. The liquid 
medium used in this study was LB broth. 
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2.4 Questionnaire 
A socio demographic and risk factor validated questionnaire consisting of 39 questions 
(appendix E 7) per questionnaire was administered to participants and entered into a database. 
Electronic data capture was done with a database created using Epi™ info version 7 
(https://www.cdc.gov/epiinfo). A total of 235 questionnaires were administered to participants 
who consented and entered into the database. Before statistical analysis was carried out, the 
database was cleaned, validated and verified by double-entry data management method. 
 
2.5 Methods for microbiological identification 
2.5.1 Bacterial vaginosis and Trichomonas vaginalis 
Detection of bacterial vaginosis and T. vaginalis was carried out at the clinic’s site laboratory.  
The high vaginal swabs were used for direct wet mount microscopy, detection of fishy amine 
odour (‘Whiff’ test) when mixed with 10% (w/v) potassium hydroxide (KOH) preparation and 
vaginal pH determination (range 4.0 – 7.0). The wet preparation was viewed microscopically 
for the presence of ‘clue cells’, yeast cells, and motile T. vaginalis. Bacterial vaginosis was 
diagnosed using Amsel’s clinical criteria, which included the presence of any three of the 
following:  1) homogeneous white vaginal discharge; 2) a vaginal pH ≥ 4.6; 3) the release of 
fishy amine odour when 10% (w/v) of KOH was added to a vaginal fluid sample; 4) the 
presence of clue cells on Gram stained microscopic examination representing about 20% of 
vaginal epithelial cells (Amsel et al., 1983). 
2.5.2 Isolation of Neisseria gonorrhoeae, Streptococcus agalactiae and   
Candida albicans 
Endocervical swabs were cultured directly on BA, CA, SDA agar plates at the clinic’s site 
laboratory and transported immediately to the Department of Medical Microbiology 
laboratory, EFSTH. Both BA and CA plates were incubated overnight at 35°C - 37°C under 
aerobic and in a moist atmosphere enriched with CO2 (5%) conditions for up to 24 - 72 hours 
for identification of Streptococcus agalactiae and Neisseria gonorrhoeae. SDA plates were 
incubated micro-aerophilically at 25
o
C - 36
o
C for 24 - 48hrs to isolate Candida albicans or 
Candida species. Colonies of interest were subcultured and incubated overnight for pure 
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isolates. Gram staining was performed on all isolated organisms. Pure colonies from overnight 
cultures were selected for biochemical identification. All tests were carried out according to 
the manufacturers’ instructions. 
2.6 Biochemical tests for identification of isolated organisms 
2.6.1 Streptococcus agalactiae 
A catalase test was performed on all pure β-haemolytic Gram- positive cocci colonies from 
overnight cultures using 3% (v/v) hydrogen peroxide (Reiner, 2010). The catalase test was 
used to differentiate bacteria that produce the enzyme catalase, such as Staphylococcus 
organisms from non-catalase producing organisms such as Streptococcus. All β-haemolytic 
catalase negative isolates were further selected for biochemical and Lancefield group 
identification using commercial latex serological test, Streptex™ rapid latex agglutination test 
(Thermo Fisher Scientific, Loughborough, United Kingdom). 
2.6.2 Candida albicans 
A Gram stain was carried out on all suspected Candida colonies for the identification of yeast 
cells and in addition, the germ tube test (GTT) was also performed. In brief, two to three 
colonies of suspected Candida colonies were emulsified in a 0.5 ml of human serum in 
a plain tube. The mixture was incubated at 37
o
C in a water bath for 3 – 4 hours. A wet 
preparation was prepared and observed microscopically for the presence of budding cells 
and/or pseudo-hyphae. Isolates that have budding cells and/or pseudo-hyphae were 
classified as Candida albicans and those without budding cells and/or pseudo-hyphae were 
classified as Candida species. 
2.6.3 Neisseria gonorrhoeae 
Gram staining was performed on N. gonorrhoeae suspected colonies for the presence of Gram-
negative diplococci. A catalase test was also carried on suspected N. gonorrhoeae isolates with 
30% (v/v) hydrogen peroxide (Reiner, 2010). N. gonorrhoeae isolates produced a positive 
reaction with a strong bubbling within 1-2 seconds. An oxidase test was also carried out on 
Gram- negative diplococci colonies using oxidase reagent strips (Sigma- Aldrich, Dorset, UK). 
These strips are impregnated with oxidase reagent N-N, Dimethyl-p-phenylenediamine and 
alpha-naphtol solution. Briefly, the paper strip was placed on a clean microscopic slide and a 
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suspected N. gonorrhoeae colony was picked using a wooden applicator stick. The colony 
was gently rubbed onto the test area of the strip. Similarly, Pseudomonas aeruginosa, a 
known oxidase positive and Escherichia coli, oxidase negative organisms (obtained from the 
Department of Medical Microbiology laboratory stock, Gambia) were added to the appropriate 
areas of the strip to act as controls. Suspected oxidase positive organisms oxidise the 
phenylenediamine in the reagent and a purple colour was observed within 10 seconds. All 
presumptive N. gonorrhoeae isolates were further confirmed using analytical profile index 
(API NH; Biomerieux, UK) following the manufacturer’s instructions. 
2.7 Antibiotic susceptibility determination of Streptococcus 
agalactiae and Neisseria gonorrhoeae isolates 
All S. agalactiae and N. gonorrhoeae isolates were tested for their antibiotic susceptibility 
profile according to the European Committee on Antibiotics Susceptibility Testing (EUCAST, 
2015) and British Society for Antimicrobial Chemotherapy (BSAC, 2015) guidelines. 
Antibiotic susceptibility testing (AST) was carried out using the disc diffusion method on BA 
plate for S. agalactiae and CA plate for N. gonorrhoeae (Oxoid, Basingstoke, UK), 
respectively. Two to three colonies were picked depending on the size of the colony using a 
sterile disposable plastic bacteriological loop and emulsified in 0.85% (v/v) sterile 
physiological saline. The turbidity of the suspension was compared with 0.5 McFarland 
turbidity control and adjusted by either adding colonies or adding sterile saline. A 1:100 
dilution was prepared from the suspension and evenly streaked onto a BA (S. agalactiae) or 
CA (N. gonorrhoeae) plate using a sterile cotton swab to produce a confluent growth. 
2.7.1  Disc Diffusion test on isolates 
All S. agalactiae isolates were tested against the following selection of antibiotic (Oxoid, 
Basingstoke UK): Ampicillin (Amp, 10 µg), Cefuroxime (CRX, 30 µg), Clindamycin (2 µg), 
Erythromycin (ERY, 15 µg), Tetracycline (TE, 30 µg), and Penicillin (P, 10 units). Neisseria 
gonorrhoeae isolates were tested against the following selection of antibiotics: Ciprofloxacin 
(CIP, 5 µg), Cefotaxime (CTX, 30 µg), Tetracycline (TE, 30 µg), Penicillin (P, 10 units), 
Ceftriaxone (30 µg). An antibiotic disc dispenser was used to place the antibiotic discs unto 
the inoculated plates for accuracy of the distance between the discs. The plates were incubated 
aerobically at 35°C - 37°C for 18 – 24 hours. The zones of inhibition observed after incubation 
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were measured using a calibrated calliper and test results were interpreted according to 
European Committee on Antimicrobial Susceptibility Testing (EUCAST, 2015) and British 
Society for Antimicrobial Chemotherapy (BSAC, 2015) guidelines. 
 
2.8 Nucleic acid analysis 
2.8.1 Preparation of swab samples for DNA extraction: 
Swab samples were transported in a specimen transport medium, Micro Test™M4® (Fisher 
Scientific, UK) for viruses, Chlamydia, Mycoplasma and Ureaplasma. The transport medium 
contains the following antibiotics Amphotericin B, Vancomycin and Colistin to inhibit the 
growth of competing bacteria and yeast. The samples were homogeneously mixed, and the 
swab sticks discarded. An aliquot of 1.5 ml of the suspension was placed in an Eppendorf tube 
and centrifuged at 13,000 g for 15 minutes and the supernatant was discarded. The cell pellets 
were suspended in a 1 ml sterile phosphate buffered saline (PBS) and centrifuged at 13,000 g 
for 10 minutes. The supernatant was discarded, and the pellets were used for DNA extraction. 
2.8.2  DNA Extraction: 
DNA was extracted from the clinical specimens using QIAamp DNA mini extraction kit 
(Qiagen, Crawley, UK). 200 µl of the prepared sample was aliquoted into a 1.5 ml microfuge 
tube and 20 µl of 20 mg/ml proteinase K, and 200 µl of AL buffer were added. The 
mixture was mixed homogenously by pulse vortexing for 15 seconds and incubated at 56
o
C 
in a heat block for 10 minutes. The mixture was briefly centrifuged in an Eppendorf 5415 D 
benchtop centrifuge to remove drops from the inside of the tube lid.  200 µl of ethanol (96-
100%, (v/v) was added to the mixture and mixed by vortexing for 15 seconds before briefly 
centrifuged.  The mixture was carefully applied to a spin column in a 2 ml collection tube 
and centrifuged at 8000 g for 1 minute. The filtrate was discarded and 500 µl of buffer AW1 
was added to the column and centrifuged as above. The filtrate was discarded and 500 µl of 
buffer AW2 was added to the column and centrifuged at 13,000 g for 3 minutes.  
The filtrate was discarded, and the spin column was centrifuged again at 14000 g for 1 minute 
to remove excess ethanol. The filtrate and the collection tube were discarded, and the spin 
column was air dried at room temperature for 10 minutes. The spin column was placed in a 
new collection tube and 200 µl of buffer AE was added and incubated at room temperature 
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for 5 minutes. The tube was then centrifuged at 8000 g for 1 minute. The spin column was 
discarded and the extracted DNA in the collection tube retained. The extraction process was 
quality controlled by including sterile distilled water in the extraction process to serve as 
template extraction (TEX) blank control in each batch of samples extracted. 
2.8.3 Quantification of DNA using Nanodrop 
The concentration of the extracted DNA was determined using Nanodrop 2000 
spectrophotometer (Thermo Scientific, Loughborough, UK). The optical density of 1 µl of 
the DNA sample was measured at 260/280 (nm).  The DNA concentration was calculated by 
the Nanodrop 2000 software. The extracted DNA was aliquoted in 50 µl aliquots in sterile 
Eppendorf tubes and stored at -20
o
C until ready for use. 
2.8.4 Primers, positive controls, and PCR. 
All primers used in this study were used in previous published studies (Yi et al., 2005, Jensen 
et al., 2004, Jensen et al., 2003, W.H.O. 2009, Gravitt et al., 2000, Kimmitt et al., 2010). A 
Basic Local Alignment Search Tool (BLAST) was carried out on all primers to check for 
specificity and binding regions of the target genes. All primers and probes used in this study 
were synthesised by Eurofins MWG, Operon, Germany. 
Unless otherwise stated, all PCR amplifications were performed with the Peltier thermal cycler, 
DNA Engine®, BIO-RAD in a 25 µL volume containing 5 µM of each primer, 1x Taq PCR 
master mix containing 2.5 units of Taq DNA polymerase, 0.2 mM deoxynucleotide 
trisphosphates, and 1.5 mM MgCl2 (Qiagen, Crawley, UK), 50 ng – 200 ng of DNA template, 
extraction control and negative control (sterile water). Positive controls used in the study were 
purchased from Genekam Biotechnology, Duisburg, Germany, unless otherwise stated. 
2.8.5 Gel electrophoresis 
All PCR amplified products were resolved in 2% (w/v) agarose gel in a 1X Tris-acetic EDTA 
(TAE) buffer. Agarose gels were prepared from crystalline powder purchased from Sigma 
Aldrich, United Kingdom. To correctly assign the PCR products the correct band size, DNA 
size markers 100 base pair DNA ladder (Sigma-Aldrich, United Kingdom) were included. The 
gel electrophoresis was run at 100 volts for 45 - 60 minutes and stained in ethidium bromide 
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for 10 – 15 minutes. The amplified PCR products were visualized under ultra violet (UV) light 
using a transilluminator. 
2.9 Histocompatibility leucocyte antigen (HLA) and β-actin PCR: 
To confirm the adequacy of the extracted cellular DNA, histocompatibility leucocyte antigen 
(HLA) and β-actin PCR were used. HLA and β-actin are house-keeping genes responsible for 
the maintenance of basic cellular functions and is expressed in all cells of organisms. These 
house-keeping genes are constantly expressed in all conditions; therefore, they are used as 
controls in an assay to facilitate the exposure of the underlying cellular infrastructure (Zhu et 
al., 2008). The thermal cycling consisted of 40 cycles of denaturation at 94
o
C for 30 seconds, 
annealing at 55
o
C for 60 seconds, elongation at 72
o
C for 2 minutes and a final extension 
step at 72
o
C for 5 minutes. Samples that were negative for HLA were retested using β-actin 
Primers (Table 1). PCR analysis was carried out on samples that showed an amplicon size of 
230 and 300 (bp) for HLA and β-actin indicating that adequate cellular DNA has been extracted 
and inhibitors were not preventing amplification. 
 
Table 2.1 HLA and β-actin primers and PCR amplicon size 
 
 
2.10 Determination of Ureaplasma parvum / urealyticum by PCR 
Ureaplasma species are frequently isolated in the genital tracts and were grouped under the 
name Ureaplasma urealyticum. The introduction of nucleic acid amplification techniques has 
changed the classification and knowledge of the distribution of disease by allowing separation 
of Ureaplasma urealyticum species into two groups, Ureaplasma urealyticum (T960) and 
 
  Primer Name                        Sequence (5- 3)                                Amplicon size (bp)                          
  HLA dQ-F             GTGGTGTAAACTTGTACCA                             230 
  HLA dQ-R            GGTAGCAGCGGTAGAGTT 
  β-actin- F               TCACCCACACTGTGCCCATCT                        300 
  β-actin- R              CAGCGGAACCGCTCATGCCCA 
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Ureaplasma parvum (parvo). The technique and common primers UU-1402F and UU-1779R 
(GenBank accession numbers AF085724 and AF085730) have previously been described and 
it has been shown that the common primers amplified both Ureaplasma parvum and 
urealyticum (Yi et al, 2005).  The primers (Table 2) amplified 378 base-pair of the urease gene. 
The amplification reaction was carried out as previously described by Yi et al, (2005) with 
slight modifications. In this study, Taq PCR mastermix (Qiagen, Crawley, UK) was used and 
the thermal cycling consisted of an initial denaturation at 95
o
C for 3 minutes, followed by 35 
cycles of denaturation at 95
o
C for 30 seconds, annealing at 58
o
C for 30 seconds, elongation at 
72
o
C for 30 seconds and a final extension step at 72
o
C for 5 minutes. 
2.11 Determination of Mycoplasma genitalium by 16S rRNA PCR: 
The M. genitalium 16S rRNA gene was amplified using the MG16-45 F and MG16-447 
R primers (Table 2), which are in the V1 and V3 hypervariable regions respectively. These 
primers previously described by Jensen et al., (2003) have high specificity binding to most 
sequences conserved in most eubacteria. The amplification reaction was carried out as 
follows and it consisted of 40 cycles of denaturation at 95
o
C for 30 seconds, annealing at 
60
o
C for 60 seconds, elongation at 72
o
C for 30 seconds and a final extension step at 72
o
C 
for 5 minutes 
 
Table 2.2 Ureaplasma and Mycoplasma genitalium primers and PCR amplicon size 
 
 
Primer Name Sequence (5- 3)                           Amplicon size (bp) 
 
 
UU-1402F TGC TGG TGG TAC AGG TAT GAA 378 
 
 
UU- 1779R GGA GCA TGT CCW* CCA CCA 
 
 
MG16-45F TAC ATG CAA GTC GAT CGG AAG TAG C                427 
 
MG16-447R AAA CTC CAG CCA TTG CCT GCT AG 
 
 
W*: A or T 
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2.12 Amplification of human papillomavirus late (L1) gene  
The HPV L1 consensus PGMY09 /11 primer pool consisting of 5 upstream oligonucleotides 
PGMY11 primer pool and 13 downstream oligonucleotides, PGMY09 primer pool (W.H.O., 
2009; Gravitt et al., 2000) was used to amplify HPV from cervical samples (Table 4). These 
primers amplified 450-bp of the L1 region of the virus. The L1 region is the major capsid 
protein of the HPV and is the most conserved among all HPV types. It is seldom lost during 
malignancies making it the targeted region for most frequently used consensus PCRs. HPV L1 
PCR was performed twice on the cervical samples, once using 1.5 mM MgCl2   and then with 
3.0 mM MgCl2 concentration on samples that were negative with the 1.5 mM MgCl2 
concentration. The use of two different MgCl2 concentrations optimises the analytical 
sensitivity of detection of the various HPV types and their detection by gel electrophoresis. 
W.H.O. International standard HPV control was purchased from National Institute for 
Biological Standards and Control, United Kingdom (NIBSC, Hertfordshire, UK) to serve as a 
positive and assay sensitivity control. 
Briefly, the standard was reconstituted in 0.5 ml nuclease free water and the DNA concentration 
measured using the Nanodrop® system. A ten-fold serial dilution was performed on the positive 
control and a PCR was carried out to determine the dilution factor that gave clearer product 
bands when resolved in a 2% (w/v) agarose gel. To determine assay sensitivity, a 1:10, 1:100, 
1:1000 dilution of the HPV positive control was included in the PCR amplification. The 
thermal cycling was carried as described in Table 4. Similarly, 3.0 mM MgCl2 PCR reaction 
was carried out as described above with the addition of 1.5 µl of 25 mM MgCl2 (stock) to the 
Taq PCR Master mix giving a final concentration of 3.0 mM MgCl2. 
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           Table 2.3 HPV PGMY09/11 pool primers and PCR thermal cycling reaction 
 
“11 primers” are the Forward primers, “09 primers” are Reverse primers, and HMB01 primers amplifies HPV 
genotype 51 
Programme: Initial denaturation at 95oC for 9 minutes, followed by 45 cycles of 94 oC for 30 seconds, 
annealing at 55 oC for 60 seconds, elongation at 72oC for 2 minutes. 
          
                                                                                                                                                                        
       
 
                                                                                                                                                                                                                                                                                                                                                                                                                     
 
Primer Name               Sequence (5’ -3’)                                     Programme 
PGMY11-A      GCACAGGGACATAACAATGG 
 
PGMY11-B      GCGCAGGGCCACAATAATGG 
 
PGMY11-C      GCACAGGGACATAATAATGG 
 
PGMY11-D      GCCCAGGGCCACAACAATGG 
PGMY11-E      GCTCAGGGTTTAAACAATGG 
PGMY09-F      CGTCCCAAAGGAAACTGATC 
 
PGMY09-G      CGACCTAAAGGAAACTGATC 
 
PGMY09-H      CGTCCAAAAGGAAACTGATC 
 
PGMY09-I       GCCAAGGGGAAACTGATC 
 
PGMY09-J       CGTCCCAAAGGATACTGATC 
 
PGMY09-K      CGTCCAAGGGGATACTGATC 
 
PGMY09-L      CGACCTAAAGGGAATTGATC 
 
PGMY09-M     CGACCTAGTGGAAATTGATC 
 
PGMY09-N      CGACCAAGGGGATATTGATC 
 
PGMY09-P       GCCCAACGGAAACTGATC 
 
PGMY09-Q      CGACCCAAGGGAAACTGGTC 
 
PGMY09-R      CGTCCTAAAGGAAACTGGTC 
 
HMB01            GCGACCCAATGCAAATTGG 
Initial denaturation at 95
o
C for 9 minutes, 
followed by 45 cycles of 94
 o
C for 30 
seconds, annealing at 55
 o
C for 60 
seconds, elongation at 72
o
C for 2 
minutes. 
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2.13 Real time-PCR (q-PCR) 
All real time-PCR reactions were performed with the Rotorgene-Q (Qiagen, Crawley, UK) in 
a 20 µl reaction volume containing Rotorgene probe mastermix kit (Qiagen, Crawley, UK), 1 
µM of each primers (unless otherwise stated), 50 ng -100 ng of DNA template, extraction 
control and negative control (sterile water) and positive controls (Genekam Biotechnology, 
Duisburg, Germany) All samples were tested in duplicate within one run and were considered 
positive if the cycle threshold (Ct) value was ≤ 35. 
2.13.1  Detection  of  Ureaplasma  parvum  /  urealyticum  by  duplex 
q-PCR 
Real time-PCR was carried out to distinguish between the two species, U. parvum (parvo) and 
U. urealyticum (T960) in both endocervical and high vaginal swabs. A common primer for the 
two species UU-1613F and UU-1524R and two species-specific probes (Yi et al., 2005) (Table 
3) were used in this reaction. The reaction was carried out in one tube, and the primers and 
species-specific probes amplified and typed Ureaplasma at the same time. The reaction 
mixture also contained 0.25 µM of each probe. Thermal cycling and detection of fluorescent 
signals on amplifying the specific target sequence were performed as previously described by 
Yi et al, (2005) with an addition of a final hold for endpoint detection of fluorescence. It 
consisted of two holdings of 56
o
C for 2 minutes, 95
o
C for 10 minutes and 40 cycles of 
95
o
C for 15 seconds, 60
o
C for 1 minute, and a final hold of 60
o
C for 10 minutes. Two channel 
wavelengths of FAM (absorbance: 470nm; emission 515nm) and JOE (absorbance: 530 nm, 
emission 557 nm) were used to identify the specific species, U. parvum and U. urealyticum 
respectively.  Black hole quencher (BHQ) 1 (quenching range:  480 – 580nm) was used for 
both probes. The fluorescence data were analysed with the allelic discrimination software of 
the Rotorgene-Q instrument. 
2.13.2 Detection of Mycoplasma genitalium MgPa gene by Real time-
PCR: 
Both endocervical and high vaginal samples were tested for the presence of M. genitalium.  A 
set of primers targeting the conserved region of the M. genitalium adhesion MgPa gene was 
used for the real time-PCR amplification. These primers and probes (Table 3) are specific for 
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the conserved region of the M. genitalium MgPa gene, which is interspersed with 
hypervariable sequences that are correlated with the MgPa repeated regions (Jensen et al., 
2004). The q-PCR reaction mixture also contained 75 nM FAM fluorophore – labelled MgPa 
probe. The cycling was carried out as follows: two holds of 50
o
C for 1 second, 95
o
C for 10 
minutes and 40 cycles of 95
o
C for 15 seconds, 60
o
C for 1 minute, and a final hold of 60
o
C 
for 10 minutes using FAM channel 470 –515(nm) wavelength. 
 
 
Table 2.4 Real Time (q)- PCR primers and probes for Ureaplasma and M. genitalium 
 
2.13.3  Detection of Chlamydia trachomatis and Neisseria gonorrhoeae 
cryptic plasmid gene by duplex quantitative real time-PCR 
A duplex real time-PCR was carried out for Chlamydia trachomatis (CT) and Neisseria 
gonorrhoea (NG), using dual-labelled probes as previously described (Kimmitt et al., 2010). 
Primers targeting the 144 bp region of the NG cryptic plasmid and 111bp region of the CT 
cryptic plasmid were used (Table 5). In addition to the reaction mixture (section 2.13), 
10 µmol/L of each primer and 10 µmol/L of each probe were added. Both thermal cycling and 
detection of fluorescent signals were performed as follows: 95
o
C for 15 minutes and 50 cycles 
for 94
o
C for 15 seconds and 60
o
C for 60 seconds acquiring at FAM 470 – 515 (nm) and JOE 
530 – 557 (nm). Black hole quencher (BHQ) 1(quenching range: 480 – 580 nm) was used for 
both probes. 
Primer and probe name                Sequence                                                         Amplicon size (bp) 
UU -1613F       AAG GTC AAG GTA TGG AAG ATC CAA                                        90 
UU - 1524R     TTC CTG TTG CCC CTC AGT CT 
UU – T960      JOE – ACC ACA AGC ACC TGC TAC GAT TTG TTC- BHQ1 
UU – parvo      FAM – TCC ACA AGC TCC AGC AGC AAT TTG – BHQ1 
MgPa – 355F   GAG AAA TAC CTT GAT GGT CAG CAA                                        78 
MgPa – 432R   GTT AAT ATC ATA TAA AGC TCT ACC GTT ATC 
MgPa – 380      FAM – ACT TTG CAA TCA GAA GGT – BHQ1 
 63 
 
Samples that were positive for N. gonorrhoeae but negative for C. trachomatis were retested 
for C. trachomatis alone to confirm the result. Confirmation of the expected product sizes was 
carried out on positive samples by gel electrophoresis.  Positive samples were purified and sent 
for confirmation by DNA sequencing. 
 
Table 2.5 Real Time (q) - PCR primers and probes for Chlamydia trachomatis and 
Neisseria gonorrhoeae 
 
 
2.14  Purification of amplified PCR products and DNA sequencing: 
2.14.1  Purification of PCR product  
Following PCR amplification, all PCR amplicons that showed single discrete bands upon gel 
electrophoresis were purified using a PCR purification kit (Sigma Aldrich, Haverhill, UK) 
following the manufacturer’s instructions. In this assay, the initial buffer, column binding 
buffer or QC (solubilising and binding buffer) was added to the PCR amplicons. This provides 
the optimal salt concentration, low pH and enhances the negatively charge DNA to adsorb to 
the positively charged silica-gel membrane in the QIAquick spin column. Contaminants 
present in the solution were then eluted by high speed centrifugation at 13,000 g through the 
column. Wash buffer (PE) was added and centrifuged as above to remove remaining 
contaminants from the DNA-bound membrane. The final step of this assay was the elution of 
DNA using a low concentration Tris buffer (EB). To maximise DNA recovery, 40 μL of EB 
Primer and probe name                Sequence (5’ – 3’)                                            Amplicon size (bp) 
NG primer F               AAC TGC CGG GCG TTT ATA TCG                                           144 
NG primer R             GAC CTT CGA GCAGAC ATC ACG 
NG probe                 JOE – ACC GAA GCC GCC AGC ATA GAG CAA CA-BHQ1 
CT primer F             GCC AAT CTT CTT TGA AGC GTT GTG                                     111 
CT primer R             CTA GGG TGC TCA GAC TCC GAC 
CT probe                 FAM – TGA AGG TCA CAG GAC ACG CAA CCC CA – BHQ1 
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buffer was added to the centre of the membrane and the column was centrifuged after 1 minute 
of room temperature incubation. 
2.14.2 DNA sequencing by LIGHTRUN™ 
Purified DNA samples were sent for sequencing to GATC Biotech (Konstanz, Germany) using 
prepaid barcodes. DNA sequencing by GATC Biotech (Konstanz, Germany) was performed 
by the LIGHTRUN™ sequencing technique. In this method, 5 μL of the purified DNA sample 
and 5 μL appropriate primer of concentration 5 μM were premixed and sent for sequencing. 
2.15 HPV and Ureaplasma genotyping 
PCR was performed on samples that were HPV positive for DNA sequencing using the L1 
consensus primers, which amplified a 450 bp region of the virus encoding highly conserved 
amino acids that is suitable for DNA sequencing. Samples that were also Ureaplasma positive 
were sent for DNA sequencing. These samples were purified and commercially sequenced by 
GATC Biotech (Konstanz, Germany) as described in section 2.14.1 - 2.14.2. The nucleotide 
sequence data produced from sequencing were then searched in NCBI BLAST (http:// 
www.ncbi.nlm.nih.gov/BLAST/), Basic Local Alignment Search Tool (BLAST). BLAST is 
software that finds regions of similarity between sequences by comparing nucleotides or 
protein input sequences to sequences in a database and calculates the statistical significance of 
the matches. The likelihood of the match occurring by chance is normally indicated by the 
Expect (E) value. The lower the E- value was, the more significant the genotype match 
was. Genotype search was carried out on each of the consensus strands (Forward and 
Reverse) produced by sequencing. HPV genotype was assigned to the closest known HPV 
type deposited in the GenBank database when the sequence is 90 – 100% identical to the L1 
gene of that genotype. 
2.16  Phylogenetic analysis of high-risk HPV sequences 
The high-risk HPV DNA sequences generated were initially identified by BLASTn analyses 
at NCBI (http://www.ncbi.nlm.nih.gov/) against the GenBank sequence database as described 
in section 2.15. Subsequent analyses on the HR/pHR-HPV sequences were carried out by Dr. 
Polly Hayes (section 2.16.1 - 2.16.2). These DNA sequences were aligned and edited using 
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Bioedit (Hall, 1999). Phylogenetic trees for the HR-HPV genotypes were constructed using 
the edited L1 variant (PYMG09/11, 412bp) sequences obtained from the study. 
The generated HR/pHR-HPV sequences were aligned with representatives of similar published 
HR/pHR-HPV sequences retrieved from the GenBank database, using MUSCLE 
(https://www.ebi.ac.uk/Tools/msa/muscle/). Phylogenetic analysis was carried out using two 
methods: Neighbour-Joining (NJ) and Maximum likelihood (ML). All phylogenetic analysis 
was undertaken using Molecular, Evolutionary Genetics Analysis version 7 (MEGAv7) 
(Kumar et al., 2016). Neighbour-joining (NJ) trees were constructed using Kimura two-
parameter correction methods. The ML analysis was generated in MEGA 7 under the 
conditions of the Tamura 3-parameter (T92+G) model as determined using the model test 
function also in MEGA 7. The T92+G model is amongst other models such as T93+1 that have 
lowest Bayesian information criterion (BIC) scores and they are considered to describe the 
evolutionary substitution model best (Tamara et al., 2011; Nei and Kumar, 2000). 
2.16.1  p-distance analysis 
As a measure of inter- and intra-divergence of the Gambian HPV-types, uncorrected pair-
wise genetic distance (p-distance) between sequences was calculated using Mega v7. This 
was carried out using the Gambian HR/pHR-HPV sequences. 
2.16.2  Regression analysis 
To determine the inter-relationships and movement of the different HPV genotypes, and 
possibly determine the origin of The Gambia sequences, geographical distance (km) was 
calculated between different geographical locations “as the crow flies” using the online 
distance calculator woflramalpha.com and plotted against p-distance (nucleotide) using linear 
regression. This was carried out using the Gambian HR/pHR-HPV sequences and other 
representatives of the different HPV genotypes from different geographical localities obtained 
from the GenBank database. HPV sequences that formed clades with a bootstrap support of ≥ 
90% with the Gambian HR/pHR-HPV sequences were used in this analysis. 
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2.17 Pseudo-typed virus neutralization assay (PsV): 
This arm of the study was a longitudinal cohort study on recruited HIV positive women (n = 
29) as described in section 2.1.4.2. Serum samples collected from this cohort were screened 
against the following high-risk HPV types: HPV 16, 18, 35, 51, 52 and 58. 
2.17.1 Amplification of HPV packaging plasmids 
Plasmid bacteria stabs p35 SheLL-HPV35 L1L2 a gift from Simon Beddows (Addgene 
plasmid # 40626) and a pVITRO-HPV 51 L1L2 a gift from Richard Roden (Addgene 
plasmid # 52583) were cultured on LB agar plates with Ampicillin (100 µg/ml) and Kanamycin 
(50 µg/ml) antibiotics, respectively. The plates were incubated at 37
o
C overnight. A single 
bacterial colony from the different plates were transferred into two different tubes each 
containing 5 ml LB broth with Ampicillin (100 µg /ml) and Kanamycin (50 µg / ml), 
respectively a n d  incubated at 37
o
C on a multi-shaker at 250 (rpm), overnight. 
Plasmid extraction was carried out from the overnight LB broth culture using the QIAGEN 
plasmid miniprep kit (Qiagen, Crawley, UK) following the manufacturer’s instructions. T h e  
c oncentration of the extracted HPV plasmid DNA was measured using a Nanodrop ND2000 
as described in section 2.8.3. To confirm the identity of the plasmid, a diagnostic restriction 
enzyme digestion was carried out on the extracted plasmids as follows: 
1400 -1500 ng of HPV plasmid DNA was incubated with 1µl (20 U/ µl) of Notl-HF, 1 µl of 
(20 U/ µl) of Nhel-HF (NEB Biolabs, United Kingdom) and 3 µl of 1 x CutSmart buffer 
in a final volume of 30 µl for 1 hr at 37
o
C. The products were run on a 1% (w/v) agarose in 
TBE buffer gel and visualised using a Syngene UV Transilluminator (Syngene). 
2.17.2  Production of HPV pseudo-typed viruses 
HPV pseudo-types for types 16, 18, 52 and 58 and the bovine papillomavirus (BPV) were 
already available at the NIBSC (Bissett et al., 2014), where I’d carried-out this part of the 
research. Pseudo-types for HPV 35 and HPV 51 were created by transfection of HPV 
plasmids into human embryonic kidney cells HEK 293TT. 7.5 million 293TT cells were 
seeded in a 75cm
2 
tissue culture flask to a 20 ml final volume   of   Dulbecco’s   modified   
eagle’s   medium   with   hygromycin (cDMEM) (Invitrogen, 11140-035) supplemented with 
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1% (v/v) Penicillin /Streptomycin and 10% (v/v) foetal calf serum (FCS). The flask was 
incubated at 37
o
C with 5% CO2 for 16 - 24 hrs. 
19 µg of HPV packaging plasmid and 19 µg pGL4.51 reporter plasmid (Promega, UK) 
were mixed together and add to 2 ml of Opti-MEM™-l reduced serum media (Invitrogen 
11058-021). 80 µl of lipofectamine™ 2000 (Invitrogen 11668-019) was added to 2 ml of Opti-
MEM™ -l and after 10 minutes at room temperature, the plasmids were added to the 
lipofectamine and further incubated for 20 minutes at room temperature. The mixture (Opti-
MEM/ lipofectamine/HPV plasmid/pGL4.51 reporter plasmid) was transferred to the HEK 
293TT cells seeded the day before.  
The cells were incubated at 37
o
C with 5% CO2 for 4 - 6hrs. The supernatant was gently 
removed at the end of the incubation period and 20 ml cDMEM was added. The cells were 
further incubated for 48 hrs. 
2.18 HPV pseudo-typed virus maturation and purification 
2.18.1 Post-transfection 
The cells were collected by trypsinisation with trypsin-EDTA (Gibco, Life Technologies, UK), 
washed with phenol red free DMEM (prfDMEM) and centrifuged at 5000 rpm for 10 minutes. 
The supernatant was discarded, and the cell pellet resuspended in 0.5 ml Dulbecco’s PBS 
(Invitrogen, UK), which was supplemented with 9.5 mM MgCl2 and 1% (v/v) Penicillin 
/Streptomycin (DPBS-Mg). The suspension was transferred into a 2 ml Eppendorf protein Lo-
bind tube and the original tube was rinsed with another 0.5 ml DPBS-Mg and combined with 
the suspended cells. The tube was centrifuged for 10 minutes at 5000 rpm and the supernatant 
was discarded. The cell pellet was resuspended in 1.5 volumes of DPBS-Mg. Cells were lysed 
by adding 1/25 cell volume of 10 % (v/v) Brij-58 detergent and RNA removed using 1/1000 
cell volume of RNase mix (Ambion, UK). The cell lysate was incubated at 37
o
C with 5% CO2 
for 24 hrs. 
HPV pseudo-typed viruses were purified on a continuous density gradient of Optiprep® 
medium (Sigma Aldrich, Haverhill, UK), which is a trade name for 60% (w/v) iodixanol 
solution. The gradient was prepared in Beckman ultra-centrifuge tubes by layering Optiprep 
three concentration of Optiprep: 39%, 33%, and 27% in PBS-Mg from the bottom to the top 
and leave to diffuse for 1- 2 hrs at room temperature. The cell lysate from the previous day 
was cooled on ice for 10 minutes and clarified by centrifuged at 10,000 rpm at 4
o
C for 10 
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minutes. The supernatant was gently loaded on the diffused Optiprep gradient and centrifuged 
at 50,000 rpm (SW-55ti rotor) at 16
o
C for 3.5hrs in an Optima X-100 centrifuge (Beckman 
Coulter). Following centrifugation, 200 µl fractions of the virus from the top of the gradient 
was transferred into a sterile 96-well plate. Virus fractions in wells 16 – 21 were pooled 
together, giving a total volume of 1.2 ml of pseudo-typed virus. An equal volume of 27% 
Optiprep gradient was added to the virus pool to increase the volume of the pseudo-typed 
virus. The pseudo-typed virus was aliquoted into Eppendorf protein Lo-bind tubes and stored 
at -80
o
C until ready for titration. 
2.19  Pseudo-typed virus titration by infectivity assay 
Tissue culture infective dose (TCID50) for each stock of the PsV was determined by titration. 
10,000 HEK 293TT cells in 100 µl of cDMEM per well were seeded in inner wells of a 96-
well tissue culture flat bottom sterile plate (Fisher Scientific, UK). The external wells (row A 
–H and column 1-12) were filled with 200 µl of sterile PBS to avoid evaporation. The 
plates were incubated at 37
o
C with 5% CO2, overnight. The PsV stock was titrated by 5-fold 
serial dilution with a starting 1/25 dilution and 100 µl of the diluted PsV was added to the 
HEK 293TT cells seeded the day before. The plates were incubated at 37
o
C with 5% CO2 for 
72 hrs. 
The supernatant from the plates was discarded without disturbing the monolayer of the cells. 
A 1:1 mixture of prfDMEM and Steady-Glo® Luciferase substrate (Promega, UK) was 
prepared and 100 µl was added to the wells. The plates were incubated at room temperature 
for 5 minutes. At the end of the incubation period, the mixture was thoroughly mixed and 90 
µl was transferred into a white opaque 96-well plate in the same format and read on a 
luminometer (Fluostar Omega, BMG Lab Tech) using the Omega software. 
The TCID50 for each virus was calculated using the Spearman Karber equation (Appendix 
C6.1). The pseudo-typed virus infectivity (titration) assay for each virus was tested three times 
in triplicate as described above and the average TCID50 of each virus was used to calculate 
the TCID50/ml for each virus stock. 
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2.20 Neutralisation assay 
The 293TT cells were seeded similarly to the infectivity assays (section 2.19). The cells were 
incubated overnight at 37
o
C with 5% CO2. Each HPV pseudo-typed virus (HPV-16, 18, 35, 
51, 52, 58 and BPV) was used at a concentration of 300 TCID50 per well in 100 µl and 
dispensed in a 96-well U-bottom plate. To each well 25 µl of sera diluted 1:8 in prfDMEM 
were added to the 100 µl PsV to give a final 1:40 dilution of the sera. Virus only control 
received 25 µl of prfDMEM. Pseudo-typed viruses and sera were incubated at room 
temperature for 1 hr. 100 µl of the mixture was added to the 293TTcells seeded the day 
before. 125 µl of prfDMEM was added to the cells only column. The plates were incubated at 
37
o
C with 5% CO2 for 72hrs. The neutralisation assay was read following the same procedure 
as described in section 2.19. 
2.20.1 Calculation of HPV antibody neutralisation 
The raw data was imported and the antibody neutralisation for each sample was calculated by 
dividing the relative light unit (RLU) values of each antibody dilution with the average “PsV 
only” RLU values. The value was then multiplied by 100 to give the percentage of cells that 
were infected, which was then subtracted from 100 to give the percentage of neutralisation.  
Antibody neutralisation assay was carried out for each of the HR-HPV serotypes listed above 
and each serum was tested in triplicate for each of the HPV serotypes including the bovine 
papillomavirus, which served as a negative control. 
2.21  Cytology 
This part of the work was carried out at the Viapath Bedford hospital, UK. The cytology slides 
were stained using the Papanicolaou stain, coverslipped and were initially reported by two 
biomedical science (BMS) cytologists. All abnormal samples were confirmed by a senior 
BMS cytologist and a final diagnosis was reported by a Pathologist / Advanced Practitioner. 
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2.22  Data entry and Statistical analysis 
Results obtained from the analysed samples were entered into the Epi™ info version 7 
(https://www.cdc.gov/epiinfo) database according to the unique study number assigned to each 
participant that corresponded with the questionnaire. The database was checked for duplicate 
recording, missing variables, and some variables were re-coded for statistical analysis. 
Statistical analysis was carried out using Epi info version 7 statistical packages. Socio-
demographic, behavioural risk factors and clinical outcomes of participants were analysed 
using standard descriptive statistics such as frequencies and percentages for categorical 
variables, standard deviation and means were applied for continuous variables. The strength of 
risk factors associated with STI as an outcome was measured using the Odds Ratio (OR). 
The ORs of the risk characteristics were interpreted as increase odds (>1.0) or decrease odds 
(<1.0) rather than a relative risk of the outcome being analysed when the p-value is not 
significant. 
Chi-square-corrected (Yates) and Fisher’s exact if any cell of the contingency table contained 
fewer than five, and Mantel Haenszel (MH) p-values were used to examine associations 
between categorical variables such as isolation of STI/genital pathogens and selected risk 
characteristic variables. A confidence interval of 95% (CI) and p-value of ≤ 0.05 were used 
to determine statistical significance. The student ‘t’ test and pair-wise analyses were also used 
in a comparative analysis between the study population. A multivariate analysis such as logistic 
regression was used to determine the association between each risk characteristics and 
diagnosis of STI in a stepwise model by starting with a single risk exposure variable and 
building it up by adding more variables. Subsequently, variables that were not significant to 
STI infection at (p ≤ 0.05) were removed from the model one at a time. adjusted for age and 
ethnic groups. The Wald p-test was used to assess the statistical significance of individual 
predictor variables on the outcome. 
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Chapter 3: Human papillomavirus genotype distribution and risk factor 
analysis amongst reproductive age Gambian women 
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3 Introduction  
HPV infection is the most common sexually transmitted infection in reproductive age women 
(Bruni et al., 2010; De Vuyst et al., 2003). More than 75% of sexually active males and females 
will be infected with the virus at some stage in their lives, which in most cases will resolve 
without treatment (Youssef et al., 2016; Dartell et al., 2012). The peak time for acquiring 
HPV infection is shortly after sexual initiation, however, penetrative sex is not required for 
transmission. Skin to skin genital contact is a well-recognised mode of HPV transmission 
(Gervaz et al., 2003; Marrazzo et al., 2001). 
Globally, more than 560,000 and 60,000 cancer cases in women and men each year are 
attributable to HPV, respectively (de Martel et al., 2017; Plummer et al., 2016; Ferlay et al., 
2015). This corresponds to 8.6% and 0.8% of all HPV-associated cancers occurring worldwide. 
In women, the percentage of HPV attributable cancers ranges from approximately 2% in 
Australia, New Zealand and the US to more than 25% in sub-Saharan Africa (de Martel et 
al., 2017).  The relative contribution of the bivalent vaccine HPV genotypes 16 and 18 and of 
the nonavalent (9-valent) vaccine types (6/11/16/18/31/33/45/52/58) are 460,000 and 570,000 
cancer cases, respectively. This corresponds to 72% and 90% of all HPV-attributable 
cancer cases in both genders (Alemany et al., 2016; Castellsague et al., 2016).  
Although HPV infection is vaccine-preventable, the widespread introduction of the vaccine 
in resource-limited countries is still in its infancy. Both HPV vaccination and HPV-based 
screening have been demonstrated to be cost-effective for a comprehensive prevention strategy 
in developed countries as well as in some developing countries (Jit et al., 2014). The 
unavailability of the HPV vaccine and the limited use of cervical cancer screening in the 
developing countries often cause challenges in cervical cancer prevention (Bruni et al., 2016; 
Santesso et al., 2016). 
In The Gambia, the age standardized rate (ASR) of cervical cancer incidence during the period 
1990 - 2009 was reported as 16.9 per 100,000 per year (Bah et al., 2013, Sighoko et al., 2010). 
Furthermore, according to The Gambia Health Management Information system (HMIS), 237 
females were diagnosed with cervical cancer in 2016 and 96% of these cases were from 
the urban regions of the country (Banjul, Kanifing Municipal Council and West Coast 
Region). Vaccine coverage of more than 70% was achieved with the quadrivalent HPV 
vaccine demonstration in the West Coast Region of the country. However, the major 
circulating HR-HPV genotypes are currently unknown in this population. Although the 
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quadrivalent vaccine targets HPV 6, 11, 16 and 18, the vaccine can only protect against 70% 
of cancers caused by HPV 16 and 18 genotypes. Other oncogenic types have been documented 
to cause cancers in the sub-Saharan Africa regions, which are not protected by the quadrivalent 
vaccine (WHO, 2017).   It is envisaged that HPV vaccination will be rolled-out nationwide by 
2019. Therefore, there is the need to have a baseline data on HPV infection rates and 
genotype distribution in this population. 
3.1 Aims and objectives 
The aims of the work presented in this chapter were to evaluate the potential value of 
introducing the quadrivalent vaccine in urban Gambia by investigating the major circulating 
HR-HPV genotypes and the behavioural risk factors associated with HPV infections.  
 
The objectives were to:  
 
• determine HPV prevalence distribution 
• characterise the major circulating HR-HPV genotypes 
 
• determine the intratype variability of the Gambia HR-HPV 
sequences and compare these with previously published HR-HPV 
sequences isolates from other geographical locations  
• determine the socio-demographic and risk characteristics of 
participants infected with HPV 
• determine the prevalence of HPV co-infection with selected STI / 
genital pathogens 
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3.2 Determination of adequate cellular DNA in samples 
Of the 235 recruited women, 3 (1.3%) had samples from which inadequate cellular DNA had 
been collected so were excluded from this study. To determine HPV prevalence and genotype 
distribution, 232 endocervical swabs (case, n = 115, control, n = 117) with adequate cellular 
DNA were screened for HPV as described in Chapter 2, section 2.12. 
3.2.1  HPV prevalence and genotype distribution amongst participants 
Of the 232 participants screened for HPV, 28 were positive for HPV DNA, 15 (13.0%) from 
the case group and 13(11.1%) from the control group. HPV DNA sequencing identified 7 
different HR genotypes, 2 different pHR and 7 different LR genotypes. Of the 13% (15/115) 
HPV positive participants from the case group, 53% (8/15) were infected with HR-HPV, none 
with pHR-HPV and 47% (7/15) with LR-HPV genotypes. In comparison with the control 
group, of the 11% (13/117) HPV positive participants, 46% (6/13) were infected with HR-
HPV, 15% (2/13) with pHR-HPV and 39% (5/13) with LR-HPV genotypes (Table 3.1). Table 
3.2 shows the distribution of the different HPV genotypes identified in both the case and 
control groups. N o  s tatistically significant difference was observed in the distribution of 
HPV in the two study groups (p >0 .05 ) by student ‘t’-test. HPV 52 was the most prevalent 
high-risk genotype identified in this study. Figure 3.1 shows the overall HPV genotype 
distribution. 
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Table 3.1 Prevalence of HPV risk types in case and control groups (number and 
percentage) 
   
 Case group Control group 
HPV risk types n (%) n (%) 
High-risk 8 (53) 6 (46) 
probable high-risk 0 (0) 2 (15) 
Low-risk 7 (47) 5 (39) 
Total HPV positive 15(13) 13 (11) 
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Table 3.2 Distribution of HPV genotypes in case and control groups, identified by DNA 
sequencing and nucleotide Blast analysis 
 
 
HPV 
genotypes 
Case group  
 
 (HPV-positive, n = 15)  
  
Control group  
  
(HPV-positive, n = 13) 
   
6 1 1 
16 0 1 
35 0 1 
42 1 0 
51 2 0 
52 2 3 
  53* 0 1 
54 1 1 
56 1 0 
58 2 0 
61 3 1 
62 1 0 
66 1 1 
  73* 0 1 
83 0 1 
89 0 1 
 
High risk-HPV (HR-HPV)  oncogenic genotypes (bold) are associated with causing cancers; 
* probable high risk-HPV (pHR-HPV) genotypes are associated with intermediate potential risk of 
cancers.  Low risk-HPV (LR-HPV) genotypes (not bold) are associated with causing genital warts or 
benign epithelial lesions. HPV 18 was not detected in any of the cervical samples. 
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 Figure 3.1 Distribution of HPV genotypes in reproductive age women attending a 
polyclinic, EFSTH, Gambia. 
HPV 52 was the most predominate circulating genotype found in this study (17.9%) followed by 
HPV 61 (14.3%), HPV 6, 51, 54, 58, 66 (each at 7.1%), 16, 35, 42, 53, 56, 62, 73, 83, and 89 (each 
at 3.6%) of all genotypes identified by DNA sequencing and nucleotide Blast analysis. 
Legend: dark grey colour:  LR (low-risk genotype), Light pink colour: HR/pHR (high risk/probable 
high-risk) 
 
3.3 HPV prevalence amongst the different age groups  
The HPV age-specific prevalence curve of participants from the case group showed a U-
shaped curve in the ages between 21 and 35 years, which was followed by a sharp 
prevalence increase (21%) in the 36 - 40 age group and a further prevalence decline in the 
41 – 49 age group (Fig 3.2). In contrast to the case group, HPV age-specific prevalence in the 
control group showed a higher peak in the 21 - 25 age group (19%), followed by a steady 
decline in the ages between 26 and 35 years. A second prevalence peak was observed in the 
36 – 40 age group, which was followed by a sharp decline in the 41 – 49 age group. In 
addition, HPV was observed in 9% of participants between the ages of 41 – 49 years in the 
case group compared to 0% from the control group (Fig.3.2). The overall HPV age-specific 
prevalence distribution of participants was investigated and an initial prevalence peak in the 21 
- 25 age group (32%, 9/28) was observed, which was followed by a steady decline in the ages 
between 26 and 40 years, and a sharp prevalence decline in the 41 - 49 age group (Fig 3.3). 
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Figure 3.2 HPV age-specific prevalence curve of both case and control groups. 
A U-shaped curve of HPV age-specific prevalence was observed in the ages between 21 and 35 
years in the case group. HPV age-specific prevalence increase was observed in the 36 – 40 years 
age group in both study groups, which is followed by a sharp prevalence decrease in the 41 - 
49 years age group. In contrast to the HPV age-specific prevalence decrease (0%) observed in 
the 41 - 49 years age group in the control group, HPV age-specific prevalence of 9% was 
observed in the 41 – 49 years age group in the case group.   
                                                                                                                                               
 
Figure 3.3 HPV age-specific prevalence curve in reproductive age women 
attending a polyclinic, EFSTH, Gambia.                                                                                                    
Overall HPV age-specific prevalence peak 32% (9/28) was observed in the 21 - 25 years age 
group, followed by a steady prevalence decline in the ages between 26 and 30 years. A 
prevalence plateau was observed between the ages 31 – 40 years of age, which was followed 
by a sharp prevalence decline in the older ages (41 – 49 years age group). 
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3.4 High-risk HPV genotypes prevalence by age and ethnic groups 
The prevalence of HR-HPV was found in the different age groups as follows: 29% (4/14) in 
21 – 25 age group, 43% (6/14) in 26 - 30, 21% (3/14) in 31 – 35 and 7% (1/14) in 36- 40 age 
gropus, respectively. Though, the HPV age-specific curves have shown a second peak in the 
36 – 40 years age group in both the case and control groups (Fig. 3.2), it is important to note 
that only one participant was infected with an HR-HPV genotype. Probable high risk (pHR-
HPV) genotypes, HPV53 and HPV73 were only identified in the 21 - 25 years age group. HPV 
infection was not detected in the 20 years old. No significant association was observed between 
age group with HPV infection (p > 0.05) 
Ethnicity-associated differences were also noted, HR/ pHR-HPV prevalence was 31% (5/16) 
in the Fulas compared to the 19% (3/16) and 12.5% (2/16) observed in the Mandinkas and 
Wollofs, respectively. However, LR-HPV genotypes were identified mostly in the Mandinka 
ethnic group, accounting for more than 40% (5/12) of the total LR-HPV types. Prevalence 
of both HR/pHR and LR-HPV genotypes was lower (12.5% and 8.3%) in the Wollofs 
compared to the other two major ethnic groups. 
3.5 Classification and distribution of HPV risk type by region 
Eighteen percent (18%) of participants from the case group resided in Banjul, the capital city, 
whilst the remaining 82% resided in the Kanifying Municipal Council and West Coast Region 
(KMC/WCR). However, the opposite was seen in the control group, 70% of the participants 
resided in Banjul and 30% in the KMC/ WCR. Figure 3.4 shows the classification of HPV 
types across the three study regions. HPV prevalence across the three regions were found as 
follows: 12.5% (13/104) in the capital city, Banjul with 6 infected with HR-HPV, 2 with pHR-
HPV and 5 with LR-HPV, 11.9% (8/67) in KMC with 3 infected with HR-HPV and 5 with 
LR-HPV and 11.5% (7/61) in WCR with 5 participants infected with HR-HPV genotypes 
(Fig.3.4). No statistically significant difference was observed between residing in the capital 
city, Banjul or KMC/WCR with HPV infection (p > 0.05). 
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Figure 3.4  Classification of HPV risk type distribution in Banjul City, Kanifying 
Municipal Council and West Coast Region 
A majority 43% (6/14) of participants infected with HR-HPV are residents of the capital city, 
Banjul, followed by WCR 36% (5/14) and KMC 21% (3/14).  No regional variation was 
observed between those residing in the capital city, Banjul or the KMC/WCR with HPV 
infection (p > 0.05).                                                                                     
Legend and colours: 
Pink– High-risk HPV genotypes (HR-HPV) 
Dark grey – Low-risk HPV genotypes (LR-HPV) 
Light grey– Probable high-risk HPV genotypes (pHR-HPV) 
KMC- Kanifying Municipal Council;  
WCR – West Coast Region. 
3.6 Risk factors associated with human papillomavirus infection 
amongst reproductive age women. 
Statistical analysis of risk characteristics of participants was carried out using bivariate analysis 
to determine relationships and strength of associations between two variables. In this analysis, 
the independent variables were participants’ risk characteristics and the dependent variable was 
HPV infection, whilst controlling for age. HPV negative participants were used as a reference 
group in this analysis. Statistical analysis showed prolonged (> 5 years) use of hormone 
contraceptive was the only variable that was associated statistically with HPV infection (95% 
CI=0.9-1.3; p = 0.03), in this study (Table 3.3). No association was found between early 
menarche, having a new sexual partner (s) with HPV infection (p > 0.05).  Although 82% 
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(23/28) of married participants were infected with HPV, marital status was not found to be 
associated statistically with HPV infection (p > 0.05) (Table 3.3).  Twenty-five participants 
had reported having sexual intercourse in the preceding 12 months and only 8% (2/25) reported 
to have used a condom (Table 3.3). In this study, the use of condoms during sexual intercourse 
was found to have some reduced risk against HPV infection (AOR = 0.7). Although not 
statistically significant, reporting partners have or had other sexual partners, and had 
undergone female genital mutilation (FGM) increased the odds of being diagnosed with HPV 
infection (AOR = 3.5 and 2.1), respectively (Table 3.3). Of the 28 participants infected with 
HPV, 82% (23/28) had their sexual debut at the age of ≥ 18 years but no statistical association 
was found between having sexual debut at ≥18 years old with HPV infection (p > 0.05). Table 
3.3 shows the statistical analysis of selected risk characteristics of participants infected with 
HPV. 
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Table 3.3 Socio-demographic and risk characteristics associated 
with HPV Infection, Negative (204), Positive (28) adjusted for age  
 
Characteristics         HPV DNA results 
   
  
   
   Adjusted OR (95% CI)       P-value 
      
     
Ethnic group#     
Fula              40 9        2.1 (1.0, 4.9) NS 
Mandinka              49 8        1.2 (0.4, 2.7) NS 
Wollof             39 3        0.5 (0.1, 1.7) NS 
Age at sexual debut    
≥18 years           131            23        2.2 (0.8, 6.2) NS 
<18 years             70  5   
Marital status     
Married           164 23         0.9 (0.3, 2.5) NS 
Unmarried             40  5   
FGM     
Yes          124 21        2.1 (0.9, 5.7) NS 
No           80  7   
Education     
<12 years           109 11        2.0 (0.9, 4.5) NS 
≥ 12years            95   7   
Lifetime sexual partner(s)    
≥2            77 14         1.8 (0.8, 4.1) NS 
  1         124 14   
Partner (s)other sex partners    
Yes 99 13       3.5 (0.4, 28) NS* 
No 27 1   
Hormone contraceptive use    
>5 years 61 13        4.2 (0.9, 1.3) 0.03 
<5years 97 10   
Low income     
<D75,000 160 20        1.7 (0.5, 5.5) NS 
>D75,000                                 8   44    
Condom use 
last 12 months     
Yes 20 2         0.7 (0.2, 3.3) NS* 
No 166 23   
 
    
#Major ethnic group, *Fisher exact due to small sample size numbers, MH- Mantel-Haenszel 
Odds Ratio, adjusted for age group.  NS = not significant, p > 0.05 
 
Negative (204)     Positive (28)    
(27) 
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3.7 Human papillomavirus co-infection with STI and other genital 
pathogens    
Two hundred and thirty-two (232) participants screened for HPV were also screened for 
selected STI/genital pathogens as described in the method section, Chapter 2, section 2.13 - 
2.13.3. Of the 28 participants positive for HPV, 15 were from the case group and 13 
from the control group. Table 3.4 shows the numbers and percentages of HPV positive 
participants co-infected with selected STI / genital pathogens. In addition, out of the 14 
participants co-infected with Ureaplasma, 50% (7/14) were additionally co-infected with one 
or more of the other screened pathogens. 
 
             Table 3.4 HPV co-infection with selected STI / genital pathogens 
 
 
genital organisms 
       Case group  
             
            n (%) 
   Control group 
           
           n (%) 
Ureaplasma 7 (46.7) 7 (53.8) 
Candida albicans 4 (26.7) 1 (7.7) 
Streptococcus agalactiae 2 (13.3) 1 (7.7) 
T. vaginalis 1 (6.7) 0 (0.0) 
Neisseria gonorrhoeae 0 (0.0) 1 (7.7) 
HIV 7 (46.7) 0 (0.0) 
Bacterial vaginosis* 2 (13.3) 1 (7.7) 
   
 
               *Bacterial vaginosis = polymicrobial syndrome; was diagnosed using Amsel criteria 
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3.8 BLASTn comparison of The Gambian  HR / pHR-HPV DNA 
sequences to sequences deposited in the GenBank database 
All the HR-HPV genotypes identified in this study showed ≥ 98% homology to entries 
deposited in the GenBank database, except HPV 35 (Table 3.5). Of the three HPV 52 DNA 
sequences identified from the control group, two were 100% identical to a type isolated in 
Quebec, Canada and one was 99% identical to a South Korean isolate (Accession numbers: 
EU077215 and KY077858, respectively). Two of the HPV 52 DNA sequences identified 
from the case group were 100 and 99% identical to isolates from Quebec, Canada and Croatia 
(Accession numbers: EU077215 and KF707618, respectively). In addition, one sequence was 
shown to have an 82% similarity with an HPV 35 isolate from Ecuador (Table 3.5). However, 
as the difference between this sequence and the reference sequence (Accession number 
KU050112) L1 gene differs by more than 10%, it was identified as a novel type. In addition, 
all other HPV genotypes with DNA homology of 98% with the closest known genotypes 
were defined as subtype and > 98% as variant types (Table 3.5). To further confirm the 
identification and relatedness of the HR/pHR-HPV sequences, a phylogenetic tree was 
constructed and evolutionary relationships within and between types determined. 
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Table 3.5 HR/pHR HPV DNA sequences comparison with isolates deposited in 
the GenBank database 
 
 
 
HPV 
genotype 
identified 
GenBank 
Accession 
Number 
Isolate Number Origins % DNA 
similarity to 
Gambian 
samples 
16 KY549284 C484604r11164343NP Netherlands 98 
 
35 KU050112 ECU-07 Ecuador 82 
 
51 KF707619 R60 Switzerland 98 
 
 KF707618 R72 Switzerland 99 
 
52 KJ676061 
 
CRO 1F6 Croatia 99 
 
 EU077215 23 Canada 100 
 EU077215 23 Canada 100 
 EU077215 23 Canada 100 
 KY077858 
 
KOR_M10- 4515 South 
Korean 
99 
53 KU951263 
 
CN10 China 99 
56 KU298919 110A.56 Brazil 99 
 
58 
 
HM639676 
 
ww100HK_973 
 
Hong Kong 
 
99 
 HQ537776 Rw644 New York 99 
 
66 KU298927 83A.66 Brazil 98 
 KU298928 
 
118A.66 
 
Brazil 98 
73 KU298936 58c.73 Brazil 99 
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3.9 Phylogenetic analysis of HR/pHR-HPV sequences 
Two phylogenetic trees were constructed using Neighbour-joining and Maximum likelihood 
methods (Chapter 2, section 2.16) to further confirm the identification of The Gambian 
HR/pHR-HPV genotypes and compare the sequences to sequences of the same types from other 
geographical locations. The maximum likelihood tree was used to determine the relationship 
within and between types and with published sequences retrieved from the GenBank database. 
Phylogenetic analysis grouped each of The Gambian HR/pHR-HPV genotype sequences within 
its respective HPV genotype clade. HPV 52 genotypes grouped with comparable sequences 
from Canada (Accession number: EU077215), Croatia (Accession number: KJ676061), South 
Korean (Accession numbers: KY077846, KY077858 and KJ676970), China (Accession 
numbers: KU721792, KT799937 and KT799938), Brazil (Accession numbers: KU298908 and 
KU298909) with a bootstrap support of 99%. The Gambian HPV 51 grouped with HPV 51 
isolates from Switzerland (Accession numbers: KF707618, KF707619, KF707624), Italy 
(Accession number: KP090001), Japan (Accession number: GQ487711), United Kingdom 
(Accession number: KP090028, KP090033) and China (Accession numbers: KT725857, 
JQ902122) with bootstrap support of 96%. The only HPV 16 genotype isolated from this study 
grouped with HPV 16 isolates from Netherlands (accession number: KY549284), an African-
1 variant (AF536180) and a European German isolate (AF536179) with a bootstrap support of 
96%. HPV 66 genotype appears to be more divergent compared to the other HPV types (Fig 
3.6).  Overall, the analysis showed that each of The Gambian isolates grouped within its 
respective genotype clades and within each genotype. Based on this analysis there was no major 
distinction between the high risk and probable high-risk genotype sequences here. Overall, no 
distinct geographical lineages were identified.
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Figure 3.5 Maximum likelihood phylogenetic tree based on L1 gene for high -risk and probable high-risk HPV 
(HR/pHR-HPV) Gambian sequences (shaded) along with similar published sequences retrieved from GenBank 
database   
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3.10  Pair-wise p-distance analysis 
Uncorrected pair-wise distance (p-distance) analyses were carried out on The Gambian HR/pHR- HPV 
sequences to establish the level of divergence within and between the HR/pHR-HPV sequences. Low 
nucleotide divergence was observed within all types particularly within HPV 52 genotypes (0.2%). In 
contrast, p-distance divergence was observed between genotypes ranged from 0.181 - 0.368 (18 % - 
36 %), however, p-distance between HPV 66 and HPV 56 genotype sequences was found to be less 
divergent (p-distance = 0.181) (Table 3.6). 
 
Table 3.5  p-distances within (in bold) and between (not bold) HR/pHR-HPV genotypes 
  HPV16 HPV51 HPV52 HPV53 HPV56 HPV58 HPV66 HPV73 
HPV16 0.008               
HPV51 0.331 0.010             
HPV52 0.250 0.314 0.002           
HPV53 0.321 0.312 0.368 0.008         
HPV56 0.289 0.299 0.325 0.201 0.004       
HPV58 0.210 0.282 0.215 0.309 0.310 0.009     
HPV66 0.305 0.336 0.339 0.232 0.181 0.326 0.017   
HPV73 0.241 0.234 0.234 0.303 0.289 0.214 0.290 0.000 
 
3.11  Regression analysis of p-distance versus geographical distance 
A regression analysis was carried out as described in Chapter 2, section 2.16.2 to detect any major 
genetic diversification events between geographical locations (km) to determine inter-relationships and 
movement of the different geographical isolates and possibly determine the origin of The Gambian 
sequences. This was carried out using the Gambian HR/pHR-HPV sequences and other representative 
sequences of the different HR-HPV types from different geographical localities (Europe, America, 
Asia, and Africa) that formed clades with a bootstrap support of ≥ 90% with the Gambian types.  No 
significant association was observed between the different geographical locations and p-distances of 
the different HPV types (p ≤ 0.05), except in HPV 66. A significant difference was observed between 
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HPV 66 p-distance (nucleotide) and distance (km) between the different geographical locations (r2 = 
0.09; p = 0.01) (Fig 3.6 and Table 3.7). 
 
Figure 3.6 Relationship of distance (km) between different geographical locations 
and p-distances of the different HPV genotypes. 
Legend: (a) - HPV genotype 16; (b) - HPV 51; (c) - HPV 52; (d) - HPV 53; (e) - HPV 56; 
 (f) – HPV 58; (g) - HPV 66; (h) – HPV 73. Each red dot represents HPV genotype from different 
geographical locations (Europe, America, Asia and Africa) including the Gambian types. 
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Table 3.6 Regression analysis between genetic distance of the high risk/probable high-risk HPV 
sequences and geographical distance (Km) 
 
HPV type Number of 
sequences 
Range of 
distances 
(km) 
Slope Intercept R-squared Degrees of 
freedom 
P –value 
16 11 279.6 - 8270 -1.48E-6 0.021982 0.19173 4 NS 
51 26 599.8 - 16843 2.30E-6 0.02131 0.049467 26 NS 
52 25 336.1 -18231 1.78E-7 0.00225 0.035478 53 NS 
53 31 1501 -19553 -7.58E-7 0.027843 0.012122 89 NS 
56 21 2271 - 18541 1.09E-7 0.004349 0.058124 26 NS 
58 33 2036 - 19011 1.68E-7 0.010115 0.016488 76 NS 
66 33 1036 - 19553 1.94E-6 0.017575 0.094088 64 0.01 
73 9 2641 -19553 -3.20E-8 0.003961 0.005342 8 NS 
No significant association was observed between the distances between different geographical locations and p-
distances of the different HPV types (p > 0.05), except in HPV 66 genotype (r2 = 0.09; p = 0.01). NS =Not 
significant (p > 0.05). 
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3.12  Discussion 
HPV is the most common sexually transmitted infection in sexually active women; more than 75% 
of sexually active women will be infected with the virus at some stage in their lives (Dartell et al., 
2012). Females between the ages of 15 - 65 years represent 52% of the Gambian population and based 
on the incidence of 32.4 per 100,000 are at risk of being diagnosed with cervical cancer. Persistent 
infection with high-risk HPV genotypes can cause HPV progression to cervical diseases. The 
introduction of any HPV vaccine prevention strategy requires consideration of the major circulating 
HR-HPV genotypes in a population and cervical diseases. HPV genotyping is very important in 
primary cervical cancer screening as persistent infections with high-risk genotypes can progress to 
cervical cancer, especially in females between the ages of 30 years and older. The quadrivalent 
vaccine has been introduced in the urban region of the Gambia and this is the first research of HPV 
genotype distribution in the area where most cervical cancer cases are reported. 
HPV prevalence was found in the three study regions as follows:  Banjul 12.5%, Kanifying Municipal 
Council 11.9%, and West Coast Region 11.5%. Forty-three percent (6/14) of the HR-HPV genotype 
distribution was observed in the capital city Banjul, followed by 36% (5/14) in the WCR, and 21% 
(3/14) in the KMC (Fig 3.4). However, no regional variation was observed in the distribution 
of HPV genotypes between participants residing in the capital city, Banjul or in the KMC/WCR (p 
> 0.05). 
 
Overall HPV prevalence was found to be 12.1%, which is similar to the 13% prevalence reported for 
rural Gambia, but less than the 18% reported in nearby Dakar, Senegal and 40.8% in Egypt 
(Youssef et al., 2016; Xi et al., 2003; Wall et al., 2005). Of the 28 HPV positive samples in this study, 
14 (50%) were HR-HPV genotypes and 2 (7.1%) were pHR-HPV genotypes. This is somewhat greater 
than the HR-HPV prevalence reported for Dakar, Senegal (17.4%) and for south-western Nigeria 
(19.6%), (Ezechi et al., 2014; Mbaye et al., 2014), where both studies focused on women within the 
ages of 18 – 80 years of age. The differences in prevalence seen in these studies could be attributed 
to the different age groups or, perhaps, more importantly could be due to t h e  variability of HPV 
genotypes in different geographical locations. The 50% HR-HPV prevalence seen in this study 
could also be reflecting selection bias since cervical samples were collected from individuals who 
chose to attend a sexual health clinic. 
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HPV 52 was the most common high-risk  genotype identified, accounting for 31.3% of the total 
HR/ pHR-HPV genotypes and 17.9% of all genotypes. HPV 61 was the most frequent LR genotype 
identified with an overall prevalence of 14.3% and accounting for 33.3% of all LR-HPV (Fig.3.1). In 
contrast to earlier work in rural Gambia, where HR-HPV 16 and LR-HPV 42 were the most 
common genotypes identified (Wall et al., 2005), this study showed that 89% of HPV genotypes 
identified did not match those included in the quadrivalent vaccine (Fig. 3.1). The different prevalence 
of HR-genotype between the two studies might be due to sensitivity of the methods used in 
detecting HPV DNA. The current study employed a pool of primers (modified PGMY09/11), 
which is more sensitive in detecting many HPV specific genotypes than the single consensus 
GP5+/GP6+ primers that amplify a 140 bp of the L1 gene. The sensitivity and specificity of the various 
HPV detection methods available vary greatly and can cause either an underestimation or over-
representation of HPV specific types especially in multiple infections (Vernon et al., 2000). 
Furthermore, the limitation in HPV detection methods has been a concern in many epidemiological 
studies, however, the past decades have seen a great improvement in the sensitivity and specificity of 
these methods due to better quality and stability of reagents and primers (Gravitt et al., 2001). 
Similarly, work carried out in an urban region of Senegal, the only country to neighbour The Gambia 
also found that HPV 52 was the most common genotype, in the Dakar region (Mbaye et al., 
2014). The same observation was also seen in studies carried out in Kenya and Tanzania (Dartell et 
al., 2012; Rahman et al., 2011; De Vuyst et al., 2003). This augments the findings of Bruni et al., 
(2010) that HPV 52 is a major genotype in Africa. HPV 16 and 18 are the predominant circulating 
genotypes found in Southern Africa, Europe and America. However, HPV 16 was found to be the fifth 
most common HR genotype with a prevalence of 7.1% and the eighth most identified genotype with 
an overall prevalence of 3.6%. HR-HPV 18 was not detected in any of the cervical samples. The reason 
for this finding is not known, it could possibly be due to chance, which need addressing with a larger 
sample size. Although cervical cancer is more prevalent in Africa compared to Europe and America, 
HPV 16 and 18 seems to lose its predominance as the major circulating genotype in some parts of 
Africa. Studies in Africa have shown that other HR genotypes such as HPV 31, 35 and 58 are the 
major circulating genotypes (Akarolo-Anthony et al., 2014; Gage et al., 2012; Okonofua, 2007; 
Thomas et al., 2004), indicating that the HPV bivalent and quadrivalent vaccine may not be as 
effective in Africa as previously thought (Luquea et al., 2010; Blossom et al., 2007; Clifford et al., 
2003).  
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Considering the high burden of cervical cancer cases and the lower prevalence of HPV16 and 18 in 
Africa, it could be that other HR-HPV genotypes may be responsible for the high burden of the 
disease. In addition, a study in Asia found that HR-HPV 52 and 58 genotypes (3.8% and 5.6%, 
respectively) were associated with a number of cases of invasive cervical cancer and high squamous 
intraepithelial lesions (HSIL) (Smith et al., 2007(a)). This finding further asserts the importance of 
determining the major HPV genotypes in cervical diseases and cancers before introduction of the 
vaccine and is an important step in effective HPV infection prevention strategies. Furthermore, it 
has been demonstrated here that 10.7% of participants were infected with HPV genotypes targeted 
by the quadrivalent vaccine and 35.7% were positive for HPV genotypes included in the Gardasil 9 
vaccine.  
This data is an important public health implication as the HPV quadrivalent vaccine may be of limited 
value for The Gambia if the circulating non-HPV 16, 18 HR- genotypes are responsible for cervical 
cytological abnormalities and progression to cervical cancer. The LR-HPV genotypes are associated 
with causing cutaneous lesion, respiratory papillomatosis and condyloma acuminate, which HPV 6 
and 11 are responsible for almost 90% of these cases, globally (Poljak, 2011). Although LR-HPV-
types associated conditions rarely result in death, they may cause significant occurrence of diseases 
such as genital warts, which is very common and highly infectious. Of the 12 LR genotypes detected, 
HPV 61 was the most identified genotype, representing 14.3% and 33.3% of the total HPV and LR 
genotypes, respectively. In contrast, HPV 6 is the most common type detected in America and Europe 
including some other parts of Africa (Youssef, et al., 2016; Mbaye et al., 2014; Munoz, et al., 
2003). However, it was the second most common LR genotype identified (16.7%) in this study. 
DNA sequence analysis has shown that none of the HR/pHR-HPV genotypes detected were 
identical to isolates from Africa found in the GenBank database, but rather isolates from America, 
Asia and Europe. In addition, The Gambian HPV 35 isolate might be a novel type as the L1 gene 
sequence differs by more than 10% to the closest known HPV 35 genotype isolated in Ecuador. 
Phylogenetic analysis also showed that all 15 HR/pHR-HPV sequences formed clades with most 
isolates detected in other geographical locations such as Europe, America and Asia except HPV 
genotype 16, which also formed clades with isolates that belong to the African branch (African-1 and 
African-2). 
Based on previous phylogenetic studies, the geographical locations of HPV 16 genotypes were 
classified as European, African-1, African-2 and Asian-American (Chen et al., 2005; Wheeler et al., 
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1997). The Gambian HPV 16 was also found to group with isolates from these three geographical 
locations (Fig.3.5). The finding of The Gambian HPV 16 as the only HR-HPV type forming clades 
with isolates from the African-1 and 2 geographical locations was not surprising as HPV 16 has been 
reported to potentially have evolved separately from Africa and Europe and transferred to the rest of 
the continent through colonial migrations (Chan et al., 1992). Studies on HPV 16 oncogenicity have 
shown that infection with the non-European variant is strongly associated with the development of 
severe cervical lesions and cervical cancer in Europe and Mexico (Tornesello et al., 2004; Berumen 
et al., 2001). 
Furthermore, the HPV 52 variants detected in The Gambia were found to form clades with isolates 
from Europe and Asia with strong bootstrap support (Fig 3.5). The p-distance between HPV 66 
sequences and HPV 56 sequences were found to be more alike to each other (p-distance = 0.181). 
This could be due to both genotypes belonging to HPV species 6, evolved from the same common 
ancestor and are closely related (de Villiers et al., 2004). Furthermore, HPV genotype 66 was the only 
type in this study that appears divergent compared to the other HR-HPV types. This could be a result 
of relatively recent divergence events reflecting migration patterns of Homo sapiens in different 
geographical regions. Based on the current results it could be that these HR/pHR-HPV genotypes may 
have been imported into The Gambia or, more likely, could be recent movement of HPV from The 
Gambia mediated by the historical movement of people. This highlights a key difference with an 
earlier study in rural Gambia, which found that most of the HR-HPV sequences were homologous 
to isolates from Africa (Wall et al., 2005). Contributing factors may be linked to the fact that the 
urban area is a popular tourist destination, therefore, the lifestyle and sexual behaviour of the 
participants may be different. 
Infection with HPV is common in young females; however, most of these infections are transient and 
resolve within 12 months, with only a small percentage developing persistent infection (Youssef et 
al., 2016; Giuliani et al., 2006).  The 32% HPV prevalence peak seen in the 21 - 25 years age group 
(Fig.3.3) follows population norms of sexual initiation as 77.8% of the participants had their sexual 
debut at the age of ≥18 years. Although not statistically significant, sexual debut at the age of 18 
years or older was found to increase the odds of being infected with HPV by two-fold (AOR =2.2; p 
> 0.05) (Table 3.3). A second HPV prevalence peak was observed in the 36 – 40 years age group in 
both study groups (Fig 3.2), which may be caused by several factors including the inability to clear 
the infection due to poor immune response, reactivation of latent infection due to hormonal factors or 
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co-infection with other genital STI pathogens. In addition, most of these women live in a polygamous 
relationship, which could also lead to the acquisition of new HPV infections. 
In contrast to a review by Clifford et al., (2005), which indicated that HPV prevalence increases with 
age in Gambian women, this study found a sharp decline in prevalence in those greater than 40 years 
old, which is consistent with viral transience. A similar finding was also observed in Abuja, 
Nigeria (Akarolo-Anthony et al., 2014). Studies carried out in Africa and Asia have reported a biphasic 
or a flat shaped HPV age-specific curve in older ages (Xi et al., 2003; Franceschi et al., 2006). 
However, 41.7% of the HR-HPV genotypes were found in the 26 - 30 years age group, which 
highlights the importance of early and regular HPV and cervical cancer screening. The data also 
revealed that 93% of participants never had cervical cancer screening (chapter 5, Table 5.1). This 
may be due to either lack of awareness about cervical cancer or accessibility to screening, or both. 
The Gambia Histopathology Laboratory is situated at the EFSTH, Banjul and it is currently the only 
laboratory offering cytology in the country.  In addition, there is no decentralised national cervical 
cancer screening programme; this makes access to screening a significant problem. Cervical cancer 
screening programmes are very limited in the developing countries and it has been documented that 
only 5% of women from these countries are screened for cervical cancer compared to 75% of women 
from developed countries (WHO, 2017). The high burden of HPV infections and low coverage of 
cervical cancer screening observed in the developing countries may be attributed to a lack of resources 
to implement efficient vaccination and screening programmes. Currently, The Gambia uses the visual 
inspection acetic acid (VIA) test for cervical cancer screening and it is being carried out in only a 
few major health facilities in the urban region of the country. Cervical cancer screening using HPV 
DNA has been shown to be better in identifying women at higher risk of developing cervical dysplasia 
than the non-genotyping screening and it has a higher negative predictive value than Pap smear or 
VIA (Cuschieri and Cubie, 2005). HPV DNA is particularly important for monitoring of the high-
risk genotypes that are associated with cancers (Venturoli et al., 2008; Brink et al., 2006). The 
minimum recall time for women who screened negative for HR-HPV DNA is 5 years compared to 
recall-time of 3 years with the VIA screening. However, it is recommended to combine HPV DNA 
with VIA screening in developing countries to detect the stages of the infection to avoid over or under 
treating of individuals (WHO, 2013). 
Whilst HPV infection plays a vital role in cervical cancer development, other socio and risk co-factors 
appear to contribute to the increased risk of disease progression. The use of hormone contraceptive 
for more than 5 years was found to be statistically associated with HPV infection (p = 0.03) (Table 
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3.3). A similar finding has also shown that women, who used hormone contraceptives for more than 
5 years are at increased risk for developing cervical cancer (Bosch et al., 2006). However, association 
studies of HPV positive women and long-term use of hormone contraceptives have failed to reach 
consensus (Smith et al., 2003). There is a potential association between HPV infection and prolonged 
use of hormone contraceptives in the development of cervical cancer, which needs addressing with a 
larger study population. 
In this study, partners having other sexual partners was found to increase the odds of being infected 
with HPV by more than three-fold (AOR = 3.5) (Table 3.3). This interaction may be linked to 
polygamy, which is a common practice in The Gambia and Africa and has implications of increased 
frequency of sexual activity with more than one partner (chapter 5). Furthermore, 91.7% (22/24) of 
participants who were HPV-infected reported they did not use a condom during sexual intercourse in 
the preceding 12 months. Eighty percent of the respondents were married and are less likely to report 
using a condom during sexual intercourse than unmarried women. Consistent use of condoms during 
sexual intercourse can reduce the risk of acquiring HPV infection. However, it has been shown that 
protection is only partial as condoms cannot prevent skin to skin HPV transmission in the genital 
areas not covered by the condom or during non-penetrative sex (Trottier and Franco, 2006; Winer et 
al., 2006). 
HPV prevalence was found to be 32% in the Fula ethnic group and this ethnic group were at increased 
odds of being diagnosed with HPV by two-fold (AOR = 2.1) than the other two major ethnic groups 
(Table 3.3). This observation was also highlighted by Wall et al., (2005) HPV study in rural Gambia. 
Similarly, Sighoko et al (2010) also noted an ethnicity variation in their study on cervical cancer in 
The Gambia. They found the Fula ethnic group was more at risk of being diagnosed with cervical 
cancer compared to the other ethnic groups. The differences seen in the prevalence of HPV infection 
in the different ethnic groups may be linked to possible genetic factors as previously reported (Sighoko 
et al., 2010; Wall et al., 2005; Allsopp et al., 1992), or FGM being a predisposing factor. FGM is a 
common cultural practice amongst certain ethnic groups of the Gambia (Chapter 5). The data showed 
that all the Fula (9/9) women who were infected with HPV underwent FGM. In The Gambia, Wollof 
women are least likely to have had FGM and possibly to be at reduced risk for HPV infection 
(AOR= 0.5) (Table 3.3). This study further showed that participants that have undergone FGM were 
twice likely to be diagnosed with HPV infection (AOR = 2.1). Similarly, studies of Senegalese and 
Malian women also found FGM to be a risk factor for HPV infection (Osterman et al., 2018; Bayo et 
al., 2002). 
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HPV-related cervical cancer can take up to 20 years to develop depending on HPV type and viral load 
(Verteramo et al., 2009). However, co-infection with other genital STI pathogens can facilitate the 
progression and integration of HPV in the host genome. Twenty-five percent of women infected with 
HPV were found to be co-infected with HIV. The incidence of HIV has been shown to exacerbate 
HPV acquisition, persistent infection with multiple genotypes and increases the carcinogenicity of 
high-risk genotypes (Cameron et al., 2016). In addition, a worldwide meta-analysis on HPV and HIV 
has shown that HR-HPV 16 and 18 accounted for most of the invasive cervical cancer compared to 
normal cytology in HIV infected women.  
However, other HR-HPV genotypes also accounted for a significant proportion of high-grade lesions 
and invasive cervical cancer in African women infected with HIV (Clifford et al., 2017; Cameron et 
al., 2016). It has also been shown here that 50% of the participants infected with HPV were co-infected 
with Ureaplasma parvum/urealyticum. Other authors have also found high Ureaplasma prevalence in 
females with HSIL compared to those with normal cytology (Ekiel et al., 2009 (a); Lukic et al., 2006). 
Although Ureaplasma parvum/urealyticum infections are known to be sexually transmitted, they are 
often not diagnosed and treated. These microorganisms can cause chronic pelvic inflammatory 
diseases and infertility if left untreated (Further discussion in Chapter 4). In addition, Ureaplasma 
can damage the vaginal epithelium and causes cervical mucus degradation thus potentially 
facilitating the progression of HPV infection to cervical cancer (Yong, 2017). This work adds to the 
body of evidence that Ureaplasma infection may be an important co-factor in HPV infection. This 
highlights the importance of probably screening for Ureaplasma parvum/urealyticum and providing 
appropriate treatment to HR-HPV infected women, especially those with abnormal cytological results. 
In conclusion, there is a difference between the major circulating HR-HPV genotypes in this study 
and the rural one; however, both studies underscore the need for a multivalent vaccine that targets all 
major HR-HPV genotypes in the general population. Although the quadrivalent vaccine has been 
piloted in The Gambia, this study raises important public health issues with HPV vaccination 
programmes in developing countries. The introduction of accessible HPV DNA testing and cytology 
screening would be beneficial to Gambian women in cervical cancer prevention. Furthermore, HPV 
DNA testing would be an effective screening method in the monitoring and evaluating the impact of 
the quadrivalent vaccine in the population. This will provide an informed policy decision as to 
whether HPV vaccine types have disappeared from the population and how the prevalence of 
genotypes not included in the vaccine is affected. Future studies to investigate HPV genotype 
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distribution in cervical cancer specimens would be necessary for better planning and cervical cancer 
intervention strategies in The Gambia. 
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Chapter 4: Distribution of Ureaplasma parvum and urealyticum in symptomatic 
and asymptomatic Gambian women seeking primary health care 
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4 Introduction 
Ureaplasma species belong to the class Mollicutes and more than 200 species are found in humans, 
arthropods, plants and vertebrate animals (Waites et al., 2005). Seventeen of the Mollicutes species 
are found predominantly residing in the respiratory and urogenital tracts of humans and five are known 
to be pathogenic. Of the five pathogens, four are urogenital pathogens, namely: Mycoplasma 
genitalium, Mycoplasma hominis, Ureaplasma parvum, and Ureaplasma urealyticum whilst 
Mycoplasma pneumoniae is a respiratory pathogen (Paralanov et al., 2012).  
Mycoplasma genitalium (MG) has been identified as a ‘true’ sexually transmitted pathogen and is 
linked to causing non- gonoccocal urethritis (NGU) in men and has been isolated in >10% of men 
with symptomatic NGU compared to < 2% in asymptomatic individuals (Kim et al., 2011; Ross 
et al., 2009). The organism has also been implicated in causing cervicitis and an increased risk of 
pelvic inﬂammatory disease (PID), endometritis and infertility in women (Umeno and Jensen., 
2017). However, Ureaplasma and Mycoplasma hominis are frequently found in the human 
urogenital tract in both healthy individuals and symptomatic patients. Although colonization with 
Ureaplasma is common, the organism can be sexually transmitted and evidence of association with a 
variety of clinical outcomes such as non-gonococcal urethritis and non-Chlamydial infections in men, 
pelvic inflammatory diseases (PID), cervicitis, infertility and chorioamnionitis have been documented 
(Yamazaki et al., 2012; Waites et al., 2005). Initially, Ureaplasma urealyticum was thought to be 
the only species from this genus to infect humans until recently when genomic characterization 
showed that the two biovars were distinctly different in size and they have differential growth 
responses to manganese (Echahidi et al., 2000). Genomic characterization shows Ureaplasma 
parvum has a smaller genome size of 0.75 - 0.76 mega base-pairs (Mbp), whereas Ureaplasma 
urealyticum has a larger genomic size of 0.88 - 1.2 Mbp. The two biovars were later classified into 
two species, Ureaplasma parvum (U. parvum) biovar 1 or parvo and Ureaplasma urealyticum (U. 
urealyticum) biovar 2 or T960. 
Fourteen Ureaplasma serotypes have been identified to infect the human mucosal tracts, which 
includes U. parvum serotypes 1,3, 6 and 14 and U. urealyticum, which includes the serotypes (2, 4, 7 
-13) (Kong et al., 2000). Some earlier studies have limited the pathogenicity and virulence of 
Ureaplasma to one or few of the 14 identified serotypes; serotypes 3, 4, 6 and 8 were initially 
associated with pathological outcomes (Polvsen et al., 2002). Recently, it has been demonstrated that 
individual serotypes are not likely to be associated with differential pathogenicity as the host factors 
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and antigen variability are also important determinants for Ureaplasma infection (Xiao et al., 2011). 
The development of nucleic acid amplification methods and the appropriate species differentiation of 
U. urealyticum and U. parvum have enhanced the understanding of the pathological role of these 
organisms in reproductive age women (Yamazaki et al., 2012; McKechnie et al., 2011).   
There is limited laboratory-based evidence of STI prevalence in the Gambia as suspected cases are 
treated using the syndromic management approach. The syndromic treatment was designed by the 
World Health Organisation (WHO) in the early 1990’s to prevent and reduce the risk of HIV 
transmission in Africa. The current STI syndromic management, which is based on symptoms alone 
may be important but is not enough as most of these clinical symptoms overlap. In The Gambia, the 
standard regime treatment guidelines for non-gonococcal urethritis, cervicitis and other PIDs 
include Ciprofloxacin (500 mg) stat dose, Metronidazole (flagyl) (2 g) and Doxycycline (100 mg) as 
first-line primary treatment as part of the syndromic management approach. Erythromycin (500 mg) 
is given as a second-line treatment option, where N. gonorrhoeae treatment with Ciprofloxacin had 
failed. Furthermore, the first national STI laboratory-based survey in The Gambia was carried out in 
1992, using antenatal women. The prevalence of STI was found to be 29% at that time and since 
then no other laboratory-based evidence has been carried out on STI, except on HIV, which was 
reported as 2% (Sentinel surveillance, 2016). 
Since studies have identified pathological conditions that are associated with Ureaplasma infection in 
reproductive age women (Yamazaki et al., 2012), the characterisation of Ureaplasma species in 
Gambian women may help investigate the significance of this organism in clinical pathology. 
Furthermore, there is no current data on the incidence of M. genitalium, C. trachomatis, N. 
gonorrhoeae, T. vaginalis in The Gambia, except Ureaplasma, which was reported as 0% (Demba et 
al., 2005). Therefore, there is a strong need to have current laboratory-based evidence data on the 
incidence of STI to strengthen the information, education and communication (IEC) on STIs 
prevention and control in The Gambia. 
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4.1 Aim and Objectives 
The aims of the work presented in this chapter were to study the epidemiological pattern and microbial 
burden of Ureaplasma and other STI/genital pathogen infections in symptomatic and asymptomatic 
reproductive age women. 
The following objectives were considered: 
 
• To determine the burden of urogenital Ureaplasma in reproductive age 
women  
• To characterise urogenital Ureaplasma serotypes amongst women with 
(case group) or without (control groups) symptoms of STI 
• To determine the socio-demographic and risk characteristics of 
participants infected with urogenital Ureaplasma 
• To determine the prevalence of selected STI pathogens  
• To determine the antibiotic susceptibility pattern of selected isolated 
pathogens. 
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4.2 Prevalence of Ureaplasma parvum and urealyticum amongst 
participants 
Two-paired samples of endocervical swabs (ECS) and high vaginal swabs (HVS) from each 
participant was screened for urogenital Ureaplasma using duplex real time-PCR (q-PCR) with 
conserved primers that detect both Ureaplasma parvum and urealyticum in a single reaction tube as 
described in chapter 2, section 2.13.1. Conventional PCR was carried out on samples that were 
positive with q-PCR as described in section 2.10. PCR amplicons were purified and sent for DNA 
sequencing as described in chapter 2, section 2.14 and 2.15. 
 
Urogenital Ureaplasma was detected in 46% (107/232) participants, 41% (47/115) were from 
participants that reported one or more symptoms of sexually transmitted infections (case group) and 
51% (60/117) were from asymptomatic participants (control group). Of the 47 participants (case 
group) positive for Ureaplasma, 89% (42/47) had vaginitis /cervicitis and vaginal discharge, 63% 
(30/47) had lower abdominal pain, 53% (25/47) had dysuria (painful and burning urination) and 51% 
(24/47) reported dyspareunia (pain during sexual intercourse). Ureaplasma parvum was identified 
in 79 participants and 48% (38 /79) were from the case group and 52% (41/79) from the control 
group (Table 4.1). Ureaplasma urealyticum was detected in 25 participants with 68% (17/25) 
identified from the control group, whilst three participants were infected with both species (Table 
4.1). However, there was no statistically significant difference between the incidence of 
Ureaplasma prevalence amongst the case and control groups (p > 0.05). Table 4.1 shows the overall 
prevalence of Ureaplasma species in both case and control groups. 
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Table 4.1 Prevalence of urogenital Ureaplasma in the study group (number and percentage 
of positive cases) 
 
Foury-one percent (41%) and (51%) participants from the case and control groups were infected with 
Ureaplasma, respectively. No statistically significant difference of Ureaplasma prevalence was observed 
in the two groups (p > 0.05) 
 
4.3 Prevalence of Ureaplasma parvum and urealyticum amongst different 
age groups  
Of the recruited age groups, Ureaplasma prevalence (56%) was found in the 31 - 35 years age group 
compared with 45% distribution in the 26 - 30 years age group (Table 4.2). 
 
 
 
 
 
 
 
Case Control  Overall Distribution 
 
(n = 115)  (n = 117)        (n = 232) 
Pathogens   n              %   n         %   n            % 
U. parvum 38            33.0 41        35.0  79          34.1 
U. urealyticum   8              7.0 17        14.5  25          10.8 
U. parvum + U. urealyticum   1              0.9  2           1.7   3             1.3 
Total  47           40.9  60       51.2 107         46.2 
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    Table 4.2 Ureaplasma prevalence amongst the different age groups 
 
 
 
A pair-wise statistical comparison was carried out amongst the age groups, firstly, Ureaplasma 
distribution in the 20 years old was compared with the other age groups (comparing to: 21 - 25 years, 
p = 0.9, 26 - 30 years, p = 0.8, 31 - 35 years, p = 0.7, 36 - 40 years, p = 0.7, 41- 49 years, p = 0.8 and 
the total p = 0.5), no statistically significant difference was observed. In addition, all other pair-wise 
comparison shows no statistically significant differences amongst the age groups (p > 0.05) with 
Ureaplasma. However, the total Ureaplasma distribution (107/232) amongst the different age group 
showed Ureaplasma prevalence decreases in the older ages, 36 - 40 years and 41 - 49 years age group 
(13%, 14/107 and 14%, 16/107), respectively. 
The distribution of U. parvum amongst the different age group showed the incidence was higher in 
the age range of 26 - 35 years of age in both study groups (Table 4.3). However, Ureaplasma 
urealyticum was more prevalent (35%) in the 21 – 25 years old in the control group when compared 
with the case group, which shows a prevalence of 25% in the 21 - 25 years and older age group (Table 
4.3). 
 
 
 Age group (Years) Total number recruited Prevalence n (%) 
 
 
20 7   3 (42.9) 
 
21 – 25 53 22 (41.5) 
 
26 – 30 57 26 (45.6) 
 
31 – 35 46 26 (56.5) 
 
36 – 40 33 14 (42.4) 
 
41 – 49 36 16 (44.4) 
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Table 4.3 Prevalence of Ureaplasma parvum and urealyticum in the different age 
groups of symptomatic (case group) and asymptomatic (control group) participants 
 
 
Ureaplasma DNA was identified in all age groups (20 - 49 years old) with 74% (79/107) 
incidence observed with U. parvum.  However, none of the participants in the 41- 49 years 
age group from the case group were infected with U. urealyticum. Both Ureaplasma parvum 
and urealyticum DNA were detected in three participants, 1 from the case group within the 
age group 41- 49 years and 2 from the control group within the age groups of 21 - 25 and 31 
- 35 years. 
 
Furthermore, the overall Ureaplasma parvum/urealyticum prevalence amongst the different age 
groups was also considered, to determine whether there would be any differences in the distribution. 
No significant difference in the total distribution of U. urealyticum was observed in the different age 
groups. U. urealyticum was still predominantly found in the 21 – 25 age group 32% (8/25).  However, 
a slight increase in the total U. parvum distribution in the 26 – 30 years age group was observed 28% 
 
 
Case group Control group 
Ureaplasma species n (%) n (%) 
 
 
U. parvum (n = 79) 
 
Total positives 38 (48.1) 41(51.9) 
Age group: 20 (years) 1 ( 2.6) 0 (0.0) 
21 – 25 6 (15.8) 7 (17.1) 
26 – 30 10 (26.3) 12 (29.3) 
31 – 35 10 (26.3) 9 (21.9) 
36 – 40 2 (5.3) 8 (19.5) 
41 – 49 9 (23.7) 5 (12.2) 
 
U. urealyticum (n = 25) 
  Total positives 8 (32.0) 17(68.0) 
Age group: 20 (years) 1 (12.5) 1 (5.9) 
21 - 25 2 (25.0) 6 (35.3) 
26 – 30 1 (12.5) 3 (17.6) 
31 – 35 2 (25.0) 4 (23.5) 
36 – 40 2 (25.0) 2 (11.8) 
41 – 49 0 (0.0) 1 (5.9) 
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(22/79). Figure 4.1 shows the total Ureaplasma species distribution in the participants by age group. 
No statistically significant difference was observed in the distribution of either U. parvum or 
urealyticum with age group (p > 0.05). 
 
 
 
Figure 4.1 Total distribution of Ureaplasma parvum and urealyticum amongst the 
different age groups of reproductive age women seeking primary healthcare, 
polyclinic, EFSTH, Gambia 
Ureaplasma urealyticum was more prevalent in the 21 - 25 years, age group (8/25) whilst U. 
parvum was detected more frequently in the 26 - 30 years age groups (22/79).  U. parvum was 
more prevalent than U. urealyticum across all the age groups except in the 20 years old, where 
U. urealyticum distribution was 8% (2/25). Both Ureaplasma parvum and urealyticum DNA 
was detected in three participants. Legend: Both = U. parvum and U. urealyticum 
 
 
4.4 Socio-demographic and risk characteristics of participants positive 
for Ureaplasma 
Socio-demographic and risk factors data have shown that 85% (91/107) of participants positive for 
Ureaplasma were married and 17% were married more than once. A number of participants (38%) 
had more than 5 pregnancies with 3% declared having more than ten pregnancies. However, the 
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numbers of miscarriages, still-births or spontaneous abortions were not captured during data collection 
as participants were only asked for the total number of pregnancies they had. Amongst the participants 
infected with Ureaplasma, approximately 72% (77/107) used hormone contraceptives. Eighty seven 
percent (14/16) from the case group and 13% (2/16) from the control group reported having their 
menstrual period stopped due to either contraceptives or breastfeeding. However, none of the 
participants had had a natural menopause. Since the overall data on Ureaplasma incidence shows a 
higher distribution between the ages of 26 - 35 years (26 - 30 years age group = 45%; 26/57; 31 - 35 
years age group = 56%; 26/46), selected risk variables were identified amongst participants between 
the ages of 26 - 35 years of age (Table 4.4). 
 
Table 4.4 Selected risk variables in 26 – 35 years old participants infected with Ureaplasma 
(n = 52) 
Variables Ureaplasma n (%)   95% CI p-value 
Hormone contraceptive used 39 (75) 
         
1.5(0.8, 2.8) NS 
≥ 5 years pregnancies 17 (32) 1.3(0.5,3.0) NS 
Sexual debut (< 18 years old) 26 (50) 0.5(0.3, 0.9) 0.05 
New sexual partner (last 12 months)  9 (17) 0.3 (0.1,1.0) 0.05 
Condom used (last 12 months) 7 (13) 1.3(0.5, 3.3) NS 
FGM 37 (71) 0.8(0.5, 1.4) NS 
 
             P- value is based on chi-square-corrected (Yates). 
 
2 – tailed-p was used in this bivariate analysis and adjusted for age group 
  
OR = Odds Ratio, 95% CI = Confidence Interval.  NS = Not significant, p-value > 0.05 
 
A bivariate analysis on potential risk characteristics that may be associated with Ureaplasma infection 
was carried out and only early sexual debut (< 18 years) and new sexual partner (last 12 months) were 
found to be statistically associated with Ureaplasma infection (p ≤ 0.05) (Table 4.4). 
 
4.5 Ureaplasma  co-infection  with  genital  STI  pathogens 
Women of reproductive age often harbour urogenital infections, therefore, the incidence of other 
selected genital STI pathogens with Ureaplasma was investigated. Bacterial vaginosis was the most 
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common infection identified in participants with Ureaplasma, accounting for approximately 22% 
(23/107), followed by Gram-negative bacteria (GNB) 15.9% (17/107) and infection with Candida 
albicans 14% (15/107). GNB was isolated more frequently from the older age groups (> 40 years old) 
compared to the younger age groups. There was no statistically significant difference observed 
between being infected with Ureaplasma and with other genital STI pathogens (Table 4.5).  
4.6 Distribution and prevalence of  Ureaplasma serotypes 
A total of four hundred and sixty-four (464) samples (paired samples, ECS = 232, HVS = 232) were 
screened for Ureaplasma. HVS specimens were collected because most reproductive age women are 
colonized by this organism in the vagina. Of the 464 samples screened, 33.6% (78/232) of the ECS, 
42.2% (98/232) HVS and approximately 14.4% (67/464) ECS and HVS samples were positive. U. 
parvum was detected in ECS, HVS, and both (ECS and HVS) as follows: 61%, 79% and 51%, 
respectively. The prevalence of U. parvum in these paired samples was found to be 30%. In 
Table 4.5 Co-infection of urogenital Ureaplasma species with selected genital 
pathogens (number and percentage of positive cases) 
  
 
     
Genital 
pathogens 
U. parvum  
(n =79) 
U. urealyticum 
(n = 25) 
  Both 
  (n = 3) p-value 
 
 
C. albicans 14 (17.7) 1 (4.0)   0 (0.0) NS 
HPV   9 (11.4) 5 (20.0)   0 (0.0) NS 
T. vaginalis   5 (6.3) 4 (16.0)  0 (0.0) NS 
S. agalactiae 10 (12.7) 2 (8.0)  0 (0.0) NS 
N. gonorrhoeae   5 (6.3) 2 (8.0)  1 (33.0) NS 
 
Bacterial. 
vaginosis* 17 (21.5) 5(20.0)  1 (33.0) NS 
 
Gram (-) bacteria   8 (10.1) 8 (32.0)  1(33.0) NS 
None of the organisms co-infecting with Ureaplasma were statistically associated with the 
infection. NS = not significant (p > 0.05). Bacterial vaginosis* = polymicrobial syndrome 
 
 
Ureaplasma species 
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comparison, U. urealyticum was detected in ECS, HVS and both (ECS and HVS) as follows: 19%, 
22% and 16%, respectively. U. urealyticum accounts for approximately 8.8% of the total Ureaplasma 
infection. 
Subtyping of positive samples was carried out by DNA sequencing as described in chapter 2, section 
2.14.2 and 2.15. An NCBI BLAST (http:// www.ncbi.nlm.nih.gov/BLAST/ ) search was performed 
for each sequenced product to allocate the Ureaplasma genotype (for ease of referencing, serotype 
will be used henceforth). Subtyping shows that U. parvum serotype 3 was the most prevalent type in 
both samples, followed by serotype 1. In addition, different serotypes of U. parvum were detected 
within the same sample. In contrast, all the samples positive for U. urealyticum were identified as 
serotype 10 (Figure 4.2). Furthermore, 61% (65/107) of participants were identified to harbour 
Ureaplasma species in both the vagina and cervix, 28% (30/107) had vaginal colonisation and 11% 
(12/107) had cervical infection with Ureaplasma. Table 4.6 shows the total number of participants 
infected or colonised with different Ureaplasma serotypes in the cervix, vagina or both. 
 
 
Figure 4.2 Ureaplasma serotype distribution in endocervical and high vaginal swab 
samples of reproductive age women seeking primary health care at a polyclinic, 
EFSTH, Gambia 
 A difference in the distribution of Ureaplasma urealyticum serotype 10, Ureaplasma parvum 
serotype 1 and serotype 3 in the cervix and vagina was observed. Ureaplasma was identified 
mostly from the high vaginal swab (HVS) samples. Legend: ECS = endocervical swab, HVS = 
high vaginal swab, ECS and HVS = endocervical swab and high vaginal swab. 
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Table 4.6 Total number of participants infected or colonised with Ureaplasma either 
in the cervix, vagina or both 
 
Three participants were identified to harbour both serotype 3 and 10 in the cervix and vagina. 
Twenty-four participants were colonised with U. parvum. Multiple colonisations with different 
U. parvum serotypes were also observed in eight participants. Six participants were colonised 
with U. urealyticum, serotype10. Both*= cervix and vagina. U. parvum serotypes detected were 
serotype 1, 3, 1+3/6/14 and 1+6/14. 
 
4.7 Prevalence of other sexually transmitted/genital pathogens amongst 
participants 
Distribution of selected STI/genital pathogens and bacterial vaginosis in participants was 
determined using either real time-PCR (q-PCR) for C. trachomatis, N. gonorrhoeae and M. 
genitalium or microbiological and biochemical analysis for C. albicans, N. gonorrhoeae, T. 
vaginalis, and S. agalactiae as described in chapter 2, section 2.5.1 – 2.13.3. STI/genital 
pathogens were identified more frequently in the case group 41% (48/115) as expected than the 
control group 38% (45/117). 16% (18/115) symptomatic patients (case group) were infected with 
C. albicans, 13% (15/115) with T. vaginalis, 7% (8/115) with S. agalactiae and 6% (7/115) with 
N. gonorrhoeae (Fig 4.3). 30% (34/115) of symptomatic participants were diagnosed with 
bacterial vaginosis.  
Approximately 39% (45/117) of asymptomatic participants (control group) were positive for one 
or more of the screened organisms. Streptococcus agalactiae was the most prevalent organism 
isolated in this group of participants, 11.1% (13/117). Figure 4.3 and 4.4 shows the prevalence 
of genital pathogens in both the case and control groups, respectively. 
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Cervical samples that were culture positive for N. gonorrhoeae were also positive by q-PCR for 
the cryptic plasmid gene. However, two N. gonorrhoeae culture negative samples had a positive 
real time-PCR result. The two samples were rescreened twice by both real time and conventional 
PCR and they remained positive. The positive PCR amplicons were purified and send for 
confirmation by DNA sequencing as described in chapter 2, section 2.15. Sequenced product 
search by an NCBI BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi) identified the organism as 
N. gonorrhoeae. Chlamydia trachomatis was not detected in any of the samples; however, a 
monoplex real time-PCR for C. trachomatis was carried out on all the cervical samples that 
were positive for N. gonorrhoeae. This was necessary as N. gonorrhoeae can compete with C. 
trachomatis for a binding site in a duplex real time-PCR. All the samples tested negative for the 
C. trachomatis cryptic plasmid gene. 
Endocervical and high vaginal swabs (n = 400) samples were screened for M. genitalium using 
primers as described in chapter 2, section 2.11 targeting the 16S rRNA gene, located in the 
V1 and V3 hypervariable region of the gene. All 400 samples were negative for this gene. 
Samples were rescreened using real time-PCR as described in chapter 2, section 2.13.2 targeting 
the M. genitalium MgPa gene using specific primers and probes for the conserved region of the 
gene. All the samples were also negative for the MgPa gene. Although none of the samples were 
positive for the targeted genes for C. trachomatis and M. genitalium, nonetheless, the targeted 
genes were identified in all the positive controls. 
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Figure 4.3 Percentage distributions of selected genital pathogens in symptomatic (case 
group) women attending a polyclinic at EFSTH, Gambia.    
Bacterial vaginosis was most prevalent in the case group accounting 30% (34/115). None of the 
participants were positive for C. trachomatis and M. genitalium. *bacterial vaginosis was 
diagnosed using Amsel’s criteria (Amsel et al., 1983) 
 
 
Figure 4.4 Percentage distributions of selected genital pathogens in asymptomatic 
(control group) women attending a polyclinic at EFSTH, Gambia 
S. agalactiae (11%) was the most prevalent organism followed by C. albicans and bacterial 
vaginosis (each of 10%) and a small percentage, 2.6 % (3/117) women were positive for T. 
vaginalis.  However, none of the samples were positive for C. trachomatis and M. genitalium. 
*bacterial   vaginosis was diagnosed using Amsel’s criteria (Amsel et al., 1983). 
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4.8 Antibiotic susceptibility determination of isolates 
The antibiotic susceptibility testing was interpreted using the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST, 2015) and British Society for Antimicrobial 
Chemotherapy (BSAC, 2015) guidelines and it showed that all S. agalactiae isolates (20/20) were 
resistant to the antibiotic tetracycline, followed by clindamycin and penicillin, each at 45% (9/20). 
Seventy-five percent (15/20) of S. agalactiae isolates were sensitive to erythromycin. 
Ciprofloxacin resistance was observed in 44% (4/9) of N. gonorrhoeae isolates. Seventy-eight 
percent (7/9) of N. gonorrhoeae isolates were sensitive to Ceftriaxone and Cefotaxime. However, 
two isolates of N. gonorrhoeae were found to be resistant to both Ceftriaxone and Cefotaxime, 
22% (2/9). 
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4.9 Discussion 
Ureaplasma species are found in the lower urogenital tracts of reproductive age women and can 
cause infections in the upper urogenital tracts. The increased use of nucleic acid amplification 
techniques has enhanced knowledge and the classification of these microorganisms.  
The aim of this chapter was to study the epidemiology and distribution of Ureaplasma species 
and its clinical significance in symptomatic (case group) and asymptomatic (control group) 
reproductive age women seeking primary health care at the EFSTH, polyclinic, Gambia. 
Ureaplasma was isolated more in the control group (51%) than in the case group (41%). 
However, no statistically significant difference was observed between the distribution of 
Ureaplasma in the symptomatic (case group) and asymptomatic (control group) (p > 0 . 0 5 ).  
A similar trend was observed in other studies, Domingues et al., (2002) reported a 43% 
prevalence rate in asymptomatic women in Guinea Bissau, and 52% was reported by Kim et al., 
(2014) in asymptomatic Korean women. The 46% Ureaplasma prevalence observed in this 
study is inconsistent with the 0% prevalence reported by Demba et al., (2005) Gambian study. 
The differences seen between their study and the current study can be attributed to the diagnostic 
methods used. In Demba et al., (2005), culture methods were used whilst this current study 
employed nucleic acid amplification techniques (NAAT). It had been well documented that 
NAAT have greater sensitivity in detecting Ureaplasma than culture (Stellrecht et al., 2004). 
Culture has an advantage of differentiating colonisation from infection, a concentration of >104 
colony forming units per millitre (CFU/ ml) is considered as an infection (Dhawan et al., 2012; 
Demba et al., 2005). However, it has longer incubation periods, which does not favour the 
isolation of Ureaplasma due to its sensitive nature to the metabolic by-products generated 
during long incubation periods (Kacerovský and Boudys, 2008; Demba et al., 2005). 
Ureaplasma species was detected in 107 participants, U. parvum accounting for 74% (79/107), 
U. urealyticum 23% (25/107) and 2.8% (3/107) participants were infected with both Ureaplasma 
species (Table 4.1). This finding is consistent with other studies carried out in reproductive age 
women in both developed and developing countries (Choi et al., 2012; Beeton et al., 2009; 
Domingues et al., 2002). Ureaplasma age-standardised prevalence was found to be 51% within 
the ages 26 - 35 years and a prevalence decrease was observed in the 36 years old and above. A 
similar prevalence distribution was also reported by Govender et al., (2009). However, U. 
parvum, which was the most frequently isolated species in this study, was found to be most 
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prevalent in the 26 - 30 years age group 28% (22/79) whilst U. urealyticum was more prevalent 
in the 21 - 25 years age group 32% (8/25). In contrast to this finding, U. parvum has been reported 
to be more prevalent in the 21 - 25 years age group and U. urealyticum in the over 25 age group 
(Domingues et al., 2002; De Francesco et al., 2009).  
The differences noted could be attributed to the fact that Gambian women may be more sexually 
active between the ages of 26 - 35 years of age compared to other countries, where sexual activity 
is reported more frequently in the under 26 years old (GDHS, 2013; Navarro et al., 2002). 
Furthermore, frequency of sexual activities has been reported to be associated with Ureaplasma 
colonisation (Waites et al., 2005). The 32% prevalence of U. urealyticum in the 21 – 25 years age 
group may be a concern as this organism has been documented to be associated with adverse 
reproductive outcomes such as infertility, habitual abortion and ectopic pregnancy (Hunjak et al., 
2014). 
 
In the current study, 81% (38/47) of participants from the case group infected with U. 
parvum had cervicitis/vaginitis, indicating that U. parvum may also cause infections and if left 
untreated may cause endometritis and salpingitis (Holmes et al., 2008). Ureaplasma parvum 
serotype 3 was the most prevalent serotype in both the endocervical and HVS samples (Figure 
4.2). This finding is consistent with the literature that U. parvum serotype 3 is the predominant 
type found in reproductive age women (Kotrotsiou et al., 2013; Polvsen et al., 2001). Serotype 3 
has been associated with spontaneous abortion in reproductive age women with cervical 
colonisation (Donders et al., 2000). The ascending infection seen with Ureaplasma from vaginal 
colonisation to cervical infection could be due to the organisms’ ability in producing protease, 
which breaks down IgA and thus facilitates the organism to evade the immune system response 
(Marovt et al., 2014).  
The 51% of Ureaplasma prevalence observed in the asymptomatic participants further support 
the hypothesis that reproductive age women can be carriers of Ureaplasma in their vaginal 
normal flora and they may be at risk of developing ascending infections. Vaginal colonisation by 
Ureaplasma was found to be 28% (30/107) in the participants and U. parvum represented 80% 
(24/30) of the total Ureaplasma vaginal distribution (Table 4.6). Ureaplasma colonisation in 
the female urogenital tract has been linked to a younger age, low socio-economic background, 
multiple sexual partners, black racial ethnicity and the use of hormone contraceptives (Marovt 
et al., 2014; Kotrotsiou et al., 2013; Tibaldi et al., 2009). Approximately 60% Ureaplasma 
prevalence has been reported in black West /Central African and in black African–American 
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women compared to other racial ethnicities (Tibaldi et al., 2009; Newton et al., 2001). This may 
explain the 46% Ureaplasma prevalence also observed in this study. Colonisation of the female 
urogenital tract with Ureaplasma is thought to be associated with hormonal status. The influence 
of hormones on Ureaplasma vaginal colonisation has been demonstrated in oestradiol-treated 
mice (Furr and Taylor-Robinson, 1989) and in human urogenital tracts (Waites et al., 2012).  
In this study, 72% (77/107) of women infected with Ureaplasma were identified to be using 
hormone contraceptives. Although not statistically significant, the use of hormone contraceptive 
(> 5 years) in the study, was found to increase the odds of being infected with Ureaplasma (OR = 
1.5, p > 0.05). Moreover, 51% of the younger age group (21 – 35 years old) reported using 
contraceptives, which may increase the vaginal epithelial glycogen content due to the high 
oestrogen level. This can enhance lactic acid production and reduces vaginal pH, therefore 
promoting Ureaplasma vaginal colonisation (Gupta et al., 2000).  A decrease in the prevalence 
of Ureaplasma between the ages of 36 – 49 years of age was observed. This could be due to 
either reduced sexual activity in the older age groups and/or an increased in the vaginal pH. 
Women of reproductive age frequently suffer from urogenital infections; therefore, the incidence 
of other concomitant organisms with Ureaplasma was investigated. Participants infected with 
Ureaplasma were mostly found co-infected with bacterial vaginosis (Table 4.5). However, there 
was no significant association between bacterial vaginosis and Ureaplasma infection (p > 0.05). 
The predominant detection of Gram-negative bacteria (GNB) 15.9% (17/107) in the older age 
groups infected with Ureaplasma can probably be attributed to either poor hygiene or an atrophic 
vaginal mucosa and /or a neural vaginal pH, providing a conducive environment for enteric GNB 
to colonise the lower urogenital tracts (Kokotos, 2006). In addition, 4% of asymptomatic (control 
group) participants were diagnosed with gonorrhoea (Fig 4.4), which could have gone untreated 
and possibly caused future adverse reproductive outcomes. This further evidenced that 
asymptomatic STI poses a significant public health challenge. 
C. trachomatis and M. genitalium were not detected in any of the screened samples (Fig.4.3 & 
4.4). This finding is inconsistent with Demba et al., (2005) study, which found chlamydial 
infection to be 15% (34/227) in symptomatic Gambian women. In a Kenyan study, a C. 
trachomatis prevalence of 6% (18/300) was reported in asymptomatic reproductive age women 
(Kohli et al., 2013). The chlamydial cryptic plasmid gene was also targeted in Demba et al., 
(2005) study; therefore, the inconsistency seen in the two studies could possibly due to the 
frequent exposure of participants to dual antibiotic treatments or past infections, resulting in 
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acquired immunity. Comparing C. trachomatis prevalence in The Gambia and Kenya with 
England, where there is a national screening programme, a prevalence rate of 46% was reported 
in 2015 amongst asymptomatic 15-24 years old (https://www.fpa.org.uk/factsheets/sexually-
transmitted-infections). The disparities observed in these studies could be attributed to differences 
in sexual behaviour as well as the targeted age groups. Reports have shown that the 15 – 24 years 
age groups are more susceptible to chlamydial infection due to persistence columnar epithelial 
cells in their cervices, which favours the growth of C. trachomatis (Johnson, 1989). 
Antibiotic resistance with Erythromycin and Ciprofloxacin against some strains of N.  
gonorrhoeae and S. agalactiae were observed. Ciprofloxacin and Erythromycin resistance 
observed in this study may be a result of selective pressure as in The Gambia all STIs suspected 
cases are treated with these first-and second-line antibiotics. Similarly, increased reports on 
treatment failure and reduced susceptibility to Cephalosporins, the last line of treatment option 
for N. gonorrhoeae have been reported (WHO, 2013, Tzelepi et al., 2008). The same pattern 
was also observed in this study as N. gonorrhoeae resistance to Cefotaxime and Ceftriaxone have 
been documented. Resistance to Tetracycline by all isolates was observed, however, this finding 
is not surprising as Tetracycline has been extensively used as a broad-spectrum antibiotic for 
more than three decades, in The Gambia.  
In summary, the 51% asymptomatic Ureaplasma prevalence and the no statistically significant 
difference in the distribution of Ureaplasma between the two study groups make it difficult to 
associate significant clinical outcomes with Ureaplasma infection. This finding adds to the 
literature that Ureaplasma may be mere co-factors associated with urogenital infections. 
Approximately in half of the women treated for STI, there was no microbiological aetiology of 
the symptoms. Therefore, a presumptive diagnosis of genital infections based on symptoms alone 
may be erroneous and can increase the burden of antibiotic resistance. The study also highlights 
the need to undertake a national laboratory-based STI and antibiogram surveillance for effective 
policy decision making in the prevention and treatment of STIs in The Gambia. 
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Chapter 5: Socio-demographic and risk factors associated with sexually 
transmitted infections in The Gambia 
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5 Introduction 
Sexually transmitted infection (STI) is a term used to refer to various clinical syndromes that can 
be acquired or transmitted through sexual activity. STIs can be caused by bacteria, viruses, fungi, 
protozoa and ecto-parasites. Sexually transmitted infections are a major global public health 
concern with 86% of the burden found in resource-limited countries (Newman et al., 2015). It is 
estimated that for those aged 15–44 years, STIs excluding HIV are the second most important 
cause of healthy life lost in women after maternal mortality and morbidity (WHO, 2015). Despite 
this burden, STIs have been accorded low priority in many developing countries and most 
countries lack an effective STI control programme.  
Several epidemiological studies have characterised risk factors associated with STI transmission 
and acquisition in adolescents and adults. These factors include urban residency, a young age at 
sexual debut, being in a multiple, sequential or concurrent sexual relationship, partners’ sexual 
behaviour, and inconsistent use of condoms (Niyazi et al., 2016; Cordova et al., 2014; 
Chadambuka et al., 2011). However, physical and sexual partner violence have been reported in 
resource-limited countries to be a contributing factor for STI transmission and acquisition 
(Rahman et al., 2014; Dhakal et al., 2014). Gender-based violence lies in the patriarchal society 
in many African countries and is used to control women, which can easily lead to risky sexual 
behaviours (Rahman et al., 2014; Garcia-Moreno and Watts, 2000). Similarly, a systematic 
review carried out in sub-Saharan Africa has evidenced that taking illicit drugs, alcohol and 
gender-based violence increases the risk of STIs and are associated with STI (Jewkes et al., 2010; 
Kongnyuy and Wiysonge, 2007; Kalichman et al., 2007; Garcia–Moreno and Watts, 2000). 
 
The risk of acquiring STI was found to be two-fold greater in those that take illicit drugs and 
alcohol compared to those that do not (Yohannes et al., 2013; Diclemente et al., 2002). Alcohol 
and drugs have been shown to have a disinhibiting effect that may lead to risky sexual behaviours 
and disease transmission (Kalichman et al., 2007). Although there is an increased risk of 
acquiring and transmitting STIs through commercial sex workers, Yohannes et al., (2013) found 
that many individuals who have sex with commercial sex workers do so mostly due to peer 
pressure, socio-economic dependency, cultural and environmental factors.  
Considerable efforts are being made to identify interventions that could reduce sexual risk 
behaviours, however, change in risk behaviours itself remains a complex issue. Therefore, it is 
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important to characterise risk factors that are associated with STIs at a national level for improved 
and more effective intervention programmes. 
Prevention and early treatment of STIs is a high public health priority in The Gambia, however, 
there is limited information on the current prevalence and behavioural risk factors associated with 
STIs for an effective development of successful prevention, diagnosis and management strategies. 
5.1 Aim and objectives: 
The aim of the work presented in this chapter was to determine STI prevalence and characterise 
the socio-demographic and behavioural risk factors associated with STI in reproductive age 
woman. 
The objectives were to: 
 
• Identify socio-demographic and risk factors that are associated with individual STI 
/genital pathogens 
 
• Determine the prevalence of STIs in symptomatic (case) and asymptomatic 
(control)groups  
 
• Identify emergent risk factors that are associated with STIs in The Gambia.
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5.2 Statistical analysis of socio-demographic and risk characteristics 
of study participants  
Socio-demographic, behavioural risk factors and clinical outcomes of participants were analysed 
as described in Chapter 2, section 2.22 
5.3 Socio-demographic characteristics of participants 
Of the 232 subjects with adequate cellular DNA samples (case, n =115, control, n=117), the 
mean age for both study participants was 31.5 (+7.4 SD) with an age range of 20 – 49 years. 
The data showed that 55% (63/115) of the older women within the age group 31 - 49 years of 
age visited the STI clinic more than the younger age group between the ages of 20 – 30 years, 
45% (52/115). The opposite was observed in the family planning clinic, where women between 
the ages of 21 - 30 years, 56% (65/117) visited the family planning clinic for contraceptive 
services more than the older age groups (Table 5.1). The three major ethnic groups of The 
Gambia were represented in this study, Mandinka (24.6%, 57/232), Fula (21%, 49/232) and 
Wollof (18%, 42/232). The Mandinka ethnic group accounted for 32% (37/115) of the total 
ethnic group that attended the STI clinic and the Wollof were the least represented ethnic group 
11% (13/115) to report to the STI clinic. However, the Wollof accounted for the greatest number 
25% (29/117) of visits to the family planning clinic. Seventy percent of participants (83/117) 
residing in the capital city, Banjul visited the family planning clinic more than the STI clinic. In 
comparison, 81% (94/115) of participants that are residents of KMC/WCR visited the STI clinic 
more than the family planning clinic (Table 5.1). 
More than 70% (82/115) of participants from the case group were married, 17% (20/115) single 
and 11% (13/115) were divorced, whilst approximately 89% (105/117) from the control group 
were married. Approximately, 43% (99/232) of participants had completed a secondary 
education and 4% from the case and 8% from the control group had a college education 
(Table 5.1). The greatest annual household income reported by both groups was between D10, 
000 – D35, 000 (Gambian Dalasi) equivalent to £153 - £537 (GBP). 46% (109/232) of participants 
lived in a household between 2 - 6 occupants. However, the data also showed that 10% (24/232) 
of participants lived in a household of more than 18 occupants. Thirty-three percent (case group) 
and 28% (control group) of participants were petty traders. Approximately 23% (26/115) and 
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30% (35/117) of participants from the case and control group gave housewife as their occupation 
and only 10% (24/232) reported being employed in the civil service. 
The acceptability of using self-sampling for STI screening was also assessed and 18% (43/232) 
preferred self-sampling. Cervical cancer screening programs have been introduced in some parts 
of the urban region of the country, but, this study has shown that more than 90% of participants 
had never undergone cervical cancer screening. Table 5.1 shows the socio-demographic 
characteristics of the participants. 
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Table 5.1 Socio-demographic characteristics of participants 
Variables Case n (%)   Control n (%) 
                                                                     (n =115)                         (n = 117) 
 
Ethnic group   
Fula* 22 (19.13)   27 (23.08) 
Jola 12 (10.43)     8 (6.84) 
Mandinka* 37 (32.17)   20 (17.09) 
Sarahule 11 (9.57)     2 (1.71) 
Serere 10 (8.70   20 (17.09) 
Wollof* 13 (11.30)   29 (24.79) 
Others 10 (8.70)   11 (9.40) 
 
Age group (Years)   
20   5 (4.35)     2 (1.71)  
21 – 25 22 (19.13)   31 (26.50)  
26 – 30 25 (21.74)   32 (27.35)  
31 – 35 26 (22.61)   20 (17.09)  
36 – 40 14 (12.17)   19 (16.24)  
41 – 49 23 (20.00)   13 (11.11)  
 
Level of education   
None 14 (12.17) 23 (19.66) 
Primary 23 (20.00) 15 (12.82) 
Secondary 45 (39.13) 54 (46.15) 
College   5 (4.35)   8 (6.84) 
Islamic studies 28 (24.35) 17 (14.53) 
 
Marital status   
Married 82 (71.30) 105 (89.74) 
Divorced 13 (11.30)     5 (4.27) 
Single 20 (17.39)     7 (5.98) 
                                                                                                 
Residency   
Banjul 21 (18.26) 83 (70.94) 
KMC/WCR** 94 (81.74) 34 (29.06) 
 
Occupation   
Civil servant 12 (10.43) 12 (10.26) 
Business woman 22 (19.13) 15(12.82) 
House wife  26 (22.61) 35 (29.91) 
Petty trader 38(33.04) 33 (28.21) 
Others 17 (14.78) 22 (18.80) 
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Table 5.1 (continued) 
 
Number of people in household   
   
2 -6 46 (40.02) 63 (53.83) 
7 -11 42 (36.52) 38 (32.48) 
12- 17 13 (11.31)   6 (5.12) 
18+ 14 (1.18) 10 (8.53) 
 
Total household income last 12 months   
<D10,000 (< £153.00)   6 (5.22)   9 (7.69) 
D10,000 - 35,000 40 (34.78) 15 (12.82) 
D35,000 - 50,000 11 (9.57) 23(19.66) 
D51,000 - 65,000 11 (9.57) 18 (15.38) 
D66,000 - 75,000 14 (12.17) 13 (11.11) 
D76,000 - 85,000   6 (5.22)   7 (5.98) 
>D85,000 27 (23.48) 32 (27.35) 
 
Acceptance of self-sampling  
Yes  11(9.57)  32 (27.35) 
No 103 (89.57)  81 (69.23) 
Don’t mind either way     1 (90.87)    4 (3.42) 
   
Past screening for cervical cancer   
Yes    7(6.09)      7 (5.98) 
No 108 (93.91)   110 (94.02) 
 
Family member diagnosed with 
cervical cancer  
Yes     2 (1.74)       3 (2.56) 
No  113 (98.26)   114 (97.44) 
 
*The three major ethnic groups of the Gambia. The Mandinka ethnic group were under-represented (42% 
of the eligible population vs 25% of those with adequate cellular DNA), the Wollof and Fula ethnic groups 
were slightly over-represented (16%, 18% of the eligible population vs 18%, 21% of those with adequate 
cellular DNA).                                                                                                     
     Key: KMC/WCR** = Residents of Kanifying Municipal Council and West Coast Region. 
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5.4 Behavioural characteristics of participants 
Participants reported risk factors that were likely to increase their chances of acquiring and 
transmitting STIs (Table 5.2). Although a small number of participants 10 (8.7%) and 6 (5.1%) 
from both the case and control groups had sexual intercourse at the age of less than 14 years due 
to early marriages, most participants 61% (case group) and 72% (control group) had their 
sexual debut at the age of 18 years or older. One participant from the case group reported 
sexual debut at the age of 9 years because of sexual abuse. Approximately, 45% (case group) 
and 33% (control group) of participants reported having more than 2-lifetime sexual partners. Of 
the women with one-lifetime sexual partner, 60% stated that their partners have other sexual 
partners. Approximately 29% (24/82) of participants from the case group and 14% (15/105) 
from the control group were married more than once. Three participants had symptoms of STI 
but reported never having had sexual intercourse. Approximately 84% (95/112) and 99% 
(116/117) of participants from the case and control groups reported having had sexual intercourse 
in the last 12 months (Table 5.2). Of the 95 participants from the case group that had one or 
more symptoms of STI, 22% (21/95) declared to have had one or more new sexual partners in the 
last 12 months compared to 15% (18/117) from the control group. Participants’ attitudes toward 
safer sex practices were assessed and the data showed that more than 80% (189/229) of 
participants’ partners had never used a condom during sexual intercourse in the last 12 months. 
Female genital mutilation (FGM), which is a cultural practice in the Gambia and other parts of 
Africa, had been performed on 73% (84/115) of women from the case group and 52% (61/117) 
from the control group, respectively (Table 5.2). 
 127 
 
Table 5.2 Behavioural characteristics of participants 
Variables Case n (%) Control n (%) 
 
Age at sexual debut**   
< 18 43 (38.39)    32(27.35) 
≥18 69 (61.61)    85 (72.65) 
Number of lifetime sexual partner (s)   
1 60 (53.57)    78 (66.67) 
≥2 52 (46.43)    39 (33.33) 
Partner (s) had sex with others *   
Yes 36 (26.67)    48 (60.00) 
No   8 (13.33)    20 (25.00) 
Don't know / not sure 16 (33.33)    12 (15.00) 
Sexual intercourse in the last 12 months**   
Yes 95 (84.81)   116 (99.15) 
No 17(15.18)      1 (0.85) 
New sexual partner (s) in the last 12 months   
Yes 21 (22.10)     18 (15.65) 
No 74 (77.89)     97 (84.35) 
Condom use in the last 12 months   
Yes  15 (15.79)      7 (6.03) 
No  80 (84.21)  109 (93.97) 
Female genital mutilation   
Yes  84 (73.04)    61 (52.14) 
No  31 (26.96)    56 (47.86) 
Smoking   
Yes/Quit     3 (2.61)                           
No 112 (97.39)                                  117 (100.00) 
                                                              
Hormone contraceptive use   
Yes  53 (46.09) 117 (100.00) 
No  47 (40.87)  
Yes, but stopped using them  15 (13.04)  
History of pregnancy   
Yes  93 (80.87) 114 (97.44) 
No  22 (19.13)     3 (2.56) 
              * n = varies as only women with one lifetime sexual partner were asked this question 
            ** 3 Participants reported to never have had sexual intercourse 
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5.5 Socio-demographic and risk characteristics of participants 
infected with HIV (n = 29)  
Of the 232 women with adequate cellular DNA in the sample collected, 29 had been diagnosed 
with human immunodeficiency virus (HIV). These participants were followed up as a cohort 
group every 9 months for a period of 24 months, to determine HPV sero- prevalence and sero-
conversion as described in Chapter 6. 
The socio-demographic and risk characteristics of HIV infected participants are shown in Table 
5.3. Of these participants, 96% (28/29) were residents of KMC/WCR and only 3% (1/29) lived in 
the capital city. Over fifty percent (17/29) of these women belonged to the two major ethnic 
groups of the Gambia; Mandinka 38% (11/29) and Fula 17.2% (6/29), with the Wollof, the third 
major ethnic group accounting for 3% (1/29) and the minor ethnic groups of the country 
constituting the remaining 41%. Sixty-two percent (18/29) reported being married and the 
remaining were either never been married 10% (3/29), divorced 17% (5/29) or widowed 10% 
(3/29). Of the 62% married women, 50% (31/62) had remarried more than once. Eighty-six 
percent (25/29) were engaged in income generating activities with petty trading, 38% (11/29) and 
business 24% (7/29) were the most common.  
Approximately 52% (15/29) had two or more lifetime sexual partners with 2 women reported to 
have had more than 6 sexual lifetime partners. Of the 48% (14/29) who declared to have had one 
lifetime sexual partner, 71% (10/14) of their partners have other sexual partners with 60% (6/10) 
declared having 2 or more co-wives. Furthermore, 62% (18/29) reported to have sexual 
intercourse in the preceding 12 months and only 22% (4/18) had used a condom. Three women 
reported having had sexual intercourse with a new partner and only 1 out of the 3 reported to have 
used a condom. 
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Table 5.3 Selected socio-demographic and behavioural characteristics of HIV positive 
women (n = 29) 
Variables Number Percentage 
 
 
Residency   
Banjul   1    3.4 
KMC/WCR 28  96.6 
Ethnic group*   
Mandinka 11  37.9 
Fula   5  17.2 
Wollof   1    3.4 
Age group (years)   
21 – 25   4  13.8 
26 – 30   7  24.1 
31 – 35   7  24.1 
36 – 40   5  17.2 
41 – 49   6  20.7 
Marital status   
Married 18  62.1 
Unmarried 11  37.9 
Occupation   
Business   7  24.1 
Petty trading 11  38.0 
Housewife   4  13.8 
Others   7  24.1 
Level of education    
<12 years 20  69.0 
≥12 years   9  31.0 
 
Total lifetime sexual partners   
  1 14  48.3 
≥2 15  51.7 
Sexual intercourse last 12 months   
Yes 18  62.1 
No 11  37.9 
 
Condom use last 12 months   
Yes    4  22.2 
No  14  77.8 
New sexual partner(s) last 12 months   
Yes    3  16.7 
No  15  83.3 
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Table 5.3 (continued) 
 
Partners had other sexual partners 
Yes  10  71.4 
No    4  28.6 
   
Number of partners’ other sexual partners   
1    4  40.0 
≥2    6  60.0 
FGM   
Yes  23  79.3 
No    6  20.7 
Ever screened for cervical cancer   
Yes    1    3.4 
No  28  96.6 
   
   
       *The three major ethnic groups 
 
5.6 Risk characteristics of participants diagnosed with bacterial 
vaginosis and trichomoniasis  
Bacterial vaginosis was diagnosed in 46 participants out of the 232 screened giving a prevalence 
of 19.8% (Table 5.4). Approximately, 30% (34 /115) and 10% (12/117) of participants were 
positive from the case and control groups, respectively. All 30% of participants positive for 
bacterial vaginosis from the case group had symptoms of offensive vaginal discharge and itching. 
Bacterial vaginosis distribution was 2 2 %  ( 1 0 / 4 6 )  in the Mandinka, compared to 17% (8/46) 
in the Fula, and 15% (7/46) in the Wollof, major ethnic groups. The data showed that bacterial 
vaginosis prevalence increases from 17% in women who reported one-lifetime sexual partner, to 
25% in women with two-lifetime sexual partners and to 36% in women with ≥ 3 lifetime sexual 
partners. 31% of participants positive for bacterial vaginosis were married more than once. 
Although not statistically significant, remarriage was found to increase the odds of being 
diagnosed with bacterial vaginosis by two-fold (AOR 2.2, p > 0.05) (Table 5.4).  
The prevalence of trichomoniasis was 16 % (3/18) in the 21 - 25, 11% (2/18) in the 26 – 30 age 
group and a prevalence increase was noted in the over 30 years age groups, with a prevalence range 
of 17% - 28%. Of the 18 participants infected with T. vaginalis, the Mandinka ethnic group 
accounts for 27% (5/18) of the distribution, followed by the Fula 22% (4/18) and the Wollof, 5% 
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(1/18). Participants with trichomoniasis had a vaginal pH range of 5.0 – 6.0.  91% (11/18) had 
symptoms of vaginal discharge and itching. Less than 12 years of education (AOR 2.5) and FGM 
(AOR 2.2) increased the odds of infection with T. vaginalis by two-fold (Table 5.4). 
 
Table 5.4 Bivariate analysis on selected socio-demographic and behavioural risk 
characteristic of participants diagnosed for bacterial vaginosis and trichomoniasis 
 Bacterial vaginosis       T. vaginalis  
Risk variables AOR (95% CI) p-value AOR (95% CI) p-value 
New sexual partner (last 12 months) 1.3 (0.5, 3.4) NS 1.0 (0.1, 3.9) NS* 
Age at sexual debut (< 18 years old) 0.7 (0.4, 1.5) NS 1.7 (0.6, 4.5) NS 
Not using condom (last 12 months) 1.8 (0.5, 9.9) NS* 1.3 (0.2, 5.8) NS 
Low level of education (< 12 years) 1.0 (0.5, 2.0) NS 2.5 (0.8, 7.4) NS 
FGM 1.2 (0.6, 2.3) NS 2.2 (0.7, 6.9) NS 
Remarriage 2.2 (1.0, 5.0) NS 1.3 (0.2, 5.2)    NS* 
Petty trading 1.2 (0.6,2.3) NS 1.8 (0.6, 4.8)     NS 
Low income 0.9 (0.4, 2.0) NS 1.4 (0.4, 4.3) NS* 
 
P- value is based on chi-square-corrected (Yates) except * where Fisher exact was used. 
 
2 – tailed-p was used in this bivariate analysis and adjusted for age group 
  
AOR = Adjusted Odds Ratio, 95% CI = Confidence Interval, NS = not significant, p-value > 0.05 
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5.7 Characteristics of participants infected with C. albicans, N. 
gonorrhoeae and S. agalactiae. 
Candida albicans was isolated from 30 participants with 60% (18/30) from the case group. 
Twelve participants from the control group were also infected 40% (12/30). C. albicans was most 
prevalence in the 26 - 30 age group 40% (12/30), followed by 23% (7/30) in the 21 - 25 age 
group. Sixty-three percent (63%) of the participants diagnosed with candidiasis lived in a 
household of more than 7 occupants with three participants living in a household of twenty 
occupants. Twenty percent (6/30) of participants infected with C. albicans were co-infected with 
HIV. C. albicans was detected in 70% (21/30) of participants who had their sexual debut at 
≥ 18 years old, 73% (14/19) of them reported taking contraceptives and 52% (11/21) had 3 
- 4 pregnancies.  
Similarly, N. gonorrhoeae was isolated most frequently in the 21 – 25 years age group, 
accounting for 45% (5/11) of the total infections. Furthermore, statistical analysis showed that 
all the age groups were at risk of infection with N. gonorrhoeae with a risk three-fold greater in 
the 21 - 25 years age group (OR = 3.7). N. gonorrhoeae distribution was 54% (6/11) in 
participants that had their sexual debut at the age of ≥18 years, but this was not associated 
statistically with the infection (p > 0.05).  
Twenty participants were infected with S. agalactiae with two co-infected with C. albicans. The 
Fula ethnic group was found to be associated statistically with S. agalactiae infection (p = 0.02). 
Fig.5.1 shows the percentage distribution of STI in the different major ethnic groups. 
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Figure 5.1 Percentage distributions of sexually transmitted infections in The Gambia major 
ethnic groups, attending a polyclinic, EFSTH 
 All the different major ethnic groups were infected with STI pathogens with the Fulas accounting for 
53% of the total Ureaplasma and S. agalactiae (14%) infections. The Mandinkas accounted for the 
highest distribution of gonorrhoeae (10%), bacterial vaginosis* (17%) and trichomoniasis (8%), whilst 
candidiasis (C. albicans), 17% was isolated more from the Wollof ethnic group. (Total number recruited; 
Mandinka = 57, Fula = 49, Wollof = 42). *bacterial vaginosis diagnosed using Amsel’s criteria (Amsel 
et al., 1983). 
 
5.8 Prevalence of STI / genital pathogens amongst participants 
Of of the 115 participants (case group) that reported one or two symptoms of STIs, a total of 69% 
(79/115) were infected with at least one of the screened pathogens (T. vaginalis, Ureaplasma, N. 
gonorrhoeae, C. albicans, S. agalactiae). Surprisingly, 67% (78/117) of participants from the 
control group were infected with one or more pathogens. Of the 232 participants screened, 157 
were positive giving an overall prevalence of 67.7%. Ureaplasma was the most prevalent 
organism representing 68% of the total isolates, however of the infections that are symptomatic, 
bacterial vaginosis was most common, followed by candidiasis, and trichomoniasis (Table 5.5). 
Approximately 57% (90/157) of participants were infected with one STI / genital pathogen, 31% 
(49/157) with two, whilst 6% (10/157) with ≥ 3 STI/ genital pathogens. Statistical analysis 
showed that T. vaginalis and bacterial vaginosis were associated significantly with STI (p = 0.01). 
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Table 5.5 Prevalence of sexually transmitted infections (STIs) in reproductive age women, 
20 - 49 years old attending a polyclinic, EFSTH, Gambia 
 
Pathogen Positive 
(n) 
   
     n = 232ǂ 
 
n =157** 
AOR 
(95%CI) 
p- 
value 
Ureaplasma 107      46.2 68.2 0.6 (0.3,1.0) NS 
Bacterial 
vaginosis** 
  46      19.8 29.3 3.8 (1.8,8.1) 0.01 
C.albicans   30      12.9 19.1 1.8 (0.8,41)   NS 
S.agalactiae   20        8.6 12.7 1.0 (0.4,2.7)   NS 
T.vaginalis   18        7.8 11.4 5.3 (1.4,19.2)  0.01 
N.gonorrhoeae   11        4.7   7.0 1.8 (0.5,6.8)   NS 
HPV                                         28      12.1             17.8 1.3 (0.6,3.1)   NS 
C. trachomatis     0        0   0 0   0.0 
M.genitalium     0        0   0 0   0.0 
 
                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ǂ Number of participants recruited  
**Number of participants infected with STI / genital pathogens 
*bacterial vaginosis was diagnosed using Amsel’s criteria.   
  NS = not significant, p-value > 0.05, AOR- Adjusted Mantel - Haenszel (MH) odds ratio, age 
group was controlled 
 
  Prevalence (%) 
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5.9 Statistical analysis of risk factors associated with STI  
Clinical outcomes of participants have shown that 157 participants were infected with one or 
more STI pathogens. Collinearity was observed between being married and had sexual 
intercourse in the preceding 12 months during stratification analysis. Since collinearity was 
observed between the two variables, it was not entered in the final analysis. A bivariate 
analysis was carried out on risk factors that may potentially associate with STIs in The Gambia. 
As more than 80% of study participants were married, marital status was looked at as a risk for 
STI and it was found to be associated statistically with STI (p = 0.001) (Table 5.6). Having ≥ 2 
lifetime sexual partners, not using condoms, contraceptive used > 5years and FGM were found 
significantly associated with STI (p < 0.05) (Table 5.6).  
Multivariate logistic regression analysis was carried out on risk factor variables that were only 
associated with STI at the p-value ≤ 0.05 levels from the bivariate analysis. To control for 
confounding effects in the analysis; age group and ethnic group were adjusted in the model. 
Ethnic group was controlled in this final analysis because there were differences in the 
distribution of ethnic groups between the sample and the eligible population (Table 5.1), 
and disease prevalence between ethnic groups (Fig 5.1). The model was created in a step- 
wise procedure by starting with a single exposure variable and building it up by adding more 
variables. Subsequently, variables that were not significant to STI infection at (p ≤ 0.05) were 
removed from the model one at a time. Marital status, and not using a condom during sexual 
intercourse were the only variables associated statistically with STI (p ≤ 0.05) when age and 
ethnic groups were adjusted (Table 5.6).  
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Table 5.6 Bivariate and multivariate logistic regression analyses showing risk factors 
associated with sexually transmitted infections 
                   
 
Bivariate 
 
Multivariate 
 
Risk variables OR (95% CI) p-value* AOR (95%C I) p-value** 
Married 0.2 (0.1, 0.5) 0.001 0.4 (0.1,0.8) 0.02 
≥2 lifetime sexual partners 0.5 (0.3, 1.0) 0.05 1.0 (0.5,2.2) NS 
sexual debut (< 18 years old) 1.7 (0.9, 2.8) NS 
  
Not using condom (last 12 
months) 
2.9 (1.1, 7.4) 0.03 0.3 (0.1,0.9) 0.03 
education (< 12 years) 1.5 (0.9, 2.5) NS 
  
FGM 2.5 (1.4, 4.3) 0.002 1.8 (0.8, 3.9) NS 
Partner(s) have other sexual 
partners 
2.2 (0.9, 5.3) NS 
  
Petty trading 1.4 (0.8, 2.4) NS 
  
Contraceptive used (>5 years) 0.5 (0.2,1.0) 0.05 0.6 (0.2,1.4) NS 
Multiparity 2.8 (0.2, 3.0) NS 
  
*p - value is based on chi-square-corrected (Yates). 2 – tailed-p was used for the bivariate analysis **Based 
on Wald test, Adjusted for both age group and ethnic group. 
 OR/AOR = Odds Ratio /Adjusted Odds Ratio. NS – not significant (p > 0.05). 
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5.10  Discussion 
In developing countries, the estimation of most of the STIs burden are based on either syndromic 
management or history of self-reported STI. In this study, samples were collected from 
reproductive age women attending a polyclinic for either STI / HIV management or family 
planning contraceptive services. These clinics attend to more than 80% of patients from the capital 
city, Banjul, the West Coast Region and the Kanifying Municipal Council as they are the only 
tertiary referral clinics. The data has shown that more than half of the women regardless of 
whether they had symptoms of STIs or not were infected with one or more STI/genital pathogens. 
The overall prevalence for at least one STI was found to be 68% with Ureaplasma being the most 
prevalent organism (46%). The STI prevalence observed in this study is consistent with other 
African studies. Oliveira et al., (2007) found an overall STI prevalence of 45% in Brazilian 
women and Siawaya, (2014) found a prevalence of 65% in Gabonese women infected with at 
least one STI pathogens. The high prevalence seen is also consistent with The Gambia national 
STI surveillance data, which reported STI prevalence of 29% (Gambia Rapid Assessment Survey, 
1992) confirming that STIs are important public health issues in The Gambia. However, the 
overall STI prevalence reported in this study is greater (68%) than the national prevalence, which 
could be attributed to the increased number of pathogens screened in this study. Another 
contributing factor is the national STI survey was conducted on antenatal women more than three 
decades ago, whilst this study focused on non-pregnant women attending a sexual health clinic. 
Secondly, the epidemiological, detection and statistical methods used have changed over time, 
therefore this could also add to the prevalence differences.  
The prevalence of each of the pathogens isolated from the participants was more than a 10% 
except for N. gonorrhoeae (7.0%), (Table 5.5), which is greater when compared with the global 
estimates (0.3 -1.2%). In the global estimates, T. vaginalis prevalence amongst reproductive age 
women is reported as 1.9% to 7.8% (Newman et al., 2015), which is in line with the 7.7 % 
prevalence reported for T. vaginalis in the current study. Though adolescents and young adults 
(15 – 24 years old) are consistently identified as having the highest rates of STI (WHO, 2014; 
Ohene et al., 2008), this research showed STI prevalence was 3 8 %  ( 88 /2 32 )  between the 
ages of 26 - 35 years of age, in The Gambia. 
STI prevalence decrease was also observed with increasing age in this setting. This finding is 
consistent with The Gambia demographic and health survey (GDHS, 2013), where STI self-
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reported was found to be 2.7% (45/1653) between the ages of 25 - 29 years and prevalence 
decrease was also noted in the older ages. The prevalence increase observed between the 26 
- 35 years of age may be due to risky sexual behaviours such as unprotected sex, a high number 
of sexual partners or partners’ sexual behaviour as 75% of participants in the 31 - 35 age group 
reported their partners had other sexual partners. STI prevalence decrease in the older ages have 
also been noted in several studies carried out in reproductive age women indicating either less 
sexual activity and /or stronger immune responses in these women (Ginindza et al., 2017; Oliveira 
et al., 2007; Kongnyuy and Wiysonge, 2007).  
Having a higher education (>12 years) has a major effect on individual’s sexual behaviour and it 
is thought to contribute to one’s attitude towards risk factors that may be associated with STI 
(Gaspar et al., 2015; Ojiyi et al., 2013). However, less than 12 years of education appears to be a 
potential risk but was not statistically associated with STI (OR 1.5, p > 0.05). This finding agrees 
with Ginindza et al., (2017) study, which found that women who have <12 years of education 
are likely to be infected with an STI. Although the GDHS, (2013) found self-reported STI 
increases with education, this study found STI to be more prevalent in women with none or less 
than 12 years educational backgrounds, which is consistent with other findings (Kakaire et al., 
2015; Arbabi et al., 2014).  It has been demonstrated that women with none or below 6 years 
educational background tends to lack formal employment and may be financially dependent on 
male sexual partners, therefore unable to negotiate for safe sex (Ncube et al., 2012). Most 
of the participants (68%) with symptoms of STIs were low-income earners (< D76, 000 per 
annum; equivalent to < £1166 GBP) and 31% (71/232) were petty traders. Among occupation 
variables, those with secured means of livelihood such as housewives were less at risk of STI 
compared to petty trading (OR =1.4). Women, whose occupation was given as petty trading 
were found to have no formal education or had only 6 years of education (primary education). 
The underlying factors might be multiple sexual partners as those who engage in sexual relations 
with multiple partners most likely do it for economic reasons (Francis et al., 2014; Okesola et al., 
2000). In addition, it has been demonstrated that low- income earners with a less than 6 years 
educational background are less likely to access health care information on STIs prevention 
(Arbabi et al., 2014; GDHS, 2013) than the high-income earners with a more than 12 years 
educational background. Furthermore, Tenkorang, (2012) has shown that highly educated 
women are more likely to practice safer sex by using a condom with their partners compared 
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with the less educated women. This may be linked to the fact that individuals with higher 
education can access information on STIs that helps to protect themselves and their partners. 
In contrast to these findings, frequent sexual activity with different partners has been reported in 
highly educated employed women compared to unemployed or employed women with none or a 
lower educational background (Siawaya, 2014; Kohli et al., 2013; Berhan and Berhan, 2012). 
These findings could be linked to women acceding to liberation bridging all sexual taboos and 
experimenting with their sexuality. Furthermore, Annang et al., (2010) have also reported that 
higher education has a differential impact on racial/ethnic groups as some racial/ethnic groups 
with higher education were at significant risk of STIs. Another possible risk factor observed 
was with multiparity, it increased twice the odds of acquiring STI (OR 2.8) (Table 5.6). This 
could probably be linked to an early sexual exposure such as early marriage, early sexual debut, 
age at first pregnancy, and multiple sexual partners through remarriages as they are all closely 
related with synergistic effects (Wand et al., 2011). Long-term exposure through unprotected 
sex in trying to get pregnant can also increase the chances of acquiring sexually transmitted 
diseases.  
Female genital mutilation (FGM) is a practice that is performed on young females and it involves 
the removal of either part or all of the external female genitalia or injury to the female genital 
organs (WHO, 1997).  FGM is a common cultural practice amongst certain ethnic groups of The 
Gambia and more than 50% of females have undergone FGM before the age of 5 years. 
However, 75% of females between the ages of 15 - 49 years old had undergone FGM in The 
Gambia with slightly a higher level of 79% seen in the rural area compared to 72% in the urban 
area. In this study, 73% (171/232) of participants diagnosed with STI had undergone FGM. This 
cultural practice is least practised by the Wollof ethnic group as shown in this study. Eighty- 
nine percent of the Mandinkas, 79% of the Fulas compared to 9% of the Wollof ethnic group had 
undergone FGM. The finding is consistent with The Gambia demographic health survey (GDHS, 
2013), which also found the Wollof to be the ethnic group least likely to practise FGM in the 
general population. Multivariate analysis showed FGM was not significantly associated with STI 
(p > 0.05) but having undergone FGM, increased the odds of STIs by approximately two-folds 
(AOR = 1.8) (Table 5.6). The observation between FGM and STI could be a result of genital 
tissue damage leading to chronic inflammation and more susceptibility to infections (Osterman 
et al., 2018). Furthermore, since most circumcised females are susceptible to recurrent genital 
infections, this can result in an impaired immune response and an inability to clear the infection. 
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In addition, FGM was found to increase the odds of being diagnosed with trichomoniasis by two-
fold (AOR 2.2), but no association with the infection was observed (p > 0.05), (Table 5.4).  
Demba et al., (2005) also reported a similar finding between FGM and bacterial vaginosis in 
symptomatic women reporting to a sexual health clinic in The Gambia. A similar study conducted 
in The Gambia has also shown FGM to be a significant risk factor of acquiring bacterial 
vaginosis and herpes simplex virus type 2 (Morrison et al., 2001). Although in this current study 
Chlamydia trachomatis was not detected in any of the samples, Morrison et al., (2001) reported 
an association of FGM with chlamydial infection. FGM was also found to be a risk factor for STI 
in studies conducted in Tanzania and Nigeria (Klouman et al., 2005; Okonofua et al., 2002). 
The role of male circumcision in STI acquisition and transmission has been controversial. Many 
cross-sectional studies carried out on the impact of male circumcision on STIs have found it to 
be a protective factor for their female sexual partners (Auvert et al., 2009; Castellsagué et al., 
2002). Contrary to these findings, some longitudinal studies found no protective effect of male 
circumcision with STIs (Turner et al., 2008; Gray et al., 2000). It is widely accepted that the 
foreskin of the penis provides a favourable environment for the growth of pathogenic organisms   
such as C. trachomatis, T. vaginalis, and N. gonorrhoeae, which causes urethral infections 
(Holmes et al., 1999). Therefore, the removal of the penis foreskin reduces the burden of these 
infections in their sexual partners compared to the female sexual partners of uncircumcised men. 
In The Gambia, more than 90% of men underwent pre-pubertal circumcision and Gambian 
women are more likely to be married to circumcised men. These findings may explain the 
low burden of STIs observed in the Wollof ethnic group as they are least likely to have undergone 
FGM. This finding adds to the controversial debate on FGM association with STI and whether 
circumcised women with circumcised male sexual partners are at greatest risk of acquiring an 
STI compared to uncircumcised women with circumcised male sexual partners. 
Being married was identified to be statistically associated with STI (p = 0.02) (Table 5.6), 
however, controversial findings on being married with STIs have been demonstrated. 
Investigations have identified being single to associate significantly with STI (Francis et al., 2014, 
de Lima et al., 2014; Nyarko et al., 2014), whilst others found an association with being married. 
The inconsistency in these findings may be a result of study bias as several studies that did not 
demonstrate a significant relationship between being married and STI had samples that were 
collected from predominantly unmarried participants. Secondly, some studies may be affected 
by a diagnostic bias. For example, if investigators are more likely to screen for and report cases 
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of STI in single young adults or adolescents, these cases may be systematically over-
represented. 
The interaction observed between being married with STI in this study may be due to polygamy.  
Polygamy is a common practice in The Gambia and in some parts of Africa and has implications 
of increase frequency of sexual activity with more than one partner. Approximately, 39% of 
married Gambian women live in polygamous union with one or more co-wives (GDHS, 2013), 
which increases the risk of acquiring and transmitting STI. In many African countries including 
The Gambia, not all sexual partners of women diagnosed with an STI are treated; therefore, this 
may increase the risk of recurrent STIs and treatment failure. 
Inconsistent use of or not using a condom during sexual intercourse has been shown to be a 
risk factor for STI (Boyer et al., 2006; Shlay et al., 2004). Not using a condom was found to be 
statistically associated with STI (p ≤ 0.05) (Table 5.6). The use of a condom in the last 12 months 
by both case and control respondents was comparatively lower than that reported by other studies 
(Karim et al., 2003; Zellner et al., 2003). This could be attributed to many of the respondents 
being married and are less likely to report using a condom during sexual intercourse than 
unmarried women. Another contributing factor could also be a poor negotiating power with their 
partners on condom use during sexual intercourse especially those in a polygamous relationship. 
In addition, studies carried out in many developing countries have shown STIs increases with 
wealth as men with high socio-economic status engage more in sexual risk behaviours, 
therefore predisposing their sexual partners to STIs (Berhan and Berhan, 2013; Awusabo-
Asare and Annim, 2008). 
Advocacy of safe sex practises and the use of condoms have been the driving message on 
STIs prevention, worldwide. In most developing countries the lack of access to free condoms is 
a contributing factor for unprotected sex. Ohene et al., (2008) reported that approximately 60% 
of sexually active Ghanaian females do not know where to obtain condoms. A similar finding 
was also reported in The Gambia demographic health survey, (GDHS, 2013) that more than 
70% of young female adults do not know where to obtain a condom compared to 22% of young 
male adults. 
Several risk factors have also been identified to be associated with sexually transmitted infections. 
Early age at sexual debut had been demonstrated to be associated statistically with STI in single 
factor analysis (Boyer et al., 2006; Navarro et al., 2002). However, none of these investigations 
demonstrated any statistically significant associations with multivariate analysis due to small 
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sample sizes, the same was also observed in this study. Sixty-six percent of participants had 
their sexual debut at the age of ≥ 18 years old. This indicates that most Gambian women have 
their sexual debut at the time of their first marriage, as 80% were married at ≥ 18 years and 
reported having their sexual debut at the same time.  
Age at sexual debut may be causally related to STI through changes in vaginal flora, mucus 
production, and persistence of columnar epithelium on the cervix, which supports the growth of 
pathogens such as C. trachomatis (Berman and Hein, 1999). Early sexual debut may also be 
an indicator of other aspects of sexual activity, which may directly increase risk. These include 
multiple sex partnerships that have an increased likelihood risk of having sex with an infected 
partner, and sexual intercourse with non-regular partners, which also have increased risk due to 
a reduced familiarity between partners (Evans et al., 1997; Kost and Forrest, 1992).  
In many developing countries, contraceptive use is associated with frequent sexual activity 
especially in young unmarried adults and could be a risk factor for STI (Tweedie et al., 2000; 
Ohene et al., 2008). It had been shown that most women associate contraceptive use with 
preventing unwanted pregnancies; therefore, its association with STIs through risky behaviours 
is normally not considered (Ohene et al., 2008). Women who use oral contraceptives or 
intrauterine device (IUD), are less likely to use barrier contraceptive (condom) and this cohort 
of women tend to have a higher STI prevalence than non-users (Navarro et al., 2002). However, 
results obtained on contraceptive studies have shown some disparities, for example; Mosure et 
al., (1997) found that contraceptive users have decreased risk of being infected with STI than 
non-users. Similarly, the use of IUD was found to be a protective factor against chlamydial 
infection (Evans et al., 1997). The investigators hypothesized that the IUD may enhance local 
immune response and accelerate the development of cervical squamous epithelial cells, which 
prevents Chlamydial infection. However, no significant difference was found for IUD use 
compared with the use of other methods by these investigators. Although, this current study did 
not differentiate the use of different contraceptive methods with STI, it has found the use of 
contraceptive for more than 5 years to be associated statistically with HPV and STI (p < 0.05) 
in a bivariate analysis (Tables 3.1 and 5.6), however when age and ethnic groups were controlled 
in a multivariate analysis, no significant association was found with STI (p > 0.05) (Table 5.6). 
The overall prevalence of 30% of bacterial vaginosis reported for the symptomatic (case group) 
participants is high when compared with the prevalence reported from other African countries. 
A prevalence of 20% was reported in Burkina Faso and in Gabon, 23% in symptomatic women 
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in Malawi, and 24 % of women seeking primary health care in Morocco (Oliveira et al., 2007; 
Costello et al., 1998; Ryan et al., 1998; Ledru et al., 1996). The finding in this study is consistent 
with Demba et al., (2005), which reported bacterial vaginosis to be present in 47% in 
symptomatic Gambian women. The risk of being diagnosed with bacterial vaginosis clearly 
increased with the reported number of lifetime sexual partners. The same finding was also 
observed in a population-based study in rural Uganda (Sewankambo et al., 1997). Bacterial 
vaginosis and trichomoniasis were found to be more prevalent in the Mandinka ethnic group 
compared to the other two major ethnic groups. However, Ureaplasma, Streptococcus agalactiae, 
and HPV (chapter 3) prevalence were observed more in the Fula ethnic groups. The difference 
seen in pathogen prevalence in the ethnic groups could be due to differences in vaginal flora or 
genetic variation in the different ethnic groups (Allsopp et al., 1992). 
Although some researchers have cited bacterial vaginosis as a syndrome rather than an STI, it is 
one of the most common conditions reported in sexual health clinics, worldwide (Demba et 
al., 2005). Bacterial vaginosis and trichomoniasis were diagnosed more in the older age group 
(> 30 years old) as observed in other studies (Ginindza et al., 2017; Oliveira et al., 2007). The 
high incidence seen in older women could be due to physiological changes such as high vaginal 
pH as bacterial vaginosis is a poly-microbial syndrome caused by a shift in the vaginal flora. The 
vaginal flora, which is predominantly made up of lactobacilli is gradually or totally replaced with 
anaerobic bacteria such as Gardnerella vaginalis, Bacteroides, Atopobium vaginae and other 
Gram-negative bacteria in older women resulting in a higher vaginal pH (Hill, 1993). 
Recent systematic reviews have indicated that the use of self-sampling for STI screening was 
highly acceptable in many developing countries (Huynh et al., 2010; Stewart et al., 2006). The 
acceptability of self-sampling for STI screening was assessed in this study and only 18% 
preferred self-sampling, citing embarrassment as a reason. Comparing the low rate of 
acceptability of self-sampling in this study with reports from other developing countries for 
example: in India, Uganda and Nicaragua, self-sampling acceptance were: 95%, 64% and 50%, 
respectively (Bansil et al., 2014). Data on self-sampling has indicated that most women preferred 
self-sampling because it is less embarrassing, less invasive and more private than the conventional 
speculum collection (Quincy et al., 2012; Dzuba et al., 2002). A good correlation between self-
sampling and health care provider sampling has been reported, therefore it could be a potential 
future collection option for cervical cancer screening programmes in developing countries 
(Gravitt et al., 2011; Safaeian et al., 2007). 
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In conclusion, the results indicate that there is a strong need to implement STI screening and 
treatment in women of reproductive age. Since many risk factor analyses were performed in this 
study (chapters 3 and 4), those factors that were statistically significant with only one organism 
may well have arisen by chance except being married and not using condoms, which were the 
only variables found to be statistically associated with STI in a multivariate analysis. Therefore, 
the use of a condom during sexual intercourse should be advocated for, to reduce the risk of 
STI acquisition and transmission. Embarrassment and social stigma could be a contributing 
factor for most women not reporting symptoms of STIs. However, 72% of participants preferred 
a health care provider sampling. Therefore, it was not a contributing factor for not reporting 
symptoms of STIs in this study. Nonetheless, women should be educated on the potential health 
and social behavioural risks of asymptomatic STIs. Furthermore, results obtained on the 
acceptability of self-sampling may not be representative of Gambian women as more data is 
needed to validate this finding. Although this study has highlighted some important public 
health issues, there is a need for STI programs to strengthen intervention strategies to increase 
awareness on risk factors associated with STIs in Gambian women, especially in women between 
the ages of 26 - 35 years of age. There is also a strong need to encourage sexual partner(s) 
treatment to reduce or prevent recurrent infections, which can lead to significant reproductive 
health complications in women and their newborn babies. 
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Chapter 6: Human papillomavirus sero-prevalence and estimation of sero-
conversion in a cohort of HIV-positive women 
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6 Introduction 
The association between HPV and genital diseases is well established. HPV infection is usually 
a transient infection in immune-competent individuals with an average duration of 8 months (Ho 
et al., 1998).  However, HPV infections in HIV-positive individuals are burdensome and the 
progression of cervical diseases is aggressive as these individuals are less likely to clear the 
infection due to reduced cell-mediated immune (CMI) responses, which increases their risk of 
developing persistent infections, cervical dysplasia and cancer (Ezechi et al., 2014). It has been 
documented that even after cancer treatment in these individuals, the chances of recurrence after 
5-years are between 40 - 60%, which can be linked to the level of immunosuppression, social and 
behavioural risk factors (Rein, 2000 (b), Cuthill et al., 1995). This association is such that in 
1993, invasive cervical cancer was added to the list of AIDS-defining illnesses. 
A meta-analysis carried out mostly in developed countries has shown an association between 
infection with multiple HR-HPV genotypes and HIV-positivity (Clifford et al., 2017; Blossom 
et al., 2007). Furthermore, HIV-positive women tend to be more susceptible to co-infection with 
HR-HPV types other than HPV 16 and 18; however, this can vary geographically (Luque et al., 
2006; Levi et al., 2004). This could be due to increased HIV prevalence in developing countries, 
where other oncogenic HR- HPV genotypes are more common (McKenzie et al., 2010; Clifford 
et al., 2017). For example, in Africa, HPV genotype 51, 52, 53, 56 and 58 have been reported to 
be more prevalent in HIV-positive women with cervical dysplasia than HPV 16 (Sahasrabuddhe 
et al., 2007; Blossom et al., 2007). 
The introduction and increased accessibility of antiretroviral therapy (ART) in resource-limited 
countries in the last decade has contributed in the improvement of clinical outcomes and life 
expectancy in HIV-positive individuals. The Gambia introduced ARVs in the early 2000s and 
started using the 2013 adopted HIV treatment guidelines recommended by the WHO, in 2015. 
The WHO recommended first-line and second-line treatment regimens for HIV-positive adults 
and adolescents are as follows: The first-line regimen includes a combination of nucleotide 
reverse-transcriptase inhibitor (NtRTI), Tenofovir disoproxil fumarate (TDF), and a nucleoside 
reverse-transcriptase inhibitors (NRTIs) e.g. either lamivudine (3TC) or Emtricitabine (FTC), and 
an integrase strand transfer inhibitor (INSTI), Dolutegravir (DTG). A combination of TDF, 
3TC or FTC, and non-nucleoside reverse-transcriptase inhibitors (NNRTI), e.g. Efavirenz 
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(EFV) is given as an alternative treatment. Zidovudine (AZT) can also be given in combination 
with EFV and 3TC or FTC as an alternative treatment.  
The preferred second-line treatment regimens include a combination of AZT, 3TC and a protease 
inhibitors (PIs) e.g. Lopinavir/ritonavir (LPV/r) or Atazanavir/ritonavir (ATV/r) if TDF was used 
in the first-line therapy or TDF, 3TC and LPV/r or ATV/r, if AZT was used in first-line therapy. 
In HIV-2 or dual infection (HIV-1 and HIV 2) treatment, the preferred regimen is a combination 
of TDF, 3TC and LPV/r or an alternative regime with AZT, 3TC and LPV/r. 
HIV-positive individuals who are prescribed on ARV treatment have been found to be at a 
reduced risk of being infected with oncogenic HR-HPV than those who are not (Ezechi et al., 
2014; Schuman et al., 2003). The consistent use of ARV drugs has been reported to restore and 
enhance the immune response of HIV-positive individuals, thus preventing infections caused by 
other STI pathogens (Broker et al., 2001). Furthermore, HIV-positive women with low CD4 count 
and who are not prescribed on ARVs may be at greater risk of latent HPV reactivation (De Vuyst 
et al., 2008). This can occur because of severe immunodeficiency and can lead to cervical 
diseases. Therefore, the use of ARV drugs may reduce persistent infection with HPV and 
facilitate cervical lesion regression in HIV-positive women (Heard et al., 2004).  
Humoral immune responses following natural HPV infection of the anogenital tract are not 
always observed. If sero-conversion does occur, antibodies against HPV capsids may persist for 
years and are therefore reﬂective not only of recent, but lifetime HPV exposure (Stanley et al., 
2006). HPV seropositivity has been associated with both virus-related (e.g persistence of 
infection, viral load, and viral type) and host-related factors (e.g increasing age, HIV-induced 
immunosuppression and sexual risk behaviour (Hildesheim et al., 2007). 
Since the introduction of ARVs in The Gambia, there is little or no information on the 
prevalence, distribution of HPV and cervical cancer in women who are HIV-positive. The 
incidence of HPV infection in African women is known to range from 30 to 60% with the most 
prevalence seen in women co-infected with HIV (Baay et al., 2004; Wright et al., 2000). Sero-
conversion following HPV infections in immune-competent individuals is estimated to be 
between 8 - 24 months, however, longitudinal studies analysing HPV sero-conversion following 
HPV infections in HIV-positive individuals are scarce. More insight into the associations between 
HIV infection and HPV sero-response is crucial to interpret results from sero-surveillance, which 
can, for example, be used to monitor HPV prevention strategies. As reproductive age women, 
especially HIV-positive, are at increased risk of HPV infection and HPV-related diseases, 
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understanding these issues among this group is important. Furthermore, immunity to HPV virus-
like particle vaccines is type-specific, it is therefore, important to also characterize the 
distribution of HPV and cervical diseases in this group to develop effective cervical cancer 
prevention strategies.  
6.1 Aim and objectives 
The aims of the work presented in this chapter were to characterise the distribution of HPV and 
cervical diseases, determine sero-prevalence, and estimate the duration of HPV sero-conversion 
in a cohort of HIV-positive women. 
 
Objectives: 
 
• To determine HPV sero-prevalence and type-specific distribution in cervical and 
serum samples 
• To estimate the time of sero-conversion over a period of 24 months 
 
• To determine cervical cytological changes over a period of 18 months 
 
• To determine and estimate cervical lesion regression, persistent infection and 
duration of immune response. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 149 
 
6.2 Baseline data on recruited HIV-positive women 
Twenty-nine women diagnosed with HIV were recruited in this arm of the study, 72% (21/29) 
were HIV-1, 14% (4/29) HIV-2 and 14% (4/29) were infected with both HIV-1 and 2 (Table 
6.1). Of the 29 women, 9 had CD4 cell count between 350 – 499 (cells/mm3) and 55% had a CD4 
count of ≥500 cells/mm3. Eighty-six percent (86%) of these women were not prescribed ART at 
the time of recruitment. It is noteworthy that at the beginning of this study, the recommended 
CD4 cut off for HIV treatment by the W.H.O was < 350 cells/mm
3
.  Table 6.1 shows the baseline 
laboratory and treatment characteristics of participants. 
 
Table 6.1 Baseline laboratory and treatment characteristics of recruited HIV positive 
women (n = 29) 
 
 
     
 
    Variables  
  
   Number and (percentage) 
   
 
    HIV status 
    
       HIV-1        21 (72)    
       HIV-2          4 (14)    
       HIV-1 and 2          4 (14)    
   CD4 cell count (cells/mm3)     
       <350          4 (14)    
       350 – 499          9 (31)    
       ≥500        16 (55)    
   Antiretroviral (ARVs) drug use     
       On ARVs          4 (14)    
      Not on ARVs        25 (86)    
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6.3 HPV sero-prevalence and cervical diseases amongst HIV-positive 
women  
6.3.1 HPV sero-prevalence and serotype distribution  
Serum samples from HIV-positive women were each mixed with one of the pseudo-typed viruses 
and a reduction of the infectivity was measured. Serum samples that did not reduce the infectivity 
to less than half at a dilution of 1:40 were deﬁned as negative for neutralization as described in 
chapter 2, section 2.20.  Fifteen samples were found to neutralize pseudo-typed viruses of one or 
more of the following HPV types: HPV 16, 18, 35, 51, 52 and 58.  
HPV sero-prevalence was found to be 51.7% (15/29) and antibodies against HPV52 were the 
most common at 24% (7/29). Of the 15 women whose samples tested positive, 8 had HPV 
antibodies to a single serotype with HPV 51 accounting for 37.5% (3/8) of the single serotypes 
detected, followed by HPV 52, 25% (2/8) and HPV16, 18, and 58 each at 12.5% (1/8). Seven (7) 
women were sero-positive with multiple HPV serotypes with neutralising antibodies against two 
HPV types detected in 3 women whilst 4 women had neutralising antibodies against three HPV 
types (Table 6.2). 
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Table 6.2 Number of women sero-positive for HR-HPV neutralising antibodies 
against one or multiple HPV types at baseline 
         
Participants were screened against selected HR-HPV genotypes in this arm of the study. HPV-52 
was the most common genotype detected in multiple infections and HPV-51 was the most 
prevalent type in single infections amongst the study participants. 
 
6.3.2 Cervical diseases, HPV DNA and neutralising antibodies at 
baseline 
Baseline cytology showed that of the 5 women diagnosed with severe high-grade cervical lesions, 
one had neutralising antibodies against HPV 16, two had antibodies against HPV 51 and the 
remaining two were sero-negative. One of the women with neutralising antibodies against HPV 
51 had severe HSIL which suggested invasive cervical cancer. HPV DNA genotype 51 was also 
detected in a cervical swab sample from this patient (Table 6.3).  
Three participants were diagnosed with low-grade cervical lesions with one woman having 
neutralising antibodies against HPV 16, 35 and 52. Of the two remaining women with LSIL, 1 
had antibodies against HPV 58 and 1 tested sero-negative. Nine women had normal cytology 
 
 
HPV serotypes 
 
Number of women 
16 1 
18 1 
35 0 
51 3 
52 2 
58 1 
16/35/52 2 
16/58 1 
18/35/52 1 
18/52/58 1 
35/51 1 
35/52 1 
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results and HPV neutralising antibodies were detected in their sera. In addition, HPV DNA (1 
high-risk and 3 low-risk types) was detected in four of the women with normal cytology (Table 
6.3). Only six women had normal cytology results, the absence of HPV DNA and were also sero-
negative against the screened HPV serotypes at baseline. 
 
Table 6.3 Number of women with CIN lesions, with and without neutralizing antibody  
and HPV DNA 
*patients were unable to give a second sample at the 9 months follow-up visit as both patients died.  ǂ 
was diagnosed with cervical cancer (HPV51*ǂ).  ** Patient sero-converted to HPV 16 at the 9 months 
follow-up visit.                                                                                                                                                              
Key: HSIL – High-grade squamous intraepithelial lesion; LSIL – Low-grade squamous intraepithelial 
lesion 
 
6.4 Presence of HPV DNA, neutralising antibodies and cervical 
lesions in HIV-positive women. 
6.4.1 Follow-up at 9 months 
Of the 29 women recruited, only 18 gave a follow-up second sample at 9 months. Of the 15 
women that were sero-positive at baseline, 10 gave a second sample, two had died and three were 
lost to follow-up. Out of these women, three were found to produce additional HPV antibodies at 
9 months. Of the 14 women that were sero-negative at baseline, 8 gave a second sample and two 
women sero-converted to HPV16 and HPV 35, respectively. However, none had HPV DNA 
detected in the cervix. The remaining 6 women remained sero-negative. A participant with normal 
 
 
 
Presence of HPV DNA (type) HPV neutralising antibodies 
             Cytology grade 
  HSIL 
  
 
              Positive  (51) 51*ǂ 
 
              Negative                        51 
 
              Negative 16* 
 
              Negative sero-negative** 
 
              Negative               sero-negative 
LSIL 
  
 
             Negative               sero-negative 
 
             Positive (58) 16,35, 52 
 
             positive (56)                         58 
Normal 
  
 
             positive (52)      51, 52 
 
             positive (42)      35, 52 
 
             Positive (6)                         51 
 
             positive (61) sero-negative 
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cytology and a presence of HPV 52 DNA at baseline (Table.6.3) was diagnosed with HSIL and 
was still found to be persistently infected with HPV52 DNA at the 9 months follow-up visit. In 
addition, the presence of HPV DNA (HPV 69) was detected in a woman who had HSIL and 
neutralising HPV 51 antibodies at baseline. Lesion regression was observed in one participant 
who was diagnosed with LSIL at baseline.  
6.4.2 Follow-up at 18 months  
At the 18 months follow-up visit, only 12 women provided a third sample and they were all on 
ARVs treatment at the time of the visit. Of these women, the 6 remaining sero-negative 
participants were found to be still sero-negative at the 18 months follow-up visit. However, of the 
6 sero-positive women, five remained sero-positive with the same neutralising HPV antibodies 
and one became sero-negative at the 18 months follow-up. The presence of HPV DNA (HPV 66) 
was found in only 1 woman who in three consecutive samplings had neutralising antibodies 
against HPV 18. 
In addition, the data also showed that three women who were sero-positive to multiple HPV 
serotypes at either baseline or at the 9 months visit became persistently sero-positive with only 
one serotype and lost neutralising activity against the other types at the 18 months visit. Cytology 
results of the 12 women who provided serum samples showed that only two of the women who 
were initially diagnosed of HSIL at baseline and at 9 months had lesion regression to LSIL at the 
18 months follow-up visit. The remaining 10 women had normal cytology. Table 6.4 summaries 
the follow-up cytology results. 
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6.4.3 Follow-up at 24 months  
At the end of the follow-up visit, only 11 women provided a fourth sample at 24 months. Of these 
women, 7 were sero-positive at baseline and sometime during follow-up.  Five women remained 
sero-positive until the end of the 24 months follow-up period (Table 6.5) and two women lost 
their neutralising antibodies by the 24 months follow-up visit. Only 4 out of the remaining 6 sero-
negative participants gave a fourth sample and one sero-converted to HPV-58. Only 3 women 
who gave four consecutive samples remained sero-negative for neutralising HPV antibodies, had 
no presence of HPV DNA and had three consecutive normal cytology results (Pap smear was not 
collected at the 24 months follow-up visit due to the timeframe as this part of the work was 
carried-out externally). Cervical swabs that were collected at the time of serum collection were 
all negative for the presence of HPV DNA. 
 
 
Table 6.4 Number of samples with normal and abnormal cytology results from 
baseline to 18 months. 
 
Among those that gave a second sample at 9 months, cervical lesion regression was observed 
in one participant who had LSIL at baseline. In addition, one participant who had a normal 
cytology result at baseline was found to have a HSIL at 9 months. Cervical lesion regression 
from HSIL to LSIL was observed in two participants at the 18 months follow-up visit. 
 
 
 
Normal LSIL HSIL 
Collection interval  
(number of samples) 
   
   
Baseline (n = 23) 15 3 5 
9 months (n = 18) 14 0 4 
18 months (n = 12) 10 2 0 
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Table 6.5 Number of women persistently sero-positive for HR-HPV neutralising 
antibodies at the 24 months follow-up visit 
 
Five women with four consecutive samples were found to persistently have the same HPV 
neutralising antibodies. HPV52 was the most neutralising antibodies detected in multiple 
infections. 
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          
 
HPV serotypes Number of women 
 
 
18 1 
52 1 
35/52 1 
52/58 1 
18/35/52 1 
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6.5 Discussion 
HPV is known to have the ability to evade the host’s immune response as the virus does not cause 
an inflammatory reaction, which enhances the full activation of the cell mediated immune 
response (Bonanni et al., 2009). However, more than 50% of infections are naturally cleared or 
become undetectable within 12- 24 months of infection (Hildesheim et al., 2007; Trottier and 
Franco, 2007). Both the innate and adaptive (cellular and humoral) immune systems play a role 
in the immune response at the site of HPV infection in the genital tract. The cell-mediated 
immune (CMI) response, which is central against the early HPV proteins, is decreased in HIV-
positive individuals (Clifford et al., 2017; Stanley, 2006; Passmore et al., 2006). Therefore, HIV-
positive individuals may be unable to mount an effective CMI response against HPV infection, 
which could lead to persistent infection with the virus. 
In this arm of the study, serum samples from HIV-positive women were screened for neutralising 
antibodies against six high-risk HPV genotypes namely: HPV 16, 18, 35, 51, 52 and 58.  Fifteen 
serum samples (51.7%) were positive for neutralising antibodies against one or more screened 
HPV types (Table 6.2). Nearly half of these participants (7/15) were sero-positive with more than 
one HPV type at baseline, which could reflect cross-reactivity or infection with multiple types 
(Stanley et al., 2006). However, subsequent follow-up data showed persistent infection with 
multiple types; therefore, it seems likely that these HIV-positive women were infected with 
multiple HPV types. Furthermore, it has been demonstrated that natural infection with HPV 
induces highly type-specific neutralising antibodies, which discriminate between even closely 
related species (Clifford et al., 2006). The high prevalence of multiple neutralising HPV 
antibodies observed can result from HPV-induced upregulation and persistence infection of HPV 
(Moscicki et al., 2004).  Importantly, it can also result from continued sexual exposure to novel 
HPV types during periods of severe immunosuppression, which may be an important factor in 
this study as more than 52% of participants reported having two or more lifetime sexual partners 
and of those with one-lifetime sexual partner, 60% of their partners have two or more co-wives. 
Furthermore, most of these women’s partners do not use condoms during sexual intercourse, 
therefore predisposing them to new infections (Chapter 5). 
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The detection of HPV type-specific antibodies in this study did not strictly correlate with the 
HPV DNA results indicating that the antibody response may most likely be due to previous 
exposure to the virus. In addition, it has been observed that persistent, rather than transient 
HPV infection is associated with sero-conversion (Petter et al., 2000). 
HPV sero-conversion to HPV 16 and 35 were observed in two women at the 9 months follow-
up visit and one participant sero-converted to HPV 58 at 24 months. This finding is 
consistent with the literature where the average time for sero-conversion is estimated to be 
between 8 -12 months. However, sero-conversion after 18 months to HPV16, 18 and 6 had 
been reported in 55-70% of women infected with HPV (Ho et al., 2004; Carter et al., 2000). 
The presence of HPV DNA was not detected in the cervical samples of the participants who 
sero-converted at 9 and 24 months, respectively. The HPV immune response generated could 
possibly be due to vulval or vaginal infections that were not detected in the cervical samples. 
Sero-conversion was found to be transient and that sero-positivity could be intermittent as 
most participants that were sero-positive with multiple neutralising antibodies lost 
neutralising activity to some other types and two women lost their neutralising antibodies by 
the 24 months follow-up visit. This may reﬂect antibody titre, which can ﬂuctuate around 
the antibody detection threshold as type-specific HPV antibody peaks and decline within 
12 months of infection (Steele et al., 2008, Carter et al., 2000). 
Although HPV infection can lead to sero-conversion, not all infected individuals will generate 
an immune response to the HPV L1 capsid protein. Approximately, 60% of individuals will 
develop serum antibodies after natural infections (Viscidi et al., 2004; Carter et al., 2000). This 
may explain why three participants with four consecutive samples neither sero-converted nor 
had HPV DNA detected up to the end of the 24 months follow-up period. Secondly, the 
participants that provided third follow-up samples were prescribed on ARVs by the 18- 
month visit and this could have partially restored their cell-mediated immunity. 
Of the participants diagnosed with HSIL at baseline, two died by the 9 month follow-up visit, 
and one had HPV 16 neutralising antibody, but no HPV DNA was detected. The failure to 
detect HPV DNA in this patient could result from loss of the L1 open reading frame during 
viral integration into the host genome as integration often occurs in the L1 region (Depuydt et 
al., 2007).  
The other participant was diagnosed with invasive cervical cancer and HPV-51DNA and anti-
HPV 51 was detected in both cervical and serum samples. This evidenced that oncogenic HPV 
types other than HPV 16/18 may cause cervical cancer in The Gambia. Cervical lesion 
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regression was observed at the 18 months follow-up visit in women who were diagnosed with 
either LSIL or HSIL at baseline or at 9 months, respectively.  
Furthermore, partial restoration of the immune function by ARVs may have induced the cell- 
mediated immune response, which would have induced the cervical lesion regression observed 
in these patients.  In addition, only 5 women were found to persistently have the same 
neutralising antibodies (Table 6.5) up to the end of the 24 months follow-up. Antibodies 
generated in response to a persistent infection may prevent sequential auto-infection within the 
genital tract. However, antibody levels after natural infections may not be adequate for long-
term immunity in these patients (Mckenzie et al., 2010). 
In conclusion, the availability and accessibility to antiretroviral therapy are such that 
HPV-associated cervical diseases and cancers may become a major problem in HIV- positive 
women in future due to increased life expectancy. The concurrent infection with multiple high-
risk HPV types in HIV-positive women increases the risk of cervical diseases. Although 31% 
(9/29) of participants had normal cytology at baseline, multiple neutralising antibodies were 
found in 66% (6/9) of those with HPV antibodies indicating that these women were exposed 
to multiple HR-HPV types. It is therefore important to routinely screen these women for early 
detection and management of precancerous lesions. The relatively low prevalence of vaccine-
type HPV16 and 18 reported in this study corroborate other findings reported in the African 
sub-regions (Gage et al., 2012; Sahasrabuddhe et al., 2007; De Sanjosé et al., 2007). This 
suggests that the current vaccine available for the Gambia will benefit only a minority of HIV-
positive women as other HR-HPV other than HPV 16 and 18 were found to constitute the 
majority of circulating types both in cervical and serum samples of this cohort. Studies on the 
safety and efficacy of HPV vaccines among HIV-positive women have demonstrated 
promising results, therefore this group would benefit from vaccination to boost their antibody 
levels and duration of protection against HPV infection. 
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Chapter 7: General conclusion, study limitations, future work and 
summary 
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7 General conclusions and recommendations 
Infection with oncogenic human papillomavirus genotypes is a major public health concern, 
globally. Persistent infection with these types can lead to cancers of the cervix, vulva, vagina, 
anus, penis, and head and neck (IARC, 2007; Bulk et al., 2007; Hoots et al., 2009).  Amongst 
the HPV-associated cancers, cervical cancer is the most common cancer affecting women 
below the age of 50 years old (de Martel et al., 2017). Approximately 70% of the global 
cervical cancer incidence is reported in developing countries, where access to adequate and 
regular cervical cancer screening and treatment is not readily available. It is estimated that if 
this trend continues cervical cancer mortality will increase by 10% each year in these countries 
(Ferlay et al., 2001). Regular cervical cancer screening and HPV vaccination programmes have 
been demonstrated to have reduced the burden of cervical cancer and anogenital warts in 
developed countries (Machalek et al., 2017). In contrast, only 13% of countries in developing 
countries have HPV vaccination programmes (LaMontagne et al., 2017). Lack of proper 
vaccination and screening programmes as well as low socio-economic development, 
environmental risk factors and co-infection with sexually transmitted infections, contributed 
to the highest mortality rate seen each year, in developing countries (Ekiel et al., 2009; Ferlay 
et al., 2004). 
The work presented here studied the distribution and prevalence of human papillomavirus 
genotypes, as well as co-infection with selected sexually transmitted pathogens in reproductive 
age women attending a primary health clinic, at Edwards Francis Small Teaching Hospital, 
Banjul, The Gambia. In addition, the ability of the human papillomavirus to persist and cause 
cervical changes in the cervix of a cohort in women infected with HIV was also studied. 
The overall prevalence of HPV infection reported (12%) in this study, the first urban Gambian 
study is similar to the Gambian rural study, which reported a prevalence of 13% (Wall et al., 
2005).  However, there was a difference in the most prevalence circulating genotypes 
distribution between the two studies. This present study observed HPV 52 genotype to be the 
most common circulating genotypes and HPV 16 the eighth genotype identified. In contrast, 
Wall et al., (2005) found HPV 16 to be the most prevalent type, in their rural study. HPV 
genotype variability in different geographical regions and within the same country has also 
been reported elsewhere (Bruni et al., 2010; Castellsague et al., 2007).  
Although The Gambia introduced the quadrivalent HPV vaccine in 2014, it has been 
demonstrated here that less than 11% of participants were infected with HPV genotypes 
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targeted by the quadrivalent vaccine. In contrast, 35.7% were positive for HPV genotypes 
included in the nonavalent vaccine. This finding will be further investigated using cervical 
cancer biopsy samples.  In addition, the prevalence of HPV antibody was found to be 51% in 
a cohort of 29 women infected with HIV. HPV 52 was also the most common type found 
(Table 6.2). Although antibodies to HPV 52 genotype was the most commonly found, it was 
predominantly found in multiple infections in HIV-positive women. On the other hand, HPV 
51 antibody was the most common type found in patients with a single genotype infection 
(Table 6.2). An HIV-infected participant was diagnosed with cervical cancer and both HPV 51 
DNA and serum antibody were detected in the samples provided. This shows further that other 
oncogenic HPV types other than HPV 16 and 18 might also be responsible for cervical cancer 
in The Gambia. Furthermore, this work also observed that nearly 42% of women between 
26 and 30 years old were infected with HR-HPV genotypes, which can resolve or progress 
to cervical diseases. Therefore, the present study supports the idea that women above 30 
years old and those that are infected with HIV should be screened regularly for the presence of 
HPV oncogenic genotypes and cytological cervical changes, for early diagnosis, treatment and 
follow-up. In addition, the “save my mother” campaign on cervical cancer screening initiated 
by the SOS Mother and Child private clinic have reported an increase in women accessing this 
service. Therefore, the Gambian Ministry of Health should encourage the use of this strategy 
across the major government health clinics that are offering VIA screening. 
The 32% prevalence of HPV infection in the 21 – 25 years old reported in this study is in line 
with the global trend of the infection as HPV infection begins shortly after sexual initiation 
(Moscicki et al., 2012; Franceschi et al., 2006; Castle et al., 2005). However, most of these 
infections are transient and will resolve spontaneously. A novel putative fragment of HPV 35 
may have been found in this study as the L1 gene sequences of The Gambian type and the 
reference type differ by more than 10%. This finding will be further investigated. 
The phylogenetic analysis carried out on the isolated HR/pHR-HPV genotypes was important 
in demonstrating the evolutionary similarities as either divergent or convergent with published 
isolates from other geographical locations (Fig 3.6). The Gambian HR/pHR-HPV isolates 
were found to group within its respective genotype clades and within each genotype. No 
major distinction between the high-risk and probable high-risk genotype sequences were found. 
Although the prevalence of the most circulating HR-HPV genotypes in both the urban and rural 
studies is different, both studies advocate for a multivalent vaccine that would also target other 
circulating oncogenic genotypes in The Gambia. The nonavalent vaccine (9-V) may be the 
best vaccine candidate for The Gambia if the current cost of the quadrivalent vaccine is 
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comparable to the cost of two doses of the nonavalent vaccine. Currently, two Chinese 
companies (Innovax and Walvax) are evaluating the efficacy of two other new HPV vaccines 
targeting HPV genotypes 16 and 18 (Wu et al., 2015; Schiller at al., 2015). The possibilities 
of introducing these two new vaccines by 2020, worldwide and the technology transfer of 
existing vaccines to manufacturers in middle income countries such as Brazil, India and 
Argentina (Baker et al., 2015; Leonardo et al., 2011; Padmanabhan et al., 2010) may increase 
market competition thereby reducing vaccine prices. 
A single dose for HPV prevention has been reported to provide enough protection to 
significantly reduce the burden of cervical diseases (Kreimer et al., 2015). However, findings 
on the efficacy and duration of protection of a single dose vaccination have been of concern 
as the numbers of incident and persistent infections in these studies were either too small 
due to the sample size and/or limited follow-ups (Basu et al., 2016). Delivery of a single dose 
of HPV vaccine with high coverage would be much easier for developing countries that face 
issues with logistics, financial and programmatic challenges. Although a single dose of HPV 
vaccine may be promising, more evidence is needed on the cross-protection effect and duration 
of protection as the peak incidence of HPV infections occurs in 20-25year olds. Therefore, 
protection with a single dose of HPV vaccine in young girls 9-14 years old must be 
demonstrated to last for at least 10 years (Wang et al., 2015) especially in countries like The 
Gambia, where the present study reported a high prevalence of oncogenic HR-HPV in women 
above the age of 25 years. 
The Gambia will be implementing a national HPV vaccination programme in 2019; it is also 
important to have a national cervical cancer screening programme.  Although the World Health 
Organisation (WHO) recommended a single visit algorithm for HPV-associated cervical 
diseases in developing countries, the most cost-effective methods to triage and treat HPV-
positive women in these countries are yet to be determined (Ogilvie et al., 2017). Presently, 
apart from small scale projects, HPV testing as a screening method has not been nationally 
instituted in developing countries. This could be due to cost as HPV testing is expensive to 
establish and maintain as a primary screening technique (Basu et al., 2017).   
The Gambia is best suited for the single visit algorithm; that is screening with VIA and treating 
at the same visit as there is only one cytology laboratory. However, including HPV DNA 
screening in the future may be beneficial to reduce unnecessary colposcopy referrals, 
provide more robust triage of women with HR-HPV genotypes, and monitor the 
replacement of the quadrivalent HPV vaccine types in The Gambia, for an effective prevention 
strategy. 
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Other findings such as HPV co-infection with other STI pathogens have also been documented. 
Of the 28 women infected with HPV, 27 (96%) were found to be co-infected with at least one 
STI/genital pathogen; 50% of these women were found to be co-infected with Ureaplasma; 
79% (11/14) of women co-infected with Ureaplasma had the organism detected in both 
endocervical and high vaginal swab samples. This finding is not novel but adds to the body 
of literature that women who are above 30 years old and co-infected with HPV may be treated 
for Ureaplasma infection, to investigate whether treatment will help prevent cervical lesions 
that may progress to high-grade cervical diseases and cancer (Ekiel et al., 2009a). However, 
treating Ureaplasma is still a controversial debate and more data is needed to determine 
treatment benefit. 
Although in The Gambia, a majority of suspected STIs are treated using the syndromic 
management approach, this study underscored the need to strengthen laboratory-based 
evidence in the diagnosis of STI to limit overuse of antibiotics. The finding of asymptomatic 
gonorrhoea in the control group (4.3%) and the isolation of ciprofloxacin, ceftriaxone and 
cefotaxime resistant N. gonorrhoeae strains is a cause for concern not only for The Gambia 
but globally as reduced susceptibility to the cephalosporins has been documented (WHO, 
2013, Tzelepi et al., 2008). This work shows further that microbiological analysis of 
clinically significant isolates and their antibiogram should be carried out to confirm a diagnosis 
and to advise clinicians on the appropriate choice of antibiotic regimen, to reduce therapeutic 
failure. 
A vital public health issue found in this study was the high STI prevalence seen in 
asymptomatic (control group) participants. Approximately, 66% (78/117) were found to 
harbour at least one or more STI/genital pathogens. Secondly, these STI infections; Chlamydia, 
gonorrhoea, and trichomoniasis are asymptomatic in women and can remain untreated, 
therefore resulting in longer infection periods (Holmes, 2008). This evidenced further that 
asymptomatic STI can pose significant public health challenges in reproductive age women. 
Furthermore, recurrent STI infection is very common, particularly with T. vaginalis following 
the current recommended single dose treatment, as male partners are normally not treated, 
which can facilitate progression of HPV infection to cervical diseases because of inflammatory 
reactions. The global trend of antimicrobial resistance, especially with N. gonorrhoeae makes 
it important to improve the monitoring and evaluation of changes in STI incidence and 
resistance profile, through robust national STI surveillance. 
In chapter 4 of this study, the distribution of Ureaplasma in reproductive age Gambian women 
was also investigated. A 46% Ureaplasma prevalence was seen in this study and 41% of 
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women that reported symptoms of STI had Ureaplasma infection, however, its clinical 
significance in this study population cannot be ascertained as 51% of asymptomatic 
participants were colonised with the organism. The substantial Chlamydia prevalence 
difference between Demba et al., 2005 (15%) and the present study (0%) despite targeting the 
same cryptic gene needs further investigation. 
Potential risk factors that may be associated with HPV/STI infections in The Gambia were 
also investigated in this study. More than 80% of women indicated that their sexual partners 
did not use condoms and this finding was also observed in HIV-positive women. This may be 
since most of the participants were married. The interaction between HPV and HIV is enhanced 
by the same mode of sexual transmission; therefore, this study proposes that clinicians should 
place emphasis on HPV prevention through counselling and regular cervical cancer screening 
for all HIV-positive women, especially in women who do not use condoms. Although the 
effectiveness of condom uses in preventing HPV infection remains controversial, health care 
providers who counsel HIV-positive women, especially younger women, should emphasize the 
importance of preventing HPV infection and other STIs through consistent condom use with 
all male sexual partners. The present work has shown that older women in a polygamous 
relationship are at greater risk of being infected with HPV/STI, in The Gambia. Therefore, 
there is a need to strengthen HPV/STI awareness in this group as well as the younger 
population using the local media, cultural drama and during clinic health sensitisation. 
The acceptability of self-sampling for HPV/STI screening was assessed in this study and only 
18% of participants preferred self-sampling. This number is comparatively lower than other 
findings in other developing countries.  Self-collected samples have been shown to have the 
potential to significantly increase HPV screening coverage (Ogilvie et al., 2017). Therefore, 
self-sampling could be an option for The Gambia, for STI laboratory base screening to facilitate 
effective treatment of patients. In future, self-sampling could be used for HPV DNA testing, 
when a national cervical cancer screening programme is in place to increase screening 
coverage. 
7.1 Study limitations and future work 
7.1.1 Study limitations. 
The present study has some important limitations, first, the sample size was small (235) as 
the initial sample size calculated was 346. Though plans were made to recruit the actual 
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sample size, this was not possible due to the 2016 political impasse in the country. Since 
the study was time limited the desirable sample size could not be achieved. Furthermore, 
since reproductive age women (20 - 49 years) were targeted, this study was unable to determine 
whether HPV prevalence in the urban population would have continued to increase, remained 
stable or decrease. Secondly, the differences between the HPV results of the present study 
and previous rural study may be explained as, this research studied an urban population of 
women attending a primary health care for either STI/HIV management or contraceptive 
services, whilst the other study was a community survey in which participants 15 -54 years old 
were visited and invited to participate. Secondly, the information on sexual behaviour was self-
reported and could be subject to recall bias.   
Due to the sensitive nature of the topic on sexual behaviour, social desirability bias cannot be 
excluded. Although confidentiality and anonymity were maintained throughout the study, 
women may have had the tendency to give more “desirable” answers such as a lower 
number of lifetime sexual partners or older age at sexual debut. 
Another limitation of the study was observed in the cohort follow-up during participant 
recruitment. Some of the participants gave an incorrect or changed their telephone numbers 
after recruitment, which led to participants lost to follow-up in each scheduled visit. Though 
follow-up studies to establish an epidemiology pattern of an infection or disease in Africa may 
be important, these are difficult to carry out in an African setting. 
7.1.2 Future work 
Characterising oncogenic HPV genotypes in cervical cancer cases before the introduction of 
any vaccine type is necessary for an effective cervical cancer prevention strategy. Therefore, 
future studies to investigate epidemiological correlates of oncogenic HPV genotypes in cervical 
cancer specimens will be useful in providing evidence for policies and future evaluation of 
the quadrivalent vaccine, in The Gambia. The use of HPV DNA testing and cytology in high-
risk groups will be advocated for monitoring replacement of HPV vaccine types with other 
HPV genotypes that may possibly cause cervical cancer in The Gambia. 
The 46% prevalence rate of Ureaplasma species reported in this study should be investigated 
further targeting women who reported gynaecological complications such as infertility, 
spontaneous abortions and preterm pre-labour rupture of membranes (pPROM) to ascertain its 
clinical importance in The Gambia. Furthermore, future work will be carried out on the 
characterisation of Chlamydia trachomatis in the collected samples targeting a different gene. 
 166 
 
7.2 Summary of findings 
In summary, HPV 52 was the most common circulating HPV genotype found in this study. 
HPV 51 genotype was found in a patient who died of cervical cancer. Prolong use of 
hormone contraceptives (> 5 years) was the only risk variable found to be statistically associated 
with HPV infection. Gambian women between the ages of 26 - 35 years were found to be 
mostly infected with STIs. Marital status and partners not using condoms during sexual 
intercourse were the only variables found to be significantly associated with STIs. Differences 
between the three Gambian major ethnic groups were noted in this study. The Wollof were the 
tribe least to be infected with HPV/STI and to practise FGM, whilst the Fula and the Mandinka 
ethnic groups tend to be infected more with HPV/ STI and FGM was a common practice. 
Multiple HPV neutralizing antibodies were found in women infected with HIV and sero- 
positivity was intermittent. Sero-conversion was observed during the 9 and 24 months 
follow-up period.  However, detectable HPV antibodies types did not strictly correlate with the 
HPV DNA genotypes results. 
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9 Appendices 
Appendix A: Preparation of reagents and solutions 
Preparation of 50X Tris base, acetic acid and EDTA (TAE) buffer 
A 1.1 Ethylene diamine tetra acetic acid (EDTA) 
 
A magnetic stirrer was used to mix the mixture and 10M NaCl was added to adjust the pH to 8.0. The volume was 
made up to 500 ml with deionised water. 
 
Table A 1. 2 50X TAE buffer (1 Litre of solution in deionised water) 
 
Note: 0.5 M EDTA was prepared at pH 8.0. The volume was made up to 500 ml with deionised water.  
To prepare a 1x TAE working buffer, the 50X TAE buffer was diluted 50X in deionised water before use. 
 
Table A1.3 10X phosphate buffered saline (PBS) in 1 Litre of solution  
 
Note: Add deionised water to bring to 1 Litre and autoclave to sterilise. 
 To prepare a 1x PBS working buffer, the 10X PBS was diluted 10X in deionised water before use. 
 
 
 
Compound Amount 
 
EDTA 
 
73g 
 
Deionised water 350 ml 
 
  
 
Compound Amount 
Tris base (Mw -121 g/mol) 242g 
 
Glacial acetic acid 57.1 ml 
 
0.5 M EDTA 100 ml 
 
Compound Amount (g) 
NaCl 58.44 
                               
                              KCl 
 
74.55 
 
Na2HPO4 
 
141.96 
 
KH2PO4 
 
136.09 
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Table A 1.4 6X gel electrophoresis loading dye 
  
Deionised water was added to bring the volume to 10 ml. The loading dye was diluted to 1X by mixing in a ratio 
of 1 part of loading dye to 5 parts of DNA sample before samples were loaded into agarose gels. 
 
Table A1.5 Preparation of Ethidium bromide (10 mg/ml) in solution 
  
The mixture was dissolved with care and deionised water was added to bring the volume to 1 litre (1000 ml). 
General precaution:  
Wear gloves and lab coat always when handling ethidium bromide or ethidium bromide 
contaminated solutions, glassware, pipette tips, etc. 
 
Appendix B: Preparation of media and antibiotics 
B 1.1 Preparation of Luria-Bertani (LB) agar and broth. 
LB agar and LB broth were purchased from Fisher Scientific, Loughborough in a powdered 
form. LB agar and LB broth were prepared following the manufacturer’s instructions. 
 
Table B 1.1 Luria-Bertani (LB) agar in 1litre solution 
 
The LB agar was dissolved, and the volume was made up to 1litre (1000 ml) and autoclave to 
sterilise 
Compound Amount 
 
Bromophenol blue 
 
2.5g 
 
Glycerol 3ml 
 
  
 
Compound Amount 
 
Ethidium bromide 
 
1g 
 
Deionised water 500 ml 
 
  
 
Compound Amount 
 
LB agar base 
 
40g 
 
Deionised water 800 ml 
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Table B 1.2 Luria–Bertani (LB) broth in 1 litre solution 
 
The LB broth powder was dissolved, and the volume was made up to1litre (1000 ml) and 
autoclave to sterilise 
B 1.3 Ampicillin 
Ampicillin was obtained from (Sigma, Gillingham, UK) and a stock of 100 mg /ml was 
prepared by dissolving 
 
Table 1.3 Ampicillin preparation (100 mg/ml) 
 
The solution was mixed to dissolve and filter sterilised with a 0.2 µm syringe filters (Millipore, 
Hertfordshire, UK). The solution was stored at -20oC in 500 µl aliquots. 
 
B 1.4 100X Penicillin-Streptomycin solution 
100X penicillin-Streptomycin was purchased from (Sigma, Gillingham, UK) and stored at -
20oC in 1 ml aliquots 
 
 
 
 
 
 
 
 
 
Compound Amount 
 
LB broth 
 
25g 
 
Deionised water 800 ml 
 
  
 
Compound Amount 
 
Ampicillin powder 
 
1g 
 
Deionised water 10 ml 
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Appendix C: Preparation of embryonic kidney 293TT cells, cell counting, pseudo-typed 
virus titration and neutralisation assays. 
 
C1: Calculation of human embryonic kidney 293TT cells for transfection 
C1.1 Cell counting 
Under sterile conditions, human embryonic kidney cells (293TT) that reached 50% confluent 
growth were trypsinised and 10 µl of cells was added to 10 µl of trypan blue dye (1:1 ratio). 
10 µl of the mixture was charged into a disposable counting chamber and counted using the 
automated countess II machine (Life Technologies, UK).  
The concentration of viable cells was calculated by multiply the number of viable cells by the 
dilution factor.  
The number of cells needed for transfection was calculated as follows: 
To seed 7.5 x106 293TT cells in a final volume of 20 ml, 7.5 x106 was divided by the number 
of viable cells =X (ml) of cells, therefore in a 20 ml final volume, X (ml) was subtracted from 
20 ml to give the amount of cDMEM medium needed to add to the cells. 
 
C1. 2: Preparation of HPV plasmid DNA for Transfection: 
To transfect 19 µg of HPV plasmids, 19 µg was divided by the virus concentration to give the 
amount needed for the transfection. Below is the concentration of each of the HPV plasmids 
with the required volume used for transfection: 
Table C1.2.1 Concentration of HPV plasmid DNA and required volume for transfection 
HPV genotype DNA concentration Volume 
35 0.773 µg/µl 24.6 µl 
51 0.708 µg/µl 26.8 µl 
52 3.7 µg/µl   5.1µl 
Reporter plasmid 
PGL4.51 
1.9 µg/µl 10 µl 
 
C1. 3: Calculation of 10,000 human embryonic kidney (293TT) cells in100µl media / well 
for infectivity (Titration) and neutralization assays 
To seed 10,000 cells /well for 1 plate (60 wells) for 100 µl /well, the cells were counted as 
described in C1.1. The following calculation was employed to determine the number of cells 
required for the assay using the following formula: 
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                                           C1V1 = C2V2 
                                           C1 = cell count 
                                           V1 = X 
                                           C2 = 1.0 x106 (10,000 x 100) 
V2= 10 ml (6 ml + extra 4 ml, for ease of calculation) 
Therefore (X ml) cells = C2V2/C1. The X value was subtracted from the final volume to have 
the amount of medium needed to add to the cells for a 10 ml volume. 
C1 - initial concentration, V1 - initial volume 
C2 - final concentration, V2 - final volume 
C1. 4: Preparation of Optiprep® step gradient solution; Optiprep 46% stock: 
The 46% Optiprep® stock was prepared as follows: 
5.2 ml of 5 M NaCl and 4 ml of Phosphate buffer saline pH7.2 was added to 30.7 ml of 60% 
Optiprep® (Iodixanol solution) (w/v).  
From the 46% Optiprep® stock, 27%, 33%, and 39% gradient solutions were prepared for a 
10 ml volume as shown below: 
 
Table C1.4.1 Preparation of Optiprep gradient solutions 
 
 
 
 
 
 
 
 
 
 
Gradient (%) 46% Optiprep (ml) 0.8M NaCl/PBS 
(ml) 
27 5.9 4.1 
33 7.2 2.8 
39 8.5 1.5 
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C1.5 Platting/seeding of 293TT cells 
10,000 HEK 293TT cells in 100 µl of cDMEM per well was seeded in an inner wells of a 96-
well tissue culture flat bottom sterile plate (Fisher Scientific, UK). The external wells (row A 
–H and column 1-12) were filled with 200 µl of sterile PBS to avoid evaporation 
 
C1.5:  Layout of 96-well U-bottom plate of human embryonic kidney 293TT cells for 
infectivity (titration) and neutralisation assay 
 
 
 
PBS           PBS 
 293TT         293TT  
            
            
            
            
 293TT         293TT  
PBS           PBS 
PBS – Phosphate buffer saline (200µl) pH7.2,                                                               
Inner plate wells were seeded with 10,000 293TTcells/well /100 µl / well. 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
D 
C 
E 
F 
G 
H 
 1               2         3          4           5          6        7           8          9       10       11       12 
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C1.6 Template for infectivity (titration) plate to determine pseudo-typed virus Tissue 
Culture Infective Dose (TCID50) 
 
 
PBS           PBS 
 293TT
+ PsV 
      293TT
+ PsV 
293TT
+ 
PsV 
293TT  
            
            
            
            
 293TT
+ PsV 
      293TT
+ PsV 
293TT
+PsV 
293TT  
PBS           PBS 
Key: 
PsV = pseudo-typed virus 
PBS = Phosphate buffered saline 
Column 11 – human embryonic kidney cells (293TT) only 
 
C6.1 Calculation of TCID50 
All pseudo-typed viruses were tested in triplicate and the TCID50 for each virus was calculated 
using the Spearman-Karber equation. 
TCID50 was calculated using the Spearman-Karber equation as follows: 
Spearman-Karber formula: M = xk + d [0.5 – (1/n) (r)] 
 xk = dose of the highest dilution. 
 r = sum of the number of “negative" responses.  
d = spacing between dilutions. 
 n = wells per dilution.  
To calculate TCID50/ml of virus stock, the original dilution was corrected by multiplying by 5 
(dilution factor) 
Each virus was used at a concentration of 300TCID50 per well in 100 µl for neutralisation assay. 
 
 
 1               2         3          4           5         6        7           8          9        10           11               12 
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C1.7 Neutralization assay 
Pseudo-typed viruses were diluted in 10 ml of phenol red free (prf) DMEM) supplemented with 
10% foetal calf serum and 1X penicillin-streptomycin to give a concentration of 300TCID50 per 
well in 100 µl. 100 µl of pseudo-typed virus was dispensed in a 96 plate well 
Serum samples were diluted in 1: 8 dilutions (10 µl of serum +70µl of prf DMEM. The mixture 
was thoroughly mixed and 25 µl was transferred to 100 µl of pseudo-typed virus (giving a final 
dilution of 1:40) and incubated for 1 hr at room temperature. 
After 1 hr incubation, 100 µl of the mixture was transferred to the cells seeded a day before as 
described in C1.5 and incubated for 72 hrs at 37oC with a humidified atmosphere of 5% CO2 in 
air. (Note: final volume = 200 µl). The plate lay out is shown on Table C1.7.1 
The presence of neutralising antibodies for each sample was determined as 50% inhibition of 
the HPV pseudo-typed infectivity. 
C 1.7.1 Layout of 96-well U-bottom plate for neutralisation assay  
 
 
PBS          Cells 
only 
PBS 
 293TT+ 
samples 
      293TT+ 
samples 
293TT+PsV 293TT  
            
            
            
            
 293TT+ 
samples 
      293TT+ 
samples 
293TT+PsV 293TT  
PBS           PBS 
Inner wells from 2-9 highlighted in pink all had 293TTcells with samples, row10 had the virus and the 
293TT cells, row 11 had only 293TT cells and row 12 had only phosphate buffered saline (PBS). 
 
 
 
 
 
 1               2         3          4           5          6        7           8          9        10         11        12 
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Appendix D: Sequence data of high and low risk HPV genotypes identified by DNA 
sequencing and nucleotide BLAST search (L1 gene, 450 bp) 
 HR- High risk genotype; LR- Low risk genotype 
 HPV 16(HR) 
ATaatnatCTTCtaGTGTGCCTCCTGgaggAGGTTGTAAACCAAAATTCCAGTCCTCCAA
AATAGTGGAATTCATAGAATGTATGTATGTCATAACGTCTGCAGTTAAGGTGATT
TTGCACAGTTGAAAAATAAACTGTAAATCATATTCCTCCCCATGTCGTAGGTACT
CTTTAAAGTTAGTATTTTTATATGTAGGTTCTGAAGTAGATATGGCAGCACATAAT
GACATATTTGTACTGCGTGTAGTATCAACAACAGTAACAAATAGTTGGTTACCCC
AACAAATGCCATTATTgTGGCCCTGCGcaaaa 
HPV 35 HR  
GGGGACCTCTAACCAGATACACCCTTTAATGACACGCCCCGGCTCTAACCGCAGA
TCCACAATAGACGGTCCCACGAGCTTCATTTAGAGATTCACGTCTATGATCACAC
TAAAAGACAGAAAAATAGGAGTAATTATCTGTTGTTTACGGTAGATGAAAGAAG
GCGTAGAATAAATATGTTTGTGTGTTATGTTGAGTATTGTAGTGTCCGTATATATA
AAAAAGATAATTGTAAGGAATATTTAAGGCATGGAGAAGAATATGATGTACAGT
TTATTTTTCAGTTATGTAAAAGAAGAGTAACAGAAGAGGATAAGACATATATTGA
TAGTAGGAAGGCGTGAGATTGGAGAGGATTGGAATTTTGGCCTTGACGCAGGGC
GTTGGGGGAGATAAGAGGAAAGATATGGTTGTGTGAGGGGGGTGTGGAGGGGG
ACAAAAAAAGGGGAATTTTCTATAGGGGGGTGTGCAGAGGGAACAGAGGGGGG
GATGTTTTTCTGGGTTTGTCGCCGGCGCCGGC 
HPV 51 HR 
AGTACAAATTTAACTATTAGTACTGCCACTGnnnnnntTTCCCCAACATTTACTCCAA
GTAACTTTAAGCAATATATTAGGCATGGGGAAGAGTATGAATTGCAATTTATTTT
TCAGTTATGTAAAATTACTTTAACTACAGAGGTAATGGCTTATTTACACACAATG
GACCCTACCATTCTTGAACAGTGGAATTTTGGATTAACATTACCTCCGTCTGCTAG
TTTGGAGGATGCATATAgGTTTGttCgAAATGCAGCCACCAgCTGTCAAAAGGACAC
CCCTCCACAGGCTAAGCCAGATCCTTTGGCCAAATATAaattTtGGGATGtTGATTTA
AAGGAACGGTTTTCgtTAgATTTAGACcAatTTGCATTGgGtCGCA 
HPV 51 HR  
CGgaggtAatGttaatCcAAAATTccactgTTCAagAaTGGTaggATCCAttgngtgtAAAtangCcaTtA
CCtctgtagTtAAagtaaTTTTGCATAactgAAAAaTAAATTgCAATTCatactcTtCCCcAtgcctAA
TATATTgCTtAAagTtacttggagtAAAtGTTGGGGAAACCGCAGCagtggcagTGCTAATagTt
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AAATTTGTACTTctGgTAGTATCAACACAGGTAATAAAAAGCTGATTGTTCCAGCA
AATGCCATTATTGTGGCCcTGCGCAgtGCa 
HPV 52 HR  
AcntcccaaanTATAGTCCTTtaaGGATCTTCCTTTCCTTTaGGTGGTGTGTTTTTTTGACA
TGTtATAGCAGTAGAAGTGACAAATCTGTATGTGTCCTCCAAAGATGCAGACGGT
GGTGGGgTAAGGCCAAATTGCCAGTCCTCTAAAATAGTGGCATCCATCTTATGAA
TGTATGTCATAACATCAGCTGTTAATGTAATTTTGCACAATTGAAAAATAAATTG
TAAATCAAATTCCTCGCCATGACGAAGGTATTCCTTAAAATTTTCATTtttatATGTG
CTTTCCTTTTTAACCTCAGCACATAAAGTCATGTTAGTGCTACGAGTGGTATCCAC
AACTGTGACAAACAACTGATTGCCCCAACATATGCCATTATTGTGGCCCTGCGc 
HPV 52 HR 
atccaCcTCCcAanCnTATAGTCCTTtaaGGATCTTCCTTTCCTTTaggTGGTGTgTTTTTTT
GACAAGTTATAGCAGTAGAAGTGACAAATCTGTATGTGTCCTCCAAAGATGCAG
ACGGTGGTGGGGTAAGGCCAAATTGCCAGTCCTctAAAATAGTGGCATCCATCTTA
TGAATATATGTCATAACATCAGCTGTTAATGTAATTTTGCACAATTGAAAAATAA
ATTGTAAATCAAATTCCTCGCCATGACGAAGGTATTCCTTAAAATTTTCATTTTTA
TATGTGCTTTCCTTTTTAACCTCAGCACATAAAGTCATGTTAGTGCTACGAGTGGT
ATCCACAACTGTGACAAACAACTGATTGCCCCAACATATGCCATTATTGTggCCcT
GCGc 
HPV 52 HR   
cngTTTTTTTGACAAGTTATAGCAGTAGAAGTGACAAATCTGTATGTGTCCTCCAA
AGATGCAGACGGTGGTGGGGTAAGGCCAAATTGCCAGTCCTCTAAAATAGTGGC
ATCCATCTTATGAATATATGTCATAACATCAGCTGTTAATGTAATTTTGCACAATT
GAAAAATAAATTGTAAATCAAATTCCTCGCCATGACGAAGGTATTCCTTAAAATT
TTCATTTTTATATGTGCTTTCCTTTTTAACCTCAGCACATAAAGTCATGTTAGTGCT
ACGAGTGGTATCCACAACTGTGACAAACAACTGATTGCCCCAACATATGCCATTA
TTGTGGCCCTGCGcAa 
HPV 52 HR 
TTTttnGAcAAGttATAGCagtagaagtGACAAAtctGTATGTGTCCTCCAAAGATGCagACG
GtggTGGGgtAAGGCCAAATTGCCAGTCCTCTAAAATagtGGCATCCATCttATGAATG
TATGTCATAACATCAGcTGTTAATGTAATTTTGCACAATTGAAAAATAAATTGTAA
ATCAAATTcctCGCCATGACGAAGgTATTCCTTAAAATTTTCATTTTTATATGTGCTT
TCCTTTTTAACCTCAGCACATAAAGTCATGTTAGTGCTACGAGTGGTATCCACAA
CTgtGACAAACAACTGATTGCCCCAACATATGCCATTATTGTGGCCCTGCGc 
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HPV 52 HR  
gtCcngTTGTGGaTnACcaCTCGTagcACtaaCATGACTTTATGTGCTGAGGttAAAAaGGA
AAGCACATATAAAAATGAAAATTTTAAGGAATACCTTCGTCATGGCGAGGAATTT
GATTTACAATTTATTTTTCAATTGTGCAAAATTACATTAACAGCTGATGTTATGAC
ATATATTCATAAGATGGATGCCACTATTTTAGAGGACTGGCAATTTGGCCTTACC
CCACCACCGTCTGCATCTTTGGAGGACACATACAGATTTGTCACTTCTACTGCTAT
AACTTGTCAAAAAAACACACCACCTAAAGGAAAGGAAGATCCTTTAAAGGACTA
TATGTTTTGGGAGGTGGATTTAAAAGAAAAGTTTTCTGCAGATTTAGATCAGTTTc
cTTTAGGTCGa 
HPV 56 HR 
tgtagtaganncTACTAGAAGTacTAACATGACTATTAGTACTGCTACAGAACaGTTAAGt
AAATATGATGCACGAAAAATTAATCAGTACCTTAGACATGTGGAGGAATATGAA
TTACAATTTGTTTTTCAATTATGCAAAATTACTTTGTCTGCAGAGGTTATGGCATA
TTTACATAATATGAATGCTAACCTACTGGAGGACTGGAATATTGGGTTATCCCCG
CCAGTGGCCACCAGCCTAGAAGATAAATATAGATATGTTAGAAGCACAGCTATA
ACATGTCAACGGGAACAGCCACCAACAGAAAAACAGGACCCATTAGCTAAATAT
AAATTTTGGGATGTTAACTTACAGGACAGTTTTTCTACAGACCTGGATCAATTTCC
ACTAGGTcg 
HPV 58 HR  
aTaccaCTCgtagcACtAaTATGACAttATGCACTGAAgtaactAAAGAagATACAtatAAAAAT
aatAaTTttAAGGAATATgtAcGtCatgTtGAAGAATATGACTtaCagTTtGTTTTTCAGCTTT
GCAAAATTACACTAActgCAGAGgtAATGACATATATACATACTATGAATTCAGATA
TTTTGGAGGaCTGgcAATTTGGTTTAACACCTCcTCCgtCTGCCaGTTTACAGGACAC
ATATAGATTTGTTACCTCCCAGGCTATTACTTGCCAAAAAACAGCACCCCCTAAA
GAAAAGGAAGATCCATTAAATAAATATACTTTTTGGGAGGTTAACTTAAAGGAA
AAGTTTTCTGCAGATCTGGATCAGttccTTtnGGGACg 
HPV 58 HR  
gtanttaCTCCAAagTATATTtATTtAaTGGATCTTCCTTTTCTTTaGGGGGTGCtgTTTTTtG
GCAAgtAATAGCCTGGGaggTAACAAATCTATATGTGTCCTgtAAACTGGCAGACGG
AGGaGGTGTtAAACCAAATTGCCAGTCCTCCAAAATATCTGAATTCATAGTATGTA
TATATGTCATTACCTCTGCAGTTAGTGTAATTTTGCAAAGCTGAAAAACAAACTG
TAAGTCATATTCTTCAACATGACGTACATATTCCTTAAAATTATCATTTTTATATG
TACCTTCCTTATTTACTTCAGTGCATAATGTCATATTAGTGCTACGAGTGGTATCA
ACCACGGTAACAAATAATTGATTGCCCCAGCAAATGCCATTGTTATgTCCCTGTGc 
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HPV 66HR 
CtnCCcAaacTtataTTTAGccaggnaTCCTGCTTTTCTGCaGGGGgcngctnCCCTctGacaTgtaat
aGCtgtgCTTttaataTACcTataTTTATCCtctAAGctaGTtGCAActggtGGGgATAAGCCAATA
TTCCAAtCGtCTAATAAAGtATTattCATATTATGCAAATATGCCatAaCTTCTGCAGTT
AAGGTTATTTTACAAAGTTGAAACACAAACTGTAGTTCATATTCCTCCACATGGC
GAAGGTATTGATTGATTTCACGGGCATCATATTTAGTTAATGTGCTTTTAGCTGCA
TTAATAGTCATGTTGGTGCTTCTGGTAGTATCCACAACAGtAACAAATACCTGATT
ACCCCAGCATATGCCATTATTATgtCCCTGTGcnca 
 
HPV 66 HR  
aancTtATATTTaGccaGgggatCCTGCTTTTCTGCAGGGGGctgnCCcntCTGACATgtaaTAG
CTGTGCTTttAaTATACCTATaTttaTCCTCtAAGcTaGTTGCAACTggtGGGGATAATCC
AatATTCCAATCGtCTAATAAAGTATTATTCATATTATGCAAATATGCCATAACTTC
TGCAGTtAaGGTTATTTTACAAAGTTGAAACACAAACTGTAGTTCATATTCCTCCA
CATGGCGAAGGTATTGATTGATTTCACGGGCATCATATTTAGTTAATGTGCTTTTA
GCTGCATTAATAGTCATGTTGGTGCTTCTGGTAGTATCCACAACAGTAACAAATA
CCTGATTACCCCAGCATATGCCATtAtnaTGTCCCTGTGCa 
HPV 53 pHR 
cAAanTtnaaTttaGATAGTGGGTCcnnCTTTTcaGGaGGggActgcaTCcTTTTGACAGGTTA
TAGCTGCACTTTTTACATATCTGTATTTGTCCTCTAAGCTAGTGGCAACAGGAGGC
GACAAACCTATATTCCAGTCTTCCAGTAAGGTAGAATTCATAGTATGTAAATAGG
CCATAACCTCAGCAGACAGGGATATTTTACATAGTTGAAACACAAATTGTAATTC
ATATTCCTCTGCATGCCTAACATACTGTTTAATTTGCTTTGAATTATATGTGGACA
TagACTGTGTGGTTGCAGAAAGAGTCATGTTTGTATTCCTGGTGGTATCCACAACA
GTTACAAATAACTGATTGTTCCAACAGATGCCATTATTATGTCCCTGTGCA 
HPV 73 pHR 
gtttGATTTACaGtTTGTTTTTCAGTTATGTAAAATTAGTTTAACTACTGAGGTAATGA
CATATATACATTCTATGAATTCTACTATATTGGAAGAGTGGAATTTTGGTCTTACC
CCACCACCGTCAGGTACTTTAGAGGAAACATATAGATATGTAACATCACAGGCTA
TTAGTTGCCAACGTCCTCAACCTCCTAAAGAAACAGATGACCCATATGCCAAGCT
ATCCTTTTGGGATGTAGATCTTAaagaAaAGTTTTCTGCAgAATTAGACCAgTTTCCC
TTGgGTCg 
HPV 6 LR 
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ccTTTtCAggAntGggCTTTTGACaGgtaatGgccTGTGACTGcACATACCTATAGGTATCTT
CTAATGTACCATTTGGGGGAGGCGATAACCCAAAGTTCCAGTCTTCCAAAACAGA
GGGATTCATTGTGTGAATATAGGCCATTACTTCAGCAGACAATGTAATGCTACAT
AATTGAAAAATAAATTGTAAATCATACTCTTCCACATGACGCATGTACTCTTTAT
AATCAGAATTGGTGTATGTGGAAGATGTAGTTACGGATGCACATAATGTCATGTT
GGTACTGCGTGTGGTATCTACCACAGTAACAAACAGTTGATTACCCCAACAAATA
CCATTGTTATGTCCCTGTGcaaa 
HPV 6 LR  
ACCTCcccAAaaaCtaaGgTTCTTATAGGGATCTGGCTTTTCCTTTTcaGGAGTGGGCTT
TTGACAGGTAATGGCCTGTGACTGCACATACCTATAGGTATCTTCTAATGTACCA
TTTGGGGGAGGCGATAACCCAAAGTTCCAGtCTTCCAAAACAGAGGGATTCATTgT
GTGAATATAGGCCATTACTTCAGCAGACAATGTAATGcTACATAATTGAAAAATA
AATTGTAAATCATACTCTTCCACATGACGCATGTACTCTTTATAATCAGAATTGGT
GTATGTGGAAGATGTAGTTACGGATGCACATAATGTCATGTTGGTACTGCGTGtG
GTATCTACCACAGTAACAAACAGTTGATTACCCCAACAAATACCATTGTTATgtCC
CTGTGCatGc 
HPV 42 LR 
AttntacataCCTATAACTATcTtCTAAAGTTcctGAAGGTGgTGGTGCAACACCAACATTC
CaCTCCTcTaatATGttaGGAttCATATTGtgtATATATGACATTACTTCAACagtnAatgTtAT
CTTACACAATTGaaaTATAAATTgcACATCataTTCTTCAGCAtgtcTTAAATATTCCTTA
AAATTATCAGCTGTatatgTATCACCAGATGTTgCAgtgncACACAAAGTCatgTtAGTAC
TacGgataCTATCnnnncanttAAAAaTAGctgaTTttCccaaca 
HPV 54 LR 
ATTTTTTTGTTGCCCTCCACACCCCCCCACTATACAAACCTATTTTTTTCTTCCCTA
CTACTTCTCCTCGGGGGGTTATACCATATTTCCTTTCCTCTACAATAGTGCCATTC
ATTCCATGAATATATGCCTTATCATCTGCTGTAAGGGTTATGGTACATAACTC 
HPV 54 LR  
tnagntCacagTCCAAAaGTAAaTTtaCTGTAAGGATCCTCCTTTTCCTTTGCAGGGGcann
nTtCTTTTGACATGCAATGGCCtgtgACTGTACAAACCTATATGTGTCCTCCAAACTA
CTTgtAGCTGGGGGGGTTATACCAAAGTTCCAGTCCTCTAGAATAGTGGGATTCAT
TCCATGAATATAGGCCATAACATCTGCTGTAAGGGTTATGGTACATAACTGAAAT
ATAAACTGTAAATCATATTCCTCCACATGTCTAATATACTCCCTAAAGTCAGAATT
ATTAAAGCTATCCTGCGTGGATGCTGTAGCACACAATGTTAGGTTAGTACTACGG
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GTGGTATCTACAACTGTTAAAAACAATTGATTGCCCCAACAAATACCATTGTTGT
GGCCCTGGGc 
HPV 61 LR 
tacaccTCtggactgCAAAAACCTAtatgtgtCTTctaGACTGGTAGAGGGTGGAGGTACCACA
CCAAAGTTCCAGTCATCCAACAAGGCTTTATTCATATTATGTAGGTAGGCCATAA
TTTCAGGGGTTAAATGTATTTTACATAACTGAAAAATGAATTGCAAATCAAACTC
TTCTGTATGGCGCAAATATTCCCTAAAGCTTGTGGCTTTATATTCAGATACAGGG
GGGGATGTAGCAGtACAaatGGTTACATtagtacTGcgnnTGGTatggacAacGGTtacAaacant 
HPV 61 LR  
tacaccTCtggactgCAAAAACCTAtatgtgtCTTctaGACTGGTAGAGGGTGGAGGTACCACA
CCAAAGTTCCAGTCATCCAACAAGGCTTTATTCATATTATGTAGGTAGGCCATAA
TTTCAGGGGTTAAATGTATTTTACATAACTGAAAAATGAATTGCAAATCAAACTC
TTCTGTATGGCGCAAATATTCCCTAAAGCTTGTGGCTTTATATTCAGATACAGGG
GGGGATGTAGCAGtACAaatGGTTACATtagtacTGcgnnTGGTatggacAacGGTtacAaacant 
HPV 61 LR 
tGnActGcanAAACCTATaTGTGTCTTCtaaaCtgntanAGGGTGGAGGTACCACACCAAAG
TTCCAGTCATCCaACAAgGCCTTATTCATATTATGTAGGTAGGCCATAATTTCAgG
GGTTAAATGTATTTTACATAACTGAAAAATAAATTGCAAATCAAACTCTTCTGTA
TGGcGCAAATATTCCCTAAAGCTTGtGGCTTTATATTCAGATACAGGGGGGGATGC
AGCAGTACAAATGgnTaCATTAgtACTGCGGGTGGTATCCACAACGGTTACAAacaAt
TCATTAAACCAACAAATACCATTGTTGTGgcCcTGg 
HPV 62 LR  
GttctgtggTGgnTncTACTagAaGTACTAATTTTACTATTTGTACCGCCTCCacTGCTGCA
GCAGAATACAAGGCTACCAACTTTaGGGAATTTTTGCGACACACGGAAGAATTtG
ATTTGCAATTTATATTTCAATTGTGCAAAATACAGTTAACCCCCGAAATCATGGC
CTACCTGCATAATATGAACAAGGACCTTTtGGATGACTGGAACTTTGGGGTTTTAC
CTCCCCCTTCCACTAGTTTAGATGAGACATATCGCTATTTGCAGTCTCGGGCTATT
ACATGTCAAAAGGGGGCTGCTTCCCCgtCCCCCAAGGTGGACCCGTATGCGCAAA
TGACATTTTGGACTGTGGATCTTAAGGACAAGTTGTCTACTGATTTGGACCAGTTT
CccTTGGgtc 
HPV 83 LR 
GAtccTtatnaGGGgCaGGGgCGGAagnCCcTTTTGgcaggtAatagCACGGgactGCagaTAGCG
ATaGgTATCATCAAGGctGGtGgAaGgAGGtnntAACACGCCAAAATTCCACTCATCCA
ATAAATGTTCATTCATACTATGTAGGTATGCCATAATTTCAGGGGTAAGATGTAT
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TTTGCAAAGTTGCAATATAACCTGTAAGTCATATTCCTCGGTGTGGCGGaGGTATT
CCTTAAAGTTAGAGGCTGTGTATTCATTAGCCTGTGTAGCAGCAGCTGAAATAGT
AATATTGGTACTGCGGGTAGTATCCACAACTGTAACAAATAACTCATTAAACCAA
CAAATGCCATtAttaTGTCCCTGTGc 
HPV 89 (Cp6108) LR 
gTTCTAcacGCTTTAaggAaTATTTAAgACACACtgaGgAaTATGACCTACAGTTTATAT
TCCAACTATGTAAGATACACCTAACGCCTGAGATAATGTCCTATTTACACAATAT
GAATGACACATTGTTAGATGAATGGAACTTTGGTGTCATTCCCCCTCCCTCCACTA
GTTTGGATGATACCTATCGCTTTCTTACCTCTCGGGCCATTACATGTCAAAAGGGC
ACTGCTGCCCCAGAACCTAAAAAGGATCCATATGATAAGTTATCCTTTTGGGATG
TGGATCTTAAGGAACGTTTGTCCACTGATCTCGACCAGTTTCCCTTGggTCGa 
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Appendix E: 
 E1 Ethics approval from The Gambia government/MRC Joint Ethics Committee 
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E2 Ethics approval from The University of Westminster 
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E 3 Permission letter for sample processing in EFSTH Laboratories 
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 E4 Letter of collaboration from the Obstetrics and Gynaecology department, EFSTH 
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E 5: PARTICIPANT INFORMATION SHEET 
Project Title: Human papillomavirus co-infection with Sexually Transmitted Infection 
Pathogens amongst Reproductive age Women in Urban Gambia 
 
You are kindly invited to take part in a research project, designed by Haddy Bah Camara of 
Edward Francis Small Teaching Hospital (EFSTH), Banjul, The Gambia in collaboration with 
the University of Westminster (UoW), London, UK. Mrs. Haddy Bah Camara and the study 
team will provide you with all the information concerning the project and your participation. 
Do not hesitate to contact the study team if there is anything you do not understand. You can 
confirm your participation by signing or thumb-printing the consent form below. 
What is the purpose of the study? 
The purpose of this study is to determine whether women infected with sexually transmitted 
bacteria will also be infected with human papillomavirus, which can cause cervical cancer. The 
study involves collaboration with Edward Francis Small Teaching Hospital, Gambia and 
University of Westminster, UK 
The results from the study will help in making health policies on HPV and STI management in 
Gambia; provide education to the community and serve as foundation for future researches on 
HPV in Gambia.  
What will you be asked to do? 
Participation in this study is voluntary. Swab or blood specimens will be collected from you as 
part of your routine clinic appointment. A sterile cotton swab will be introduced into your cervix 
(womb) to collect the sample or a sterile syringe and needle will be introduced into your vein 
to collect a venous blood sample (where applicable). This will be done by an experienced staff 
of the clinic in the safest way possible. You have every right to withdraw from the exercise if 
you are uncomfortable or unwell.  
Risks and Discomfort 
It is very unlikely that there will be any side effects for taking part in the study. You may 
experience slight discomfort when swab / blood sample are being taken. However, this will be 
done in the safest way possible. 
Why have I been asked to participate? 
You have been asked to participate because of your present condition and history of infection 
/Non existing infection (Family Planning client) 
Do I have to take part? 
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Participation is voluntary. However, if you decide to take part, a copy of this information sheet 
will be given to you to keep. You are free to withdraw at any time without giving reasons and 
can request the removal of your sample from the study. Moreover, your decision to withdraw 
will not affect the health care you receive. 
What do I have to do? 
To be recruited for the study, you are kindly requested to answer some few questions below. 
You can then confirm your participation by signing/ thumb printing the consent form below. 
Confidentiality 
This is a student research project which may be published.  During the project and in the event 
of subsequent publication, your participation and any other personal details will be kept highly 
confidential. Your sample will be given a specific research number and anonymized. Access to 
identifiable data will be held in The Gambia only by your respective health provider, who has 
access to your information. Dr Patrick Kimmitt, Dr Edward Wright and Haddy Bah Camara 
will only handle anonymized samples with no bearing to your identity. 
Expenses and Payments 
Participation is entirely voluntary and as such there will be no payment for your participation 
in the study.   
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E6 Participant consent Form 
Project Title: Human Papillomavirus co-infection with Sexually Transmitted Pathogens 
amongst Reproductive aged Women in Urban Gambia 
Statement by subject 
     I have read the written information OR 
      I have had the information explained to me by study personnel in a language that I  
understand*  
and I 
• confirm that my choice to participate is entirely voluntarily, 
• confirm that I have had the opportunity to ask questions about this study and I am 
satisfied with the answers and explanations that have been provided, 
• understand that I grant access to identifiable data about me to authorised persons 
described in the information sheet, 
• am aware that part of my sample will be taken abroad for further analysis 
• agreed for my sample to be stored for future research 
• have received time to consider taking part in this study, 
• agree to take part in this study.  
 
Participant Details 
Participant Identification Number: |__|__|__|__|__|__|__|__|__|__|__|__| 
Age: ……………… 
Contact number…………………                          ----------------------- - - - - - - - - - - - - - - -                                                                          
Signature/Thumbprint of volunteer:   
                                                                                       Date ……………… 
* Only required if the participant is unable to read or write 
This form has been read by / I have read the above to  
  _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ (Write name of volunteer) 
in a language that she understands. I believe that she has understood what I explained and that 
she has freely agreed to take part in the study. 
Signature of field worker: _ _ _ _ _ _ _ _ _ _ _  
Name of field worker: _ _ _ _ _ _ _ _ _ _ _ _ _ _  
Date:    |___|___| / |___|___| / |___|___|___|___| 
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Contact for further information  
If you have any problem or query about any aspect of the study at any time, please do not 
hesitate to contact the researcher or the Hospital Public Relation Officer (PRO) on the contacts 
given below:  
EFSTH PRO                                   Momodou Lamin Jammeh 
                                                         
PhD student:                                 Haddy Bah Camara 
A copy of this consent document has been provided to the participant. 
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E 7: QUESTIONNAIRE 
Please allow me 20 minutes of your time to answer the following questions. Your genuine 
answers will help the health care provider to make corrective decisions in providing quality 
health care. Your answers will be kept confidential and known only to the health care provider. 
Your identity will not be distributed, published or sold. 
1.  Health facility  
Name……….    Type………… 
2   Participant Identifier number ………… 
3   What is your date of birth? : Age in Years (………….)      
4. Region………………District…………………. 
5. What is the purpose of your visit today?  
__ Family Planning visit (go to Ques. 7)     
__ STI   visit, (go to Ques. 6)  
__ HIV management visit (go to Ques. 7)     
6.Do you have any of the following symptoms today? 
__Vaginal itching\ discharge with fishy or strong odour (Tick) 
__Pain or burning when urinating   
__bleeding between periods  
__Pain during sex      
__Sores, skin rashes with rough red or reddish brown spots on hands or feet  
__Genital warts  
__ Lower abdominal pain  
__Others (specify) …………… 
• If YES to any of the questions, find out how long she has/had the symptoms----- 
SECTION B: Socio economic background 
7. What is your ethnicity?  
   __ Wollof 
   __ Mandika 
   __ Jola 
   __ Serere 
   __ Sarahule 
   __ Fula 
   __ Others (Specify) 
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8. What is the highest level of education you have completed? 
     __ None 
     __ Primary level 
     __ Secondary level 
     __ College 
     __ University 
     __ Quaranic studies 
9. What is your current occupation?  
      __ Student 
     __ Petty trader 
     __ Business woman 
    __ Civil servant 
   __ House wife 
   __ Farmer 
   __ Others (specify) 
10. How many people are currently living in your household, including yourself? ___ 
a. Of these people, how many are children ≤18 years old? ___ 
11. Which of these categories best describes your total combined family income for your 
household for the past 12 months? 
__ <D10, 000  
__ D 10,000 - 35,000 
__ D35, 000 - 50,000  
__ D51, 000 – 65,000  
__ D66, 000 – 75,000 
__ D 76,000 – 85,000 
__ D85, 000 - 100,000  
__ > D100, 000  
__ Don’t Know / Not sure  
12. Have you ever smoked cigarettes? 
__ Yes (How many a day?) Specify_ 
__ No 
__ Quit  
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13. Have you ever been screened for cervical cancer? 
__ Yes 
__ No 
__ Don’t Know 
__Not sure 
14. Have any of your family members been diagnosed with cervical cancer? 
__ Yes 
__ No 
__ Don’t Know 
15. This visit, swab samples will be collected from you by a health care provided, but would 
you have preferred to collect the samples yourself?  
__ Yes. (if yes, why?) 
         -  Embarrassment 
          - Others ………… (Specify) 
          - Don’t mind either way 
__ No 
SECTION C: Reproductive and Hormonal factors 
B. Menstrual periods 
16. At what age did your menstrual periods begin? 
__ 10 years 
__ 11 years 
__ 12 years 
__ 13 years 
__ 14 years 
__ 15 years 
__ 16 years 
__ 17 years or older 
17. Have you had a menstrual period within the last 12 months?  
__ Yes, I still have a menstrual cycle (go to question18) 
__ Yes, but my menstrual cycle stopped within the last year  
__ No, my menstrual cycle stopped more than one year ago 
__ Don’t know 
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18. When was your last menstrual period?  
|___||___| / |___||___||___||___| OR |___||___| 
Month  YEAR   AGE 
__ Don’t know  
19. Which of these best describes why your menstrual cycle stopped? 
__ Breastfeeding 
__ Birth control or medications 
__ Natural menopause 
__ Surgery to remove the uterus or ovaries 
__ Other (specify) ________________________ 
__ Don’t know 
Pregnancy 
20. Have you ever been pregnant?  
__ No (go to question 24) 
__ Yes 
__ Don’t know (go to question 24) 
 
21. How old were you when you first became pregnant? 
__ Less than 15 years 
__ 15-19 years 
__ 20-24 years 
__ 25-29 years 
__ 30-34 years 
__ 35-39 years 
__ 40-44 years 
__ 45 years or older 
__ Don’t know  
22. How many times have you been pregnant? Please include stillbirths, miscarriages, 
abortions, tubal or ectopic pregnancies, and live births. 
__ 1 
__ 2 
__ 3-4 
__ 5-9 
__>10 
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SECTION D. Contraceptive use 
23. Did you ever take birth control pills for birth control or to regulate menstrual periods? 
__ No, never (go to question 28) 
__ Yes 
__ Yes, but stopped taking them now (go to question 25 &26) 
24. How old were you when you first started taking birth control pills? 
__ less than 15 years 
_ 15-19 years 
__ 20-29 years 
__ 30-39 years 
__ 40-49 years 
25. How old were you when you last took birth control pills? 
__ Still taking birth control pills 
__ Less than 15 years 
__ 15-19 years 
__ 20-29 years 
__ 30-39 years 
__ 40-49 years 
__ 50 years or older 
26. How many total years of birth control pills have you used? 
__ less than 5 years 
__ 5-9 years 
__ 10-14 years 
__ 15-19 years 
__ 20-24 years 
__ 25-29 years 
__ 30-34 years 
__ 35 years or more 
*Could repeat 14-17 for injectable contraceptive or shot, contraceptive hormonal patch, vaginal 
ring, intrauterine device, other (specify) 
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SECTION E. WOMAN’S SEXUAL HISTORY 
The next questions are about your sexual history.  I do realise that, this is a personal subject, 
but it is very important to the study. Please take the time to recall the information as accurately 
as possible.  I want to remind you that this is a private interview and that the information you 
give me will not be linked to your name.  
27. Are you married? 
 __ Married*, (Is this your first married)?  
       __ Yes (go to question 28) 
        __ No (How many times have you been married?), Specify__  
__ Single 
__ Divorced 
__ Separated 
__Widow     
28. Have you been circumcised? 
__ Yes 
__ No 
__ Don’t Know 
29. How old were you when you first had sexual intercourse with a man?  
|__|__|AGE 
 __NEVER HAD INTERCOURSE 
30. Throughout your life, with how many different men have you had sexual intercourse with?  
|__|__| 
No. of Men 
__Don’t know 
 
 
 
 
 
 
 
 
31. Did your partner have any other sexual partners besides yourself, either before he met you 
or during the time you were together? 
BOX E1 
IF NUMBER OF MEN = 1 …………………………..CONTINUE 
IF NUMBER OF MEN = GREATER THAN 1 Q.34 
IF DON’T KNOW Q.35 
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__ Yes 
__ No 
__ Don’t Know 
32. Besides yourself, how many sexual partners would you say he had?  
         |__|__|  
NO. OF PARTNERS 
__ Don’t Know 
33. Would you say it was . . .  (READ) 
__ 2 or 3, 
__Between 4 and 6,  
__Between 7 and 10 
__ More than 10 
 __ DON'T KNOW 
 
34. Within the last year, have you had sexual intercourse? 
__ Yes (go to 34b) 
               34b. Does your partner (s) use condoms during sexual intercourse? 
                     ---Yes 
                   ----No 
__ No 
35. During the last year, what is the total number of men with whom you have had sexual 
 intercourse? 
|__|__| (go to question 38) 
NO. OF MEN 
__DON'T KNOW 
36. Would you say it was...? (READ) 
__ 1 
__ 2 
__ between 3 and 5 
__ >5 
 
37. Within the last year, were any of these partners new partners, that is, partners with whom 
you had sexual intercourse for the first time? 
__ Yes 
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__ No 
38. With how many new partners did you have sexual intercourse in the last year? 
          |__|__|  
NO. OF NEW PARTNERS 
__ DON'T KNOW  
39.  Would you say it was……… (READ) 
  __ 1 
  __ 2 
  __ between 3 and 5 
  __ >5 
 Thank you for your participation. 
 
 
 
 
 
 
